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1 Introduction 
Cancer is the second most common cause of death in Germany (total incidence of 469,800 
in 2008 [1]) as well as in the rest of the Western world [2, 3]. Each type of cancer is 
classified by the specific tissue initially affected. With an incidence of 71,660 (32.1%) 
breast cancer is most common in women, whereas in men prostate cancer is most frequent 
with an incidence of 63,440 (25.7%) [1]. In general, cancerous cells emerge due to mostly 
age-dependent genetic modifications resulting either in up-regulated gene function or in 
down-regulated tumor suppression [4]. Due to demographic changes as well as increasing 
obesity, a dramatic rise of cancer incidence rates is expected over the next decades [1]. 
Based on the assumption that practically all mammalian cells share a similar molecular 
repertoire of pathways controlling their proliferation, differentiation and death, literature 
suggests a multi-step process of events progressively leading to neoplastic development. 
During tumorigenesis malignant cells aquire a set of novel capabilities which successfully 
disrupt tissue-own cancer defense mechanisms [4, 5]. Literature states six main 
characteristics that apply for the formation of virtually all malignant cells (Table 1-1): 
Table 1-1 Six generally applicable characteristics for development of malignant tumor cells. [4, 5] 
Characteristic property Mechanisms 
Self-sufficiency in  
growth signals 
Well-controlled proliferative pathways are misregulated due to signals governing 
cell growth-and-division cycle. This is can be caused by autocrine production of 
growth factors or over-expression of receptors (e.g. tyrosine kinases such as the 
epidermal growth factor receptor (EGFR) (I.3.4.4)) answering to growth signals [6]. 
Evasion of 
growth-inhibiting signals 
Tumor suppressor genes, such as RB (retinoblastoma-associated) [6], process 
extracellular signals necessary for cell cycle activation. The TP53 protein acts as a 
DNA damage sensor [7] and receives intrinsic stress signals (e.g. O2 or growth 
factor levels). As a result, it can halt the cell cycle or induce apoptosis. Defective or 
missing genes result in uncontrolled proliferation. 
Evasion of apoptosis 
Typically apoptosis is activated by various physiologic stresses [8] but is inactivated 
in high-grade malignant cells by pro- and antiapoptotic regulatory proteins. For 
example blocking of caspases 8 and 9, as well as activation of the Bcl-2 family 
apoptosis inhibitor oppresses programmed cell death [9, 10]. 
Replicative immortality 
Due to absent telomerase, telomers of healthy cells become shorter with each 
replication cycle. Elevated telomerase levels in about 90% of all cancers ensure 
addition of hexanucleotide tandem repeats to telomers thus creating immortal cells 
[11].  
Sustained angiogenesis 
Cancer cells and tumors possess an exorbitant need for nutrients and oxygen which 
leads to never-ending neovascularization. Angiogenesis is for example induced by 
up-regulation of the vascular endothelial growth factor A (VEGF-A) or by 
inactivation of the angiogenic inhibitor thromospondin-1 (TSP-1) [12]. 
Tissue invasion and metastasis 
Alterations in cell attachment and changes in the extracellular matrix, e.g. 
inactivation of the adhesion molecule E-cadherin [13], induce detachment of cells 
which then evade surrounding tissues, or release of malignant cells that build 
metastasis at different locations. 
Tumors do not merely comprise a cluster of abnormal cells, but develop an organ-like 
complexity. Multiple distinct cells are recruited by malignant cells creating a tumor 
microenvironment which for example provides necessary signals and growth factors, or 
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structural foundation (fibroblasts). During the hyperproliferative phase of a tumor, even 
whole subpopulations of cancer stem cells (CSC) are formed that promote malignant 
growth and metastasis [14, 15]. [4, 5] 
1.1 Pancreatic cancer 
The pancreas is an organ of mainly glandular tissue located behind the stomach. Its 
exocrine gland comprises more than 95% and produces the pancreatic juice containing 
enzymes to digest fats, proteins and carbohydrates. The remaining parts are endocrine cells 
arranged in small clusters (islets of Langerhans) responsible for hormone release, for 
example insulin, into the blood. Tumors originated from glandular tissue are classified as 
adenocarcinomas. [16, 17] 
1.1.1 Statistics 
The pancreatic adenocarcinoma is a rare but very aggressive type of cancer. In 2008, the 
morbidity in Germany was 18/100,000 people with a total incidence of 14,960, which 
corresponds to only 3% of all cancers (Table 1-2). Despite its low incidence rate, 
pancreatic cancer is the 4
th
 most common cause of cancer-related deaths [1]. 
Table 1-2 Statistical data on pancreatic cancer in Germany in 2008 with a prognosis for 2012. [1] 
 2008 2012 
 
♂ ♀ ♂ ♀ 
Incidence 7,390 7,570 7,800 7,600 
Deaths by pancreatic cancer 7,327 7,508 N/A N/A 
Morbidity1 18.4 18.1 19.5 18.3 
Age at diagnosis2 70 76 N/A N/A 
Mortality rate1 18.2 17.9 N/A N/A 
Relative 5-year survival rate 8 7 N/A N/A 
1 per 100,000 persons, 2 median 
The main reason for this high mortality is its distinctly invasive growth behavior in 
addition to an enormous potential for premature lymphogenic and hematogenic metastasis 
into neighboring organs, such as liver, lymph nodes, and lung [16, 18, 19]. Fast metastatic 
spread and high tumor resistance towards radiation and chemotherapy result in a mortality 
rate of nearly 100% (Table 1-2) [1, 16, 19]. This implies that the prognosis of a patient is 
strongly dependent on the progression of disease at the time of diagnosis. Except for very 
early diagnosis, pancreatic cancer is always lethal resulting in an average 5-year patient 
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survival rate of 1 – 5% and a median life expectancy of 4 – 6 months when diagnosed after 
metastasis or local spread [1, 16, 18, 20, 21]. 
1.1.2 Risk factors 
Definite reasons for pancreatic cancer are not exactly known, but classified risk factors are 
excessive abuse of alcohol and cigarettes, as well as obesity in combination with type 2 
diabetes [22-24]. In 5 – 10% of the patients, malignant pancreatic cancer is due to a 
genetically induced risk, inherited from a likewise diseased first-degree relative with 
cancer or hereditary pancreatitis [16, 25]. Currently identified genetic alterations include 
amongst others, mutations in codon 12 of the oncogene KRAS2 which is involved in the 
regulation of cellular growth factor signal transduction [26] or inactivating mutations of the 
tumor suppressor genes TP53 (inactivated in approximately 60% of pancreatic cancers) or 
p16 (inactivated in 90% of pancreatic cancers). Normally, TP53 is activated after DNA 
damage occurs thus inducing apoptosis in the G1-phase of the cell cycle, whereas active 
p16 acts as cyclin-dependent kinase inhibitor. Its inactiviation leads to unhindered cell 
proliferation. Mutations, which result in deviant methylation patterns of for example 
FoxE1, NPTX2, CLDN5 or SPARC [19, 27, 28], influence rates of receptor-ligand signal 
transduction. Prevalence of mutations for the hereditary and sporadic pancreatic carcinoma 
is evaluated similarly. Moreover, a genetic predisposition to develop pancreatic cancer 
originates in the mutation of gametes [19, 27, 28]. Altogether, all genetic factors account 
for approximately 20% of all cases but could also lead to a differential diagnosis.  
1.1.3 Diagnosis 
The asymptomatic disease pattern of early-stage pancreatic cancer and the lack of adequate 
and reliable cancer markers in combination with poor molecular imaging techniques 
complicate an early and correct diagnosis. Primary tumors are located deep inside the body 
and cannot be seen or felt during routine examinations. Acute clinical symptoms, for 
example severe pain, weight loss and jaundice, usually do not arise before metastasis has 
occurred and the tumor has reached an irresectable stage [16, 19]. In case of suspected 
pancreatic cancer, classical sonography and CT examinations (optionally with contrast 
agents) are employed to visualize tumor growth. By means of additional tests, such as 
endoscopic retrograde cholangiopancreatography combined with tissue biopsy, MRI or 
laparoscopy, the tumor spread is estimated preoperatively. Other examination methods 
may include intraductal or endoscopic sonography (possibly combined with a Fine-Needle-
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Aspiration biopsy), angiography or positron emission tomography (PET) [16]. Tumors are 
staged according to the American Joint Committee on Cancer (AJCC) using the Tumor-
Nodus-Metastasis system [29]. At time of diagnosis, the disease is exclusively localized to 
the pancreas in 20% of the patients, another 40% are diagnosed with local spread whereas 
visceral metastasis are found in the rest of the patients [30]. Malignant tumors of the 
exocrine pancreas originate predominantly (95%) within the ductal epithelium [20, 31]. 
Many pancreatic tumors express carbohydrate antigen (CA 19-9), carcinoembryonic 
antigen (CEA), cytokeratins 7, 8, 13, 18 and 19, as well as B72.3 (TAG-72), CA 125, 
DUPAN2 or mucins (Muc 1, 3, 4 or 5AC). These markers can be detected via 
immunohistochemistry staining techniques of biopsy tissue or blood samples. CA 19-9 is 
the most commonly used tumor marker (gold standard) for serum and tissue analysis with a 
sensitivity of 80% for asymptomatic pancreatic cancer and 55% at occurrence of small 
resectable tumors < 3 cm. However, no diagnostically significant results are possible from 
CA 19-9 serum concentrations in asymptomatic patients with invasive lesions [19]. 
Therefore, CA 19-9 is mostly only used for follow-up examinations during medical 
treatment. Genetic testing rarely appears promising since inherited DNA mutations are 
often linked to many different kinds of cancers.  
1.1.4 Therapy 
Despite marked advancements in molecular tumor biology, the treatment efficiency of 
pancreatic cancer has not significantly increased within the last 25 years [1, 20]. Basically, 
three main types of treatment are available: (a) Surgery, (b) chemotherapy and (c) radiation 
therapy. Surgical tumor removal (pancreatico-duodenectomy or Whipple procedure) is 
currently the only curative treatment with prospects of success [16, 32]. It can be 
performed in 15 – 20% of the patients; but even if R0 resection of the tumor was 
successful, the 5-year survival rate amounts to only 25 – 30%. Survival decreases to 10% 
after lymph nodes have been invaded [16, 33]. Only approximately 5% of all tumors are 
truly resectable at the time of diagnosis.  
Nowadays, adjuvant therapeutic approaches consisting of systemic chemo- or radiation 
therapy, or a combination of both, are employed to reduce the mortality rate [34, 35]. Best 
results are currently obtained by combining the cytostatic adjuvant Gemcitabine 
(2’, 2’-Difluordesoxycytidin, Gemzar
®
) with resection [36-38]. Since its approval in 1996, 
it is applied during first-line treatment of advanced and metastasized pancreatic carcinoma 
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but with limited success. Besides a pain-reducing and weight-gaining effect, Gemcitabine 
was successfully applied during adjuvant treatment of operable tumors. In comparison to 
5-FU (5-Fluorouracil, Efudex
®
), used until the late 1990s, Gemcitabine is better tolerated 
and results in an improved treatment outcome with a 1-year survival rate of 18% instead of 
2% [37, 39, 40]. Both adjuvants are cytostatic pyrimidine analogues and belong to the 
family of antimetabolites. They intervene during DNA synthesis, especially in highly 
proliferating tumor cells, leading to cell cycle arrest and subsequent apoptosis. While 
Gemcitabine is metabolized intracellular to Gemcitabine-triphosphate and inserted into the 
DNA instead of the human cytidine, 5-FU irreversibly blocks the enzyme thymidylate 
synthase thus inhibiting thymidine and DNA synthesis.  
Since 2007, Erlotinib (Tarceva®) is approved for chemotherapeutic treatment of pancreatic 
cancer. It is a selective inhibitor targeting the tyrosine kinase domain of the epidermal 
growth factor receptor (EGFR) and is mostly applied in combination with Gemcitabine 
[41, 42]. EGFR is highly expressed, and sometimes mutated, in a lot of cancerous cells. 
Erlotinib reversibly attaches to the adenosine triphosphate (ATP) binding site of EGFR 
thus interrupting cell signal transduction. Usually two EGFR molecules have to form a 
homodimer for signal transmission. This linking process which activates cellular pathways 
is induced by ATP. Its blocking consequently results in a missing signaling cascade. 
During adjuvant radiation therapy, ionizing high-energy X-rays (photons) or charged 
particles are used to eliminate cancer cells as pre-operative or post-operative tumor 
treatment. Ionization of atoms either damages ssDNA and dsDNA of cancerous or dividing 
cells directly leading to apoptosis. On the other hand, free radicals (hydroxyl radicals) are 
formed after ionization of water molecules which indirectly damage cellular DNA. 
Computer-controlled radiation is focused on the tumor by external beam radiation devices, 
such as intensity-modulated radiation therapy (IMRT) or the robotic arm CyberKnife
®
. 
They place precise multiple-directioned doses of radiation on the tumor according to its 3D 
shape to minimize exposure of normal tumor-surrounding tissue [43, 44]. Post-surgery 
radiation therapy combined with chemotherapy, currently yields the best prognosis for 
pancreatic cancer patients [31]. 
Due to the high resistance of pancreatic cancer towards conventional chemotherapeutics 
and radiation therapy, repeated high-dosage treatment causes unspecific damage to healthy 
tissue surrounding the tumor. Subsequently this leads to various adverse side effects, such 
as nausea, hair and weight loss. Chemotherapeutics also damage the bone marrow and the 
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subsequent production of new blood cells causing an increased chance of infection 
(lymphocytes) as well as bleeding and bruising after minor injuries (platelets), or fatigue 
(erythrocytes). This dramatically reduces a patient’s life quality [17, 45, 46]. 
1.1.4.1 Prognosis 
Residual tumor cells (minimal residual disease (MRD)) are responsible for a high relapse 
rate featuring liver metastasis as dominating recurrence in 50 – 70% of the patients [16]. 
Current treatment options are rarely curative and mostly palliative and life-prolonging. The 
prognosis remains devastating, especially considering the increasing tendency towards 
malignant diseases as a result of demographic change (incidence of pancreatic cancer 
peaks between 7
th
 and 8
th
 decade of life) [1]. Therefore, the need to investigate clinical and 
tumor biological factors that enable an improved targeted therapeutic approach becomes 
apparent. 
1.2 Immunotherapy 
Immunotherapy is a relatively novel but fast advancing field of targeted cancer therapy. It 
exploits characteristics of cancerous cells, which specifically distinguish them from 
healthy ones, to eliminate malignant cells with minimal side effects. Within the last 20 
years various strategies for targeted tumor treatment have been developed. 
Immunotherapeutics [31, 47] in form of antibody-drug-conjugates (ADC) present a 
promising alternative approach which has already led to an increased therapeutic 
specificity for other types of cancer [48, 49]. Moreover, specific antibodies conjugated to 
an imaging molecule (e. g. fluorophore, Fe
2+
-particles) may be applied for tumor 
diagnostics [50-52] in addition to targeted therapeutic drug delivery. 
Active immunotherapy stimulates the immune system directly into attacking diseased cells 
by induction of an efficient cytotoxic T lymphocyte (CTL) response. Moreover, inate 
mechanisms of the immune system to initiate, program and regulate tumor specific 
immune responses are exploited [53], including dendritic cells (DCs) as powerful 
antigen-presenting cells. DCs process unfamiliar endogenous proteins to antigenic peptide 
fragments and present them on their surface as MHC class I complexes for CD8+ T-cell 
recognition [31, 54]. Exogenous antigens, on the other hand, are digested by proteases after 
uptake via lysosomes, presented as MHC class II complexes and recognized by CD4+ T-
cells [31, 54]. T-cells then secrete interferons (e. g. IFN-Ȗ) or cytokines (e. g. tumor 
necrosis factor TNF-α) as well as interleukins (e. g. IL-4, IL-10) to activate DCs and CTLs 
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[31, 55, 56]. T-cell activation is often additionally linked to a humoral antibody-based 
immune response. Known and frequent surface antigen mutations of pancreatic cancer, 
such as KRAS [57], CEA [58], p53 [59] or human telomerase reverse transcriptase 
(hTERT) [60], are perfect targets for immunotherapeutic approaches [31]. Particularly 
interesting targets concerning pancreatic cancer therapy are its treatment-suppressing 
mechanisms, caused by immune suppressive cells within the tumor microenvironment. 
Among other mechanisms, this comprises the expression of surface molecules suppressing 
immune response (e. g. vascular endothelial growth factor) [61], which repress CD8+ CTL 
function by IL-10 secretion [31]. Vaccines, consisting of inactive whole tumor cells as 
vehicle, can be utilized to deliver specific tumor-associated antigens (TAA) into the body. 
Another possibility are peptide vaccines mimicking a small immunogenic region of a 
defined TAA, which induce a TAA-specific T-cell mediated immune response [31]. For 
cell-based vaccines, synthetic peptides from known tumor antigens are inserted into DC for 
MHC class I and MHC class II complex presentation [31]. Other options include insertion 
of tumor cell lysates or transfection with whole tumor cell DNA or RNA [31]. 
Immunogenicity of tumor cells can be increased by transfection of DCs with genes coding 
for example for the co-stimulating granulocyte macrophage colony-stimulating factor [62]. 
In a variation of cell-based immunotherapy, certain cell types (DCs, CTLs) from a cancer 
patient are amplified, modified ex vivo and re-injected into the patient [63, 64]. As a direct 
result, these molecules inhibit tumor growth, indirectly act anti-angiogenic or increase 
immune response (progress was shown during melanoma therapy by injection of tumor 
infiltrating lymphocytes (TIL) [65-67]). As for pancreatic cancer, these active 
immunotherapeutic approaches are currently under preclinical and clinical investigation. 
During a passive immunotherapeutic approach, recombinant monoclonal antibodies (mAB) 
specifically recognize tumor-associated antigen (TAA) structures on target cells ideally 
over-expressed on the tumor as well as its metastasis [68, 69]. This specific activity is 
associated with a reduction of side effects and poses a huge advantage for therapeutic 
mABs. Their therapeutic effector mechanisms can be direct or indirect. The direct effector 
function only depends on the binding performance of the mAB to a specific target antigen. 
Binding recombinant mABs disrupt receptor-ligand interactions by blocking either 
receptor (e. g. EGFR) or ligand (e. g. TNF-α, VEGF). Similary, disabling of surface 
structures also prevents interactions between cells, for example after transplantations (e. g. 
IL-2 against CD25). An additional direct effector function is the mediation of intracellular 
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apoptotic impulses by cross-linkage of two surface receptors. Indirect effector mechanisms 
are dependent on the Fc-moiety of a mAB and thus the antibody isotype. Effector cells 
(e. g. macrophages, T-cells) are recruited via the Fc-effector function, resulting in the 
elimination of a diseased cell by apoptosis, phagocytosis or activation of the complement 
system. Complement-dependent cytotoxicity (CDC) is induced after opsonisation with 
mAB leading to complement activation and cell lysis [70]. So-called antibody-dependent 
cellular cytotoxicity (ADCC) is stimulated by attachment of the Fc-part of bound mABs to 
receptors on effector cells [70, 71]. These cells then secrete substances, such as perforin 
and Granzyme B, or mediate phagocytosis. Table 1-3 exemplarily lists recombinant mAB 
with direct and indirect effector function. 
Table 1-3 List of approved exemplarily mABs with a direct and indirect effector mechanisms. 
mAB Mechanism Effector molecule Application 
Infliximab 
(Remicade®) 
direct  
ligand-mediated 
binding to cytokine TNF-α blocks receptor 
reaction, inhibition of proinflammatory 
signals 
rheumatoid arthritis,  
Crohn’s disease [72] 
Adalimumab 
(Humira®) 
direct  
ligand-mediated 
binding to cytokine TNF-α blocks receptor 
reaction, inhibition of proinflammatory 
signals 
rheumatoid arthritis,  
autoimmune diseases [73] 
Basiliximab 
(Simulect®) 
direct  
receptor-mediated 
binding to IL-2 receptor CD25 prevents 
rejection after kidney transplants 
organ transplantation [74] 
Daclizumab 
(Zenapax®) 
direct 
 receptor-mediated 
binding to IL-2 receptor CD25 prevents 
rejection after kidney transplants 
organ transplantation [75] 
Bevacizumab 
(Avastin®) 
direct  
ligand-mediated 
binding to secreted VEGF inhibits 
angiogenesis 
advanced colorectal, lung,  
breast, kidney and  
cervix carcinoma [76] 
Trastuzumab 
(Herceptin®) 
Direct 
 receptor-mediated 
indirect (ADCC) 
binding to EGF blocks HER2/neu receptor, 
inhibits growth and proliferation-inducing 
signals 
breast cancer [49, 71] 
Rituximab 
(MabThera®) 
direct  
receptor-mediated, 
indirect  
(CDC and ADCC) 
Binding to and cross-linking of CD20 
receptors on B-cell, induces apoptotic 
signals 
lymphoma, leukemia,  
transplant rejection [48, 70, 71] 
In Europe, currently twelve mABs are approved for cancer therapy (10.3) [77], for 
example Rituximab, Trastuzumab or Cetuximab [48, 49, 78], but none for an effective and 
specific treatment of pancreatic cancer. To improve their therapeutic effect, the natural 
binding function of mABs is enhanced by covalent conjugation to cytotoxic substances, 
such as low-molecular chemical compounds, to form radioimmunoconjugates (e. g. I
131
 or 
Y
90
 [79, 80]) or non-radioactive chemoimmunoconjugates (e. g. Doxorubicin [81]), as well 
as macro-molecular protein-based immunotoxins (IT) [69, 82]. 
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1.2.1 Immunotoxins 
Immunotoxins (ITs), also known as cytolytic fusion proteins, are passive humoral 
immunotherpeutics. They consist of a tumor-specific binding moiety and a cytotoxic 
effector domain, where the mAB acts as a carrier molecule for targeted delivery. In order 
to reach complete cytotoxic potency and consequent selective elimination of malignant 
cells, ITs have to be internalized and translocated to the cytoplasm after surface binding 
[83]. Hence, the choice of target protein is important since not every binding ligand is also 
internalized and suitable to induce apoptosis with a limited number of receptors. Protein-
based cytotoxic effector domains can be derived from plants (e. g. Ricin or Saporin (also 
called ribosome inactivating protein (RIP)) or bacteria (e. g. diphtheria toxin, Exotoxin A 
(ETA) [84, 85]). A frequently used bacterial toxin is the truncated version of the Exotoxin 
A (ETA’) [85-87] from Pseudomonas aeruginosa, whose genetic mutation does not 
influence its catalytic activity but prevents unspecific toxicity caused by premature 
separation of ligand and toxin. Due to their high immunogenicity, plant and bacteria-
derived toxins have their limitations during repeated treatment cycles since they may 
induce an immune response, ranging from fever to kidney toxicity and vascular-leak-
syndrome [88]. Next generation toxins are of human origin, such as human RNAse 
(angiogenin) [89], kinases (DAPK2) [90] or serin proteases (Granzyme B) [91, 92]. 
Human toxins are smaller than ETA’ which is favorable for efficient protein expression 
and presents an advantage for tissue penetration during solid tumor treatment [31, 68, 69, 
93-96]. 
1.2.2 Monoclonal antibodies 
Antibodies are part of the natural immune reaction and responsible to mark foreign 
substances or mutated cancer-related protein structures on cells [97]. In cancer therapy, 
antibodies are used to detect tumor-specific target structures. While the idea of targeted 
cell toxins was already phrased by Paul Ehrlich in the 1800s [98], it was impossible to be 
realized until the invention of hybridoma technology [99], which was a huge mile stone in 
the field of specific recombinant mAB development. Hybridoma technology uses 
immunized mice to isolate antibody-secreting B-cells which are then fused to immortal 
myeloma cells (cancer B-cells) for antibody production.  
Murine as well as human mABs belong to the immunoglobuline (Ig) superfamily [97]. An 
Ig consists of four poly-peptide chains with two identical light chains (L-chain) and two 
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identical heavy chains (H-chain) which are covalently inter-linked via disulfide bridges 
[97]. Each chain is divided into a constant region (C-region) and a variable region 
(V-region). The constant heavy chain (CH) has three domains (CH1, CH2, CH3), whereas the 
variable chain has just one domain (Figure 1-1). V-regions of both chains (VH and VL) are 
divided into three hypervariable regions, denoted complementarity determining regions 
(CDRs) which are stabilized by four genetically conserved framework regions (FWRs) 
with ȕ-sheet structure [100, 101]. These CDRs are the specific antigen binding sites and 
identically presented on the two arms of the Y-shaped antibody protein. Antibody 
specificity is mainly determined by the amino acid sequence of the CDRs, whereas the 
three domains of the C-region mediate effector functions, such as the activation of the 
complement system or binding to surface receptors of macrophage.  
The high level of immunogenicity in first-generation recombinant mABs, caused by their 
hybridoma technology-related murine origin, often resulted in a human anti-mouse 
antibody (HAMA) immune response during clinical studies [102]. HAMA is amplified 
when a therapeutic is applied repeatedly and antibodies are neutralized before they can 
take effect. This may cause severe side effects, from fever to life-threatening renal failure. 
Moreover, in vivo tumor penetration was impaired by the large size of full-length 
antibodies (150 kDa) [103]. Since 1975, the rapid progress in recombinant DNA 
technologies and antibody engineering has contributed fundamentally to overcome the 
problems of size and immunogenicity. Recombinant molecular biological techniques 
allowed the artificial in vitro generation of genetically modified antibody fragments with 
higher binding affinity, stability and less immunogenicity. To reduce antibody size and to 
improve mobility and diffusion properties through tumor tissue, different antibody 
fragments can be designed for therapeutic use [97, 104]. Besides the full-length antibody 
(150 kDa), monovalent Fab fragments (fragment of antigen binding, 50 kDa) are produced 
with protease treatment [105]. Another option are bivalent F(ab)2 fragments (100 kDa) [97] 
or monovalent single chain fragment variables (scFv) (Figure 1-1) [97, 106]. With only 
25 kDa, recombinant scFv molecules are the smallest antibody fragments. They consist of 
protein heterodimers with associated variable domains of VH and VL chains which are 
connected by a glycine-serine linker (GS-linker) for stabilization and proper folding. 
 
Introduction 
 
 
11 
 
Figure 1-1 Schematic drawing of monoclonal antibody, F(ab’)2fragment and scFv to illustrate the 
structure of immunoglobulins (Ig) and derived antibody fragments. 
(A) shows the monoclonal full-length antibody (150 kDa) marked with its important regions: CDR = 
complementarity determining region (hypervariable regions), L-chain = light chain (yellow), H-chain = 
heavy chain (blue), C-region = constant region (red arrow), V-region = variable region (red arrow), VL = 
variable light chain, VH = variable heavy chain and the three constant domains of the heavy chain CH1, CH2, 
CH3. (B) The F(ab’)2 fragment (50 kDa) shows two fragments of antigen binding connected via a disulfide 
bridge. (C) The scFv (single chain fragment variable) as the smallest recombinant antibody (25 kDa) linked 
with a glycine-serine (GS) linker for correct folding and stability. 
To minimize the HAMA immune reaction caused by murine recombinant antibodies, 
second-generation chimeric antibodies are constructed by exchanging the murine C-region 
with a human sequence. Third-generation humanized antibodies are created by murine 
CDR-grafting into a human antibody framework. These antibodies still cause an immune 
reaction against the residual murine portion (HACA = human anti-chimeric antibody) or 
against allotypic epitopes and glycosylation of the foreign human C-region 
(HAHA = human anti-human antibody) [107, 108]. Nevertheless, these antibody formats 
are preferable since they only result in low antibody titers and may still be used for 
therapeutic applications. Latest-generation antibodies are composed of completely human 
antibody sequences acquired by immunization of transgenic mice carrying human Ig genes 
[109] or via isolation from human phage display libraries [110, 111]. 
All mentioned molecules can be constructed by means of recombinant antibody 
technologies, with the option for immunotoxin expression and in vitro as well as in vivo 
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analysis. For this thesis, only scFv antibody formats were utilized. Their low molecular 
size supports rapid and efficient tumor penetration but results in a shorter circulation time 
due to renal clearance from the system, which occurs up to about 60-70 kDa [112]. Larger 
constructs are cleared through the digestive system and consequently have a longer 
retention time [113]. Recombinant scFv antibodies lack the functional Fc effector moiety 
[114, 115] and are easy to produce in large high-quality quantities by means of prokaryotic 
and eukaryotic expression systems. 
Essential parameters to choose a suitable molecule for tumor targeting are: (a) High 
specificity, (b) missing cross-reactivity towards undiseased tissues, and (c) high affinity 
(preferably in the low µmolar and nmolar range during in vivo targeting) [116]. 
1.3 Phage display technology 
Phage display technology is a powerful, fast and efficient tool to select specifically binding 
antibodies or scFv fragments (also Fab fragments) against almost any antigen [111], for 
use in targeted immunotherapy or diagnostic optical imaging techniques. In contrast to the 
hybridoma technology [99], phage display is performed completely in vitro. A huge 
advantage of this technology is the potential to construct large phage libraries with high 
sequence diversity [110, 117]. Compared to traditional approaches, it allows for in vitro 
screening and selection of billions of scFv fragments or peptides/proteins to identify lead 
candidates of monoclonal therapeutic antibodies [110, 111, 118]. Moreover, it facilitates 
the construction of recombinant antibodies with a completely human framework, thus 
minimizing adverse immune reactions [118]. It is distinguished between immunized 
libraries constructed from antigen-reactive B-cells or naïve libraries created from B-cells 
without antigen contact [111]. In addition, CDRs can be artificially mutated to enhance 
diversity by means of polymerase chain reaction (PCR) and randomized oligonucleotide 
primers [119]. Once high-affinity antibodies have been identified from a phage library, 
their synthesis is straightforward and can be optimized by conjugation or cloning [120]. 
Besides the described system of antibody phage display (1.3.1, 1.3.2, 1.3.3), this method 
has also been established on yeast or ribosomes [121]. 
1.3.1 M13KO7 bacteriophage 
Phage display technology is based on the fusion of a scFv antibody to a bacteriophage coat 
protein where the phage is responsible for presenting the scFv antibody for selection [122]. 
The M13KO7 bacteriophage (Figure 1-2), used in this thesis, is a ssDNA virus, and 
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belongs to the filamentous non-lytic bacteriophage that infects gram-negative bacteria, 
such as TG1F
+
 E.coli. M13KO7 decreases bacterial growth but keeps the host cell intact 
while producing and secreting scFv-phage particles into the surrounding medium. 
M13KO7 phage particles have a diameter of 6.5 nm and are 939 nm long with a viral mass 
of 16.3 kDa [123]. Its genetic information is contained on a circular ssDNA of 
6407 nucleotides encapsulated inside the phage coat proteins. It encodes eleven proteins 
(pI - pXI) responsible for the coat proteins (pIII, pVI, pVII, pVIII, pIX), phage assembly 
(pI, pIV, pXI) and DNA replication (pII, pV, pX). Its flexible cylinder-shaped body is 
composed of approximately 2700 copies of coat protein pVIII and is capped by each five 
copies of the minor coat proteins pIX and pVII on one side, and by each five copies of pVI 
and pIII on the other side (Figure 1-2A). For most phage display applications, the pIII coat 
protein is N-terminally fused to a peptide, protein or scFv fragment, which is then 
presented on the phage particle exterior for selection. Moreover, the pIII protein is required 
for infection of the TG1F
+
 E.coli bacteria carrying the conjugative F-plasmid (F = fertility 
factor), which allows expression of F-pili essential for M13KO7 absorption. After 
attachment of the phage coat protein pIII to the tip of the F-pilus, it is drawn inwards; the 
phage genome is injected and translocated into the cytoplasm [124]. The complementary 
strand of the ssDNA is synthesized by the bacteria which results in a supercoiled dsDNA 
template for replication and protein translation inside the host cell. Proteins pVII, pIX, 
pVIII, pIII and pVI are directed to the periplasmic membrane where they are assembled 
and subsequently secreted after completion [125]. The oxidizing environment within the 
periplasm ensures correct folding and disulfide bound formation of fusion proteins for 
phage display. Phage proteins pII, pX and pV remain in the cytoplasm since they are only 
engaged in the replication process. Genetic information of the different scFv fragments 
fused to the pIII proteins is encoded on a plasmid-based phagemid. This merely carries the 
gene for the scFv-pIII fusion but none of the other phage genes and has been transformed 
into TG1F
+ 
E.coli. Phagemids have an E.coli origin for expression as well as a phage 
origin locus and an ampicillin resistance. Additionally, a multiple cloning site is integrated 
in front of the pIII gene (gIII) to insert the scFv antibody fragment. The phagemid is 
missing all genetic information for assembly, coat proteins and DNA replication thus 
lacking the ability to build phage particle on its own. To achieve that, phagemid-containing 
bacteria are infected with “empty” helperphage which complements the missing genes 
including the pIII wild-type protein [126] thus combining genotype and phenotype. This 
process is called phage rescue. This non-complex phagemid system simplifies any 
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subsequent cloning procedures and enables the construction of larger and more diverse 
libraries. Moreover, this system allows adjusting the valency of the scFv-presenting phage. 
 
Figure 1-2 Schematic of filamentous M13 bacteriophage and E.coli with F-pili.  
(A) Schematic drawing of filamentous M13 bacteriophage showing coat proteins pIII, pVI, pVII, pVIII and 
pIX as well as the ssDNA within the phage body (drawing adapted from [123]), (B) Electron microscopic 
picture of E.coli bacterium displaying F-pili [127], (C) Electron microscopic picture of filamentous 
bacteriophage [128].  
Two types for M13KO7 phage exist: (a) Monovalent M13KO7 helperphage, which still 
contain genetic information for the pIII wild-type protein, can incorporate between zero 
and one copies of the pIII-scFv fusion protein during assembly [129], and (b) polyvalent 
M13KO7ΔpIII hyperphage, being a helperphage with a deletion of the pIII gene, can 
integrate five copies of pIII-scFv fusion protein during assembly to avoid heterogenicity 
[130]. Since the helperphage genome encodes the wild-type coat proteins, typically over 
90% of rescued phages do not display the library protein at all. Nevertheless, monovalent 
display by using phagemid vectors may be essential when selecting antibodies of higher 
affinity [131]. 
1.3.2 In vitro selection procedure 
The in vitro selection process of specifically binding scFv fragments by means of phage 
display is called biopanning. The selective antigens (purified proteins, viable cells, 
membrane fractions or sugars) are immobilized on immunotubes or microtiter plates 
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(MTPs) with maxisorb surfaces [110, 111, 119, 132-134]. Phage particles displaying the 
scFv-pIII fusion protein (scFv-phage) are expressed in TG1F+ bacteria and incubated on 
these antigen target structures. Unbound or low-affinity scFv-phage particles are removed 
during stringent washing cycles and bound antibody fusion proteins can be eluted via 
pH-shift. To complete the biopanning cycle, obtained scFv-phage binders are amplified by 
infection with fresh TG1F+ E.coli and the selection cycle is repeated three times [135, 
136]. Washing stringency is increased with each selection round whereas the concentration 
of immobilized antigen is decreased. Figure 1-3 illustrates a biopanning selection cycle as 
performed during this work. 
 
Figure 1-3 General schematic illustration of phage display panning procedure for the selection of 
specific scFv-phage particles.  
(A) Infection of unselected TG1F+ E.coli library, transformed with the scFv-carrying phagemids. Either the 
monovalent M13KO7 helperphage or the polyvalent M13KO7ΔpIII are used for infection of the library. (B) 
Amplification of scFv-phage particles. (C) Subtractive selection of scFv-phage molecules that show 
unspecific binding to a depletion antigen (e. g. peripheral blood mononuclear cells (PBMCs)); unspecifically 
bound scFv-phage particles are discarded. (D) Positive selection of scFv-phage particles that specifically bind 
to the target antigen. (E) Unbound or weakly bound scFv-phage molecules are removed by several stringent 
washing steps supplemented with different detergents if necessary. (F) Specifically bound scFv-phage 
proteins are eluted via pH-shift and used to infect “empty” TG1F+ E.coli to amplify fresh scFv-phage 
particles for the next panning round. In order to isolate specific scFv-phage binders, the shown selection 
cycle is repeated three times. 
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Biopanning is ideally conducted on a certain homogeneous target protein in form of 
purified protein [137] but heterogeneous panning strategies are also feasible [134, 138]. 
Since surface proteins are integrated into the lipid layer of the membrane, selections are 
then performed on whole viable cells to preserve their native protein conformation or on 
membrane fractions which imitate the intact cell surface [134, 138]. A great advantage of 
selections on purified protein is that only one protein is targeted compared to the entire 
repertoire of membrane proteins, phospholipids, polysaccharides and glycoproteins on 
living cells or membrane fractions. Heterogeneous conditions favor enrichment of 
unspecific scFv-phage particles which can be removed by means of subtractive selection 
on different cells as well as vigorous washing [138]. A complementary selection strategy is 
concentrated on the isolation of internalizing scFv-phage particles since this attribute is 
essential for therapeutic approaches [139], such as immunotoxins or other antibody 
conjugates. All eukaryotic cells are able to take up extra cellular substances in vesicles via 
endocytosis. Ligand-binding receptors then transport cytolytic antibody immunoconjugates 
to their target location within the cell. Internalizing antibodies are best selected on viable 
cells where they mostly target surface proteins with a very high expression density. 
Isolation of a desired and specific scFv antibody from an antibody phage library may 
require a combination of different selection methods. 
1.3.3 Tomlinson Libraries I and J 
High diversity (normally 10
9
 - 10
11
 clones/library) and quality of phage display libraries 
are essential for successful antibody selection [140-142] by phage display. It is generally 
distinguished between naïve and immunized libraries. Immunized libraries are constructed 
from V-genes of mice [128] or other animals whereas naïve libraries are either derived 
from natural human non-immunized or synthetic V-genes [143]. Random rearrangement of 
VH and VL genes of naïve human B-cells, enables the design of highly diverse libraries 
consisting of scFv antibody fragments. The probability to isolate a specific high-affinity 
binding peptide from an antibody phage display library increases with the structural 
diversity of the library [144]. Naïve libraries are advantageous over immunized libraries 
which are limited in their diversity [145]. Within several days, binders against any 
arbitrary antigen may potentially be generated from the same naïve phage library. This 
includes toxic substances, haptens and carbohydrates as well as intra- and extra-cellular 
proteins of cells and viruses, or body-own antigens which evade immunization through 
natural tolerance mechanisms [141]. 
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This work uses the Tomlinson phage libraries I and J [135] for the isolation of recombinant 
monoclonal scFv antibody fragments. Both libraries are naïve semisynthetic filamentous 
phage display libraries of human origin with over 100 million diverse scFv fragments. 
Library size is only limited by transformation efficiency (10
7
 - 10
9
 clones/library) of the 
pIT2 phagemid vector (Figure 1-4) into the E.coli strain TG1F+ [135]. Each single chain is 
constructed of a polypeptide consisting of a VH and VL domain connected by a flexible 
synthetic glycine-serine [(Gly4Ser)3] linker [110] (1.2.2, Figure 1-1). All scFvs bind to 
protein A and L for detection, purification or immobilization purposes and in addition 
carry a myc-tag and His6-tag. In order to maximize side chain diversity, CDRs of library I 
have been diversified via DVT triplets [135, 146], in a total number of 18 residues 
(D = adenine, guanine, thymine, V = adenine, guanine, cytosine, T = thymine). This results 
in a library size of 1.47 x 10
8
 clones with 96% insert-carrying plasmids. For library J, CDR 
diversity was artificially enhanced by NKK triplet mutations (N = any base, K = cytosine, 
guanine) to a library size of 1.37 x 10
8
 clones, comprising 88% insert-carrying plasmids. 
As a drawback, NNK diversification generates the amber stop triplet TAG with a statistical 
probability of 3% [147]. Besides incorporated side chain diversity both libraries are based 
on a single human framework with VH (V3-23/DP-47 and JH4b) [148, 149] and VΚ 
(O12/O2/DPK9 and JΚ1) [149, 150]. Expression patterns of these V-gene families 
dominate the human antibody repertoire [151] and feature high stability [152]. During 
scFv-phage expression in the E.coli suppressor strain TG1F+ the amber stop codon is 
translated as glutamine. This is necessary since the pIT2 phagemid system includes a 
systematically inserted TAG triplet that theoretically separates the scFv from the pIII 
fusion protein during soluble protein expression in a non-suppressor strain, such as 
HB2151 E.coli. Random amber stop codon insertion within the CDRs imposes a 
disadvantage during soluble protein production resulting in early protein termination or 
translation of non-sense proteins. Consequently, TAG triplets in CDRs have to be removed 
via site-directed mutagenesis before expression of soluble proteins. During this procedure 
thymine is exchanged against cytosine, thus encoding for a glutamine triplet instead of an 
amber stop codon [153, 154]. Protein expression in the pIT2 phagemid (Figure 1-4) is 
under the control of the IPTG-inducible lac promoter located up-stream of the ribosomal 
binding site (RBS). Down-stream of that, the N-terminally located bacterial pectate lyase B 
leader signal sequence (pelB) is responsible for transporting the expressed proteins into the 
periplasmic space for subsequent secretion of scFv-phage particles. 
Introduction 
 
 
18 
 
Figure 1-4 Schematic illustration of pIT2 phagemid and corresponding expression cassette for 
production of scFv-phage particles.  
(A) pIT2 phagemid vector for production of scFv proteins fused to the pIII M13KO7 phage coat protein in 
TG1F+ E.coli as well as for soluble protein production in HB2151 E.coli without pIII-fusion controlled by an 
IPTG-induced lac-operon. Soluble protein expression ends after the His6-tag and myc-tag as shown in (B). 
(B) Schematic of pIT2 expression cassette for prokaryotic expression of soluble proteins in HB2151 E.coli. A 
pelB signal peptide is located up-stream of the scFv sequence mediating periplasmic protein expression and 
eventual protein secretion into the culture medium. Within the scFv, the heavy chain VH is connected to the 
light chain VL through a glycine-serine (GS) linker peptide. IPTG-inducible scFv expression is controlled by 
a lac-operon. Down-stream of the scFv sequence a His6-tag and myc-tag are integrated followed by the amber 
stop triplet TAG to separate the scFv and pIII phage coat protein. Potential restriction sites (HindIII, SfiI, 
NotI, XhoI, SalI) for subcloning into other expression vectors are indicated. [135] 
The M13KO7 phage carries a kanamycin resistance so that infected bacteria carrying the 
ampicillin-resistant pIT2 phagemid grow and produce scFv-phage particles only in culture 
medium complemented with both antibiotics; hence uninfected and phagemid-lacking 
bacteria or contaminating organisms are sorted out. 
1.3.4 L3.6pl target cell line 
The pancreatic carcinoma cell line L3.6pl was chosen as phage display target cell line for 
its highly metastasizing properties and the existence of a well-established orthotopic mouse 
model [155]. L3.6pl was developed from the human ductal pancreas adenocarcinoma cell 
line COLO357. This generated the FG cell line (FG = fast growing) after several 
transplantation and selection cycles of in vivo pancreas-liver transplants in nude mice and 
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subsequent in vitro cultivation [156]. FG was then injected into the spleen of nude mice, 
and potentially developed liver metastasis were removed and cultivated in vitro. Several 
repetitions of this process resulted in the L3.6pl which exhibited very aggressive tumor 
growth and extreme potential for metastasis [155]. The L3.6pl-based orthotopic mouse 
model, developed by Bruns et al. [155], has proven useful to treat and image L3.6pl 
tumors, or to examine effects of novel proapoptotic therapeutics on pancreatic tumors [157, 
158]. 
1.3.5 Epidermal growth factor receptor 
Similar to many other cell lines derived from epithelial tumors, the pancreatic cancer cell 
line L3.6pl features an increased over-expression of the epidermal growth factor receptor 
(EGFR) [157, 159] which accounts for a very high proliferation index and inhibited 
apoptosis of malignant cells [160, 161]. EGFR is a membranous glycoprotein 
(MW = 170 kDa) with tyrosine kinase activity integrated into the cell membrane and is 
involved in signal transduction pathways. EGFR over-activation often coincides with 
increased resistance against conventional chemotherapeutic treatment options, as well as 
advanced tumor stages and a reduced survival rate [162]. Binding to an EGFR molecule 
causes dimerization of two receptor molecules, thus inducing autophosphorylation of 
tyrosine residues of the intracellar EGFR tyrosine kinase. This activates a signal 
transduction cascade and mediates the internalization of the EGFR-ligand-complex by 
endocytosis [163]. High internalization capability is also required for potentially 
therapeutic scFv antibodies isolated by phage display throughout this work. Therefore, the 
EGFR and its corresponding well-documented single chain antibody fragment 425(scFv) 
[164], offer an excellent positive control for all binding and internalization processes on 
the L3.6pl cell line used for comparison of the newly isolated scFv binders. 
1.3.6 Monoclonal anti-EGFR antibody fragment 425(scFv) 
During this work, the monoclonal anti-EGFR antibody fragment 425(scFv) [164], binding 
to the EGFR, was used as a positive control. Several studies have proven that anti-EGFR 
mAB can inhibit growth of some EGFR-positive (EGFR+) cell lines in vitro as well as 
EGFR+ tumor growth in transplanted immunodeficient mice [165, 166]. Selective tissue 
treatment was shown, resulting in the mAB IMC225 Cetuximab (Erbitux®) against 
metastasizing colon carcinoma [167]. Cetuximab binds to a different surface epitope of the 
EGFR than 425(scFv) [164, 168]. The latter has not been approved for therapeutic use but 
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has proven very efficient in the lab when used as 425(scFv)-ETA’ immunotoxin on 
EGFR+ cell lines, as for example A431 or L3.6pl [157-159, 169].  
1.3.7 Generation of 14.1(scFv) 
In addition to the clones selected from Tomlinson libraries I and J, the recombinant clone 
14.1(scFv) was characterized in this work. It has originally been isolated from an 
immunized library created from murine B-cells by Beate Stadler at Fraunhofer IME 
(Aachen). Therefore, mice have been immunized, with a total of 1 x 10
7
 L3.6pl cells or 
membrane fractions [134] in combination with GERBU Adjuvant 10, by applying six 
subcutaneous boosts within 13 weeks. Antibody saturation in serum was documented from 
weekly blood samples by ELISA analysis. After 15 weeks, spleens were dissected to 
isolate and prepare mRNA. After subsequent cDNA synthesis of VH and VL genes 
followed by SOE-PCR amplification, the generated scFv antibody fragments were cloned 
into the pHEN4II phagemid via the restriction sites SfiI and NotI and transformed into 
TG1F+ E.coli. The library (size ~10
6
) construction process was carried out according to 
Tur et al, 2003 [134]. Analogous to the method described in chapter 0, the 
pancreas-specific antibody fragment 14.1(scFv) has been isolated on L3.6pl antigen via 
biopanning prior to this work. 
1.4 Protein expression 
1.4.1 Prokaryotic protein expression 
Non-human proapoptotic proteins are often toxic for the host organism when produced in 
eukaryotes. Hence, recombinant cytolytic proteins are usually expressed in prokaryotes 
such as E.coli. This microorganism is one of the most commonly used hosts for the 
expression of recombinant proteins and well-studied as prokaryotic production system. It is 
easy to manipulate on genetic level and uncomplicated to handle during cultivation. 
Recombinant proteins can either be expressed in the cytoplasm or secreted into the 
periplasmic space of the bacteria [170].  
Periplasmic expression: During this process, recombinant proteins are secreted into the 
periplasmic space via the inner membrane by means of signal peptides, such as pelB or 
ompA. The oxidizing environment of the periplasm in E.coli contains disulfide-
oxidoreductases [171, 172] and chaperons [173], which favors the generation of disulfide 
bonds and consequently correctly folded proteins. Moreover, low content of contaminating 
Introduction 
 
 
21 
bacterial proteins presents an advantage for subsequent purification processes. 
Additionally, the periplasm comprises few proteases thus reducing proteolytic degradation 
to a minimum [174]. Improved expression protocols and systems increase production 
efficiency by use of compatible solutes and osmotic stress [175], facilitating the 
accumulation of up to 95% of functional protein in the periplasmic space. Combined with 
high expression vectors, for example pET-derived vectors [171], very high productivity 
rates are attained. Nevertheless, subsequent protein secretion from the periplasmic space 
into the culture medium is not always feasible but strongly depends on protein size and 
culturing conditions that increase membrane porousness. 
Cytoplasmic expression: In comparison to the periplasmic production, the cytoplasmic 
expression produces considerably higher yields during recombinant protein production 
[176, 177]. However, these proteins are mostly stored within the cell as insoluble 
aggregates, known as inclusion bodies (IBs) [178]. Proteins in IBs exist in a denatured and 
cross-linked form with a strongly diminished biological activity of varying degree [178]. 
To reconstruct functional proteins, costly and elaborate back-folding is necessary which 
often leads to low recovery rates of functional protein as well as decreased protein stability 
and diminished aggregating behavior [179]. Nevertheless, the high concentration of 
recombinant protein in IBs can be an advantage, since they also protect proteins from 
degradation by cytoplasmic proteases [180]. 
During human protein production in E.coli, differences of codon usage in prokaryotes and 
eukaryotes have to be considered [181]. When neglected, the effect on translation 
efficiency and folding can be dramatic. Certain E.coli strain derivatives, such as BL21 
Rosetta 2 (DE3), contain the pRARE2 plasmid supplying tRNAs for 7 rare codons (AGA, 
AGG, AUA, CUA, GGA, CCC, CGG) [182] enabling the bacteria to translate human 
triplets; thereby enhancing the yield for expression of mammalian proteins. Another 
limiting factor is the inability of bacteria to accomplish post-translational modifications 
and glycosylation, which may lead to misfolding and disturbed functionality of expressed 
proteins [172]. 
1.4.2 Eukaryotic protein expression 
Alternatively to prokaryotic systems, recombinant protein expression in eukaryotes allows 
the production of a homogenous protein product in high quantity and quality with correct 
post-translational modifications. The existence of glycosylation and diverse other 
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modifications is of utmost importance for subsequent use in clinical applications. In 
addition, expression systems accomplish the production of larger and more complex 
proteins (e. g. 150 kDa full-length mAB). Responsible for proper protein folding and 
functionality are disulfidisomerases and chaperones located in the endoplasmic reticulum 
(ER), which guarantees formation of disulfide bonds as well as clustering of protein 
domains [172]. Moreover, eukaryotic cells secrete recombinant proteins into the culture 
medium when directed by a signal sequence. This renders a continuous protein expression 
possible since the destruction of production cells becomes unnecessary. Media collection is 
sufficient and, due to low level of unwanted proteins, purification is simplified. One 
possible system for the secretion of eukaryotically expressed proteins is the 
pSecTag-derived pMS vector system (2.10) [183], where an N-terminal Ig-Kappa (Igț) 
signal sequence controls secretion of transfected protein from the cells and promotes fast 
production of high amounts of recombinant target protein. By using mutated cell lines, 
unsusceptible towards the catalytic domains of the cytotoxic proteins [184], it is also 
possible to employ eukaryotes for the production of functional recombinant cytolytic 
proteins when modified in their binding activity and cytotoxicity [92, 185]. Commonly 
used mammalian production cell lines are cos7 (monkey kidney cells), CHO (Chinese 
hamster ovary) and the human embryonic kidney cell line HEK293T. HEK293T and cos7 
cells are equipped with the SV40 origin of replication (ori), expressing the large-T antigen 
of the SV40 virus. This supports high-copy production transfected plasmids and is 
especially suitable for transient transfections. 
1.5 Protein tags 
1.5.1 Affinity tags 
In recent years, the field of high-yielding production of recombinant heterologous proteins 
has grown rapidly. To facilitate purification of a single target protein from a heterologous 
protein solution, protein fusion tags, called affinity tags, are applied. Commonly, these tags 
are employed for specific and efficient affinity purification by means of chromatography, 
for example during immobilized metal-ion affinity chromatography (IMAC), or 
immunodetection of proteins during Western blotting or analysis via enzyme-linked 
immunosorbent assays (ELISA). The most frequently used affinity tags, their use and 
amino acid sequence are listed in Table 1-4 below. 
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Table 1-4 List of common affinity tags including matrices, sequences and molecular size [186] 
Name Matrix Sequence Size (kDa) 
Polyarginine-tag 
(poly-arg) 
Cation-exchange resin RRRRR 0.80 
Polyhistidine-tag 
(poly-His) 
Ni2+-NTA, Co2+-CMA 
(Talon) 
HHHHHH 0.84 
FLAG-tag Anti-FLAG mAB DYKDDDDK 1.01 
Strep-tag II Strep-Tactin WSHPQFEK 1.06 
c-myc-tag mAB EQKLISEEDL 1.20 
S-tag S-fragment of RNaseA KETAAAKFERQHHMDS 1.75 
HAT-tag 
Natural histidine affinity tag 
Co2+-CMA 
(Talon) 
KDHLIHNVHKEFHAHAHNK 2.31 
Larger affinity fusion tags that are well-established are: 3 x - FLAG-tag, 
calmodulin-binding peptide, cellulose-binding domains, streptavidin-binding peptide 
(SBP), chitin-binding domain, glutathione S-transferase (GST) or maltose-binding protein 
[186]. Moreover, the Fc-part of recombinant mABs may be utilized likewise as affinity tag. 
1.5.2 Reporter proteins 
Literature mostly features three major reporter systems. In 1980, the first article was 
published about reporter fusions with ȕ-galactosidase (lacZ gene) [187] used to determine 
tissue-specific promoter activity, to perform blue/white screening by indicating bacterial 
colonies carrying a certain DNA region or to monitor transcriptional regulation in various 
biological processes [188]. Furthermore, luminescence-based reporter systems, for 
example in form of firefly luciferase (luc) or bacterial luciferase (luxCDABE), are state of 
the art [188, 189]. The third category of reporter proteins comprises the fluorescent 
proteins; such as the green fluorescent protein (GFP) and its derivatives, or flavin 
mononucleotide-based fluorescent proteins (FbFPs). They enable rapid and simple 
detection or even quantification of molecular and genetic occurrences since the system 
provides an easily measurable signal output after protein expression [190]. Fluorescence 
proteins have been used to study biofilm formation, protein expression in prokaryotes and 
eukaryotes in vitro as well as in vivo. 
1.5.2.1 Fluorescent reporter tags 
Green fluorescent protein (GFP) and its derivatives: Conventional fluorescent reporter 
proteins, such as GFP [191] and its derivatives are state-of-the-art and often used as fusion 
tags for detecting recombinant proteins during cultivation, screening and bioprocess 
optimization; or to analyze localization, movement and interaction of proteins in vitro and 
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in vivo. GFP was first described in 1961 [192, 193] as a protein originated from the jelly 
fish Aequorea Victoria emitting green fluorescence after excitation with blue or ultra violet 
light. Currently, GFP is an important tool for gene-specific fusions to investigate protein 
expression or protein targeting in living cells, tissue, or organs. Its protein sequence 
consists of 238 amino acids with a molecular mass of 26.9 kDa [191]. The chromophore, a 
p-hydroxybenzylideneimidazolinone, is formed by an autocatalytic reaction starting from 
the tripeptide sequence Ser65–Tyr66–Gly67 within the native protein structure. For 
fluorescence formation, GFP folds into a nearly native conformation where the 
imidazolinone is formed by nucleophilic attack of the amide of Gly67 on the carbonyl of 
residue 65, followed by dehydration. The molecular oxygen dehydrogenates the α-ȕ-bond 
of residue 66 to connect its aromatic group with the imidazolinone [191]. Afterwards, the 
chromophore acquires visible absorbance and fluorescence ability. This mechanism 
requires atmospheric oxygen for fluorescence development. Fluorescence of anaerobically 
preformed GFP develops with a simple exponential time course only after air is readmitted. 
This means that fluorescence formation does not correlate with the concentration of the 
GFP itself. Considering the secondary structure of GFP, almost the whole primary 
sequence is used to build an 11-stranded ȕ-barrel threaded by an α-helix running up the 
axis of the cylinder (Figure 1-5). The chromophore is attached to the α-helix and is buried 
in the center of the cylinder. A large number of polar groups and structured water 
molecules are adjoining the chromophore [191]. The excitation maxima of wild-type GFP 
occur at wavelengths 395 nm and 475 nm resulting in an emission at 509 nm. GFP mutants 
have been generated with optimized features or variations of fluorescent proteins have 
been discovered in other organisms, displaying other fluorescence spectra, such as CFP 
(cyan), YFP (yellow), mCherry or dsred (red), eGFP (enhanced GFP), color-switching FPs 
and many others [194]. The GFP gene itself comprises all necessary information for 
post-translational synthesis so that fluorescence formation is not based on external 
jellyfish-specific enzymes even though it requires an oxygen-sufficient environment.  
However, some drawbacks discussed in literature may arise during the use of GFP as 
reporter protein. This may render on-line monitoring a challenging affair where fluorescent 
proteins are detected using non-invasive, specific and sensitive devices that monitor 
product formation and localization in vivo. One disadvantage of fluorescent proteins, based 
on GFP, is their relatively high molecular mass (26.9 kDa) compared to typical target 
proteins which might impose stress on the host metabolism during fermentation. Moreover, 
its oxygen-dependency may result in a lag-time between expression and fluorescence 
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detection rendering quantitative real-time measurement impossible. Detection of the GFP 
fluorophore can even be completely inhibited in an oxygen-limited or anaerobic 
environment [191, 195-197]. As a conclusion, on-line measurement of GFP is feasible, but 
not ideal in oxygen-insufficient fermentation systems or ones that yield active protein 
products, particularly for products with a low molecular weight. Moreover, hydrogen 
peroxide generation via oxidation with O2 during fluorophore formation, at a 
stoichiometric 1 : 1 ratio with mature GFP, can be problematic during high-yield protein 
over-expression, since it imposes stress and damage to the host cell [191]. 
Flavin mononucleotide-based fluorescent proteins: Recently, flavin mononucleotide 
(FMN)-based fluorescent proteins (FbFPs), such as the blue light receptor Evoglow®, 
were developed as an alternative to GFP. FbFPs are derived from the blue light receptor of 
the light-oxygen-voltage family and are widely spread in prokaryotic and eukaryotic 
organisms as well as in plants [198, 199]. In contrast to plants, the physiological function 
of the receptors is practically unknown in bacteria. FMN (phototropin) serves as 
chromophore excitable by blue light. Following excitation, the thiol group of a preserved 
and photoactive cysteine residue bonds with FMN, thus forming a FMN-cysteine-C(4a)-
thiol adduct. One example is the bacterial YtvA receptor from B. subtilis (Figure 1-5) 
[200]. It has a length of 261 amino acids including an N-terminal photoactive LOV-domain 
(residues 25 - 126) and a C-terminal sulfate transporter and anti-sigma factor antagonist 
domain (residues 147 - 258) carrying a nucleotide triphosphate-binding motif [199]. When 
excited at 450 nm, these FbFPs emit weak intrinsic auto-fluorescence at 495 nm. Using 
genetic manipulation, the respective photoactive cysteine was replaced by a non-polar 
alanine to enhance fluorescence performance as a result of reduced fluorescence quenching 
[200, 201]. In order to enhance fluorescence intensity in E. coli the N-terminal LOV-
domain was adjusted to E.coli usage [200]. In comparison to GFP, which is limited to 
biological systems containing sufficient cellular oxygen, FbFPs also fluoresce under 
oxygen-limited and even anaerobic conditions, thus rendering in vivo labeling and 
detection without oxygen possible [200]. Furthermore, the genetically modified FbFPs are 
much smaller, only 15.7 kDa, (42% of GFP by molecular weight) [196, 200, 202] which 
presents an advantage for the host organism during protein synthesis. 
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Figure 1-5 Illustrated protein structure of GFP and YtvA LOV domain from Bacillus subtilis 
exemplarily for the FMN-based fluorescent proteins. (A) Figure displays the 11-stranded ȕ-barrel (green) 
and the chromophore attached to the α-helix in its center (brown) [203]. (B) Its FMN-binding domain 
consists of five ȕ-sheet structures (blue) that are flanked by two α-helices (red and yellow). The chromophore 
is indicated in green, and the photoactive cysteine in the center is colored red [200]. 
1.5.3 Synthetic labels and SNAP-tag technology 
Artificial post-expression coupling of a target protein to a particle, small molecule or dye, 
is an essential method for some targeting approaches. Conveniently, proteins and peptides 
naturally display four different reactive groups that are used for chemical conjugation, such 
as amino, sulfhydryl, carboxyl and carbonyl groups in glycoproteins. These groups can be 
modified with a variety of available cross-linking reagents. Such labeling reactions are 
random and may change or interrupt protein activity. Especially small scFv antibody 
fragments often do not tolerate chemical modifications as they consist only of the antigen 
binding variable domains where the majority of residues is involved in antigen recognition 
or essential for scFv structure. Due to difficulties in site-specific coupling causing 
alterations in protein activity, scFv antibodies are less frequently used for post-expression 
labeling than mABs or peptides, despite their excellent affinity, specificity and flexibility 
to the respective antigen. Therefore, coupling via predefined residues has been introduced, 
such as cysteine residues or unnatural amino acids, with unique reactive groups. Tag-based 
systems are available for the labeling of proteins with fluorophores including the Halo-tag 
and the lumio-tag [204, 205] or enzyme-based tags including trans-linked systems by the 
biotin holoenzyme synthetase, sortases and the Sfp phosphopantetheinyl transferase [206-
208]. Still, the use of these systems for in vivo applications is limited since they are not 
broadly applicable, unspecific and labor intensive. 
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Another excellent alternative to direct genetic labeling is the SNAP-tag (Figure 1-6) [209]. 
It is an artificial post-expression labeling technique and allows coupling of a protein of 
interest to all kind of dyes, nanoparticles, radioactive labels or even the generation of 
theranostics. The SNAP-tag is a genetically engineered version of the human DNA-repair 
enzyme O(6)-alkyllguanine DNA alkyltransferase (hAGT) [210], which allows substrates 
containing O(6)-benzylguanine (BG) derivatives to be covalently linked to a recombinant 
protein thus providing a strategy to equip an antibody with various imaging reagents [211]. 
The benzylguanine (BG) derivates are substituted with a label at position 4 of the benzyl 
ring and guanine is cleaved off during the covalent labeling process. The label itself is 
chemically attached to the free amines of BG which react with commercially available 
activated carboxyl esters, such as N-hydroxysuccinimide (NHS) attached to a fluorescent 
dye [209, 212]. Its molecular size is approximately 20 kDa and either N- or C-terminal 
fusion proteins can be generated. In its natural function, hAGT supports DNA integrity. It 
scans DNA for alkyl adducts on guanine and thymine bases and removes them by a 
nucleophilic substitution reaction, thus inactivating the enzyme followed by its degradation 
[213]. 
 
Figure 1-6 Schematic illustration of SNAP-tag coupling mechanism. [214] 
This technology has been employed in a multitude of experimental applications ranging 
from labeling of proteins within living cells with cell-permeable BG-fluorophore dye [212] 
to protein immobilization on BG-modified chip surfaces [215]. Specific scFv antibodies 
labeled with the near infrared dye BG-747 were shown to accumulate rapidly and 
specifically at tumor sites. Its small size ensured efficient renal clearance, thus generating a 
much higher signal-to-background ratio than the full-length antibody [158]. The coupling 
reaction is highly efficient and specific for any kind of substrates modified for covalent 
binding (e. g. particles, radioactives or fluorescent dyes). Similarly to the SNAP-tag, an 
O(2) benzylcytosine reactive tag, called CLIP-tag has recently been described [216]. 
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1.5.4 Tryptophan and potential tryptophan-based tags 
Although FbFPs are an improvement over GFP, considering its suitability for anaerobic 
environments, even smaller fluorescent protein tags are preferable to further reduce the 
impact on host strain metabolism. This would allow more resources to be committed to the 
production of the recombinant target protein. In general, larger tags are less favorable due 
to increased protein interactions, disturbance of proper protein folding or production 
related stress on the host organism. One possible solution is to develop novel and even 
shorter tags based on the auto-fluorescent properties of aromatic amino acids such as 
tryptophan (W), tyrosine (Y) or phenylalanine (F) [217]. Within these amino acids, 
delocalized π-electrons in the aromatic ring structures are excited to higher energy states 
when exposed to certain wavelengths of light, emitting fluorescence in the UV-range when 
returning to their ground state. All three amino acids depict hydrophobic properties but 
feature differing Stoke’s shifts. Tryptophan displays a larger Stoke’s shift (~70 nm) than 
the other two aromatic amino acids which is combined with a relatively high quantum 
yield with an excitation maximum at 280 nm and an emission maximum at 350 nm.  
These characteristics make tryptophan a suitable choice for the design of a novel protein 
reporter tag with auto-fluorescent optical activity. Moreover, its fluorescence is highly 
sensitive to the properties of the surrounding environment (i. e. polarity) and arrangement 
of neighboring amino acids [218]. Spectral characteristics of tryptophan may also be 
enhanced in the presence of tyrosine [219] since it is able to share its delocalized 
π-electrons. Most proteins are statistically likely to contain tryptophan but the number and 
distribution of residues vary [220]. Tags with tryptophan residues have previously been 
used to improve protein isolation by creating a hydrophobic affinity patch rather than a 
fluorescent label [221]. 
1.6 On-line monitoring of micro-scale shaking cultures 
Generation of novel pharmaceutically relevant target proteins has led to a constantly 
growing demand for efficient and high-throughput screening systems in the field of 
molecular biotechnology. Complex gene and protein libraries allow the identification of 
new lead candidates for the drug industry by initial screening [222]; for example in 
microtiter plates (MTPs) followed by scale-up for industrial production. MTPs are 
frequently used for the high-throughput parallel characterization of microbial cultures 
under identical conditions, small-scale screening and as a lab-scale model for shaking 
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bioreactors. Simple and functional design makes them a cost-efficient and fast tool for 
parallel experiments (MTPs with 48, 96, 384 and 1536 up to 3456 wells) during multiple 
fermentation parameter analysis, such as measurement of temperature, oxygen transfer 
rates (OTR), dissolved oxygen tension (DOT), pH value and biomass. The recently 
developed BioLector® technology [223] even allows monitoring of continuously shaking 
E.coli cultures via on-line measurements using specially adapted MTPs [224, 225]. 
In the late 1990s, the first shaking high-throughput systems were engineered from 
Erlenmeyer flasks equipped with standardized pH and DOT sensors for real-time 
monitoring [226] in form of a fed batch system connected to feeding lines consisting of 16 
parallel flasks (20-300 mL). The Respiration Activity Monitoring System (RAMOS) is 
another advanced shaking system [227] where the head of the flasks is equipped with an 
oxygen and a pressure sensor to assess the oxygen transfer rate (OTR), carbon dioxide 
transfer rate (CTR) and the resulting respiratory quotient (RQ). RAMOS can operate up to 
eight flasks simultaneously on an orbital shaker with working volumes of 10 – 50 mL in 
250 mL flasks. To reduce developmental periods and to increase throughput, the design of 
new micro bioreactors with minimized sample volumes and higher number of 
simultaneous samples was necessary. This resulted in a progression from Erlenmeyer 
flasks to microtiter plates [228], for example systems consisting of 48-well (SimCell 
system, Bioprocessors Inc., MA, USA) [229] and 24-well (Micro-24 system, Microreactor 
Technologies Inc., CA, USA) [230]. MTPs were developed that were aerated by rising 
bubbles assisted by additional orbital shaking. Nevertheless, integration of on-line sensors 
into those bubble columns proved difficult due to strong foaming and uneven oxygen 
distribution. With the BioLector® technology [223, 224], used in this work as a modified 
device, 96 samples and more can be analyzed in parallel at a sample volume of 
100 - 200 µL and continuously shaken during measurements. Supplementary equipment, 
such as multipipetes, pipetting robots, microscale readers and autosamplers, ensure 
reproducible results [228]. Aeration of microtiter cultures is primarily influenced by the 
ratio of gas-liquid exchange area to volume, and secondly by surface tension. Latter 
counteracts liquid movement and flow under impact of g-forces caused by orbital shaking 
so that the air-liquid surface area is sustainably reduced in wells of less than 8 mm 
diameter. Nevertheless, a satisfactory OTR can be achieved in small vessels, when small 
volumes are combined with high rotational velocity thus antagonizing surface tension 
[228]. An additional essential aspect of fermentation systems in MTPs, and subsequent 
quantitative and statistical analysis, is the sealing method of the individual wells to prevent 
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cross-contamination and to limit evaporation. Very often semi-permeable adhesive plastic 
foil is successfully used, ensuring sufficient oxygen exchange from the outside and tight 
well closure to minimize water loss at the same time. The production of recombinant 
protein products, during cultivation in non-invasive fermentation systems, is often 
monitored using fluorescent fusion proteins [231], classically GFP or one of its derivatives. 
Common measurement systems for fluorescence intensity documentation are microplate 
readers. 
1.7 Objective 
The thesis at hand is focused on two different topics:  
(1) The phage display-based isolation of novel recombinant scFv antibodies as potential 
tools for early diagnosis or as prospective therapeutic approach against metastasizing 
pancreatic cancer, and  
(2) the design of a short optically active reporter tag based on the auto-fluorescent 
properties of tryptophan for on-line monitoring of product formation during 
micro-scale fermentation. 
In the first part of this work, the primary scientific goal aims at the development of novel 
recombinant scFv antibodies for possible future application as efficient diagnostic tools in 
early stage tumor detection or post-operative disease monitoring of pancreatic cancer. 
Moreover, such novel recombinant proteins provide the opportunity for a therapeutic 
approach to specifically remove residual metastatic pancreatic carcinoma cells thus 
significantly increasing the average survival rate and life quality of patients. 
Pancreatic cancer is characterized by a mortality rate of nearly 100%. This is due to a high 
relapse rate, as a result of very aggressive tumor metastasis and incomplete elimination of 
malignant cells after treatment, as well as insufficient reliable options for early diagnosis. 
Extensive surgery, radiation and chemotherapy are state-of-the-art treatments but 
unspecific and hardly add to an improved prognosis. As a consequence the demand for 
novel and efficient therapeutic options is very high and research advances for early 
diagnosis are desperately needed. Recombinant antibodies are a promising tool and already 
established for diagnosis and specific targeted immunotherapy of other types of cancer. 
During a three-step panning strategy, the scFv libraries Tomlinson I and J are selected by 
means of phage display technology on living cells and functional membrane fractions of 
the metastasizing pancreatic cancer cell line L3.6pl to isolate new and highly specific scFv 
antibodies against unknown tumor-associated antigens in vitro. Their potential as 
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diagnostic imaging tool is evaluated by functionalizing scFv antibodies via SNAP-tag 
fusions by means of in vitro binding analysis. Additional in vitro investigations of 
internalization behavior assess the drug delivery potential for prospective fusions of the 
recombinant scFv ligand to a toxic effector domain to generate cytolytic fusion proteins for 
therapy. 
The second part of this thesis is focused on the development of short-chained optically 
active reporter tags based on the accumulation of tryptophan residues (W) and their ability 
to auto-fluoresce. These tags will be evaluated with regard to their applicability as 
non-invasive on-line monitoring tool for production of antibody-based therapeutics. 
Production up-scaling of recombinant pharmaceutically relevant therapeutical proteins still 
poses a bottle neck. Laboratory-scale fermentation systems, for example with the 
BioLector® device, simulate large-scale fermentation conditions thus rendering 
time-saving and cost-efficient parallel high-throughput characterization and screening of 
microbial cultures under identical conditions in microtiter plates (MTPs) possible. 
Commonly, the product formation of recombinant proteins during cultivation is monitored 
off-line after sampling, or on-line using conventional genetically fused fluorescent reporter 
proteins, such as green fluorescent protein (GFP) and its derivatives, or flavin 
mononucleotide-based fluorescent proteins (FbFPs). A major drawback of those 
conventional reporter proteins is their relatively high molecular size which imposes stress 
on the host metabolism during fermentation and possibly causes steric hindrance during 
protein folding and secretion. Moreover, the strong oxygen-dependency of GFP for 
fluorophore formation is problematic. In general, smaller fluorescent tags are preferable 
since this minimizes occurrence of potential problems. Therefore, five 
low-molecular-weight protein tags (W-tags) will be designed comprising different numbers 
of tryptophan residues, thus exploiting the auto-fluorescence of tryptophan-clustering. A 
genetic in-frame fusion of these newly designed W-tags with the anti-CD30 antibody 
fragment Ki-4(scFv) serves as proof-of-concept model to assess bacterial growth versus 
target protein formation. One aim is to visualize tryptophan fluorescence intensity during 
on-line monitoring in E.coli cultures as well as the dependency of fluorescence on the 
number of involved tryptophan residues. Besides that post-expression in vitro functionality 
and specificity analyses, are intended to demonstrate the potential of these novel W-tags as 
an alternative tagging method during fermentation of recombinant pharmaceutical proteins 
in comparison to conventional reporter proteins. 
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Figure 1-7 Flow chart illustrating the two objectives of this thesis and their experimental approach. 
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2 Material 
2.1 Chemicals and consumable supplies 
Chemicals and consumable supplies used in this work were purchased from the following 
companies: Applichem (Darmstadt), Becton, Dickinson & Co., BD Bioscience 
(Heidelberg), Biocompare (San Francisco, CA, USA), Carl Roth GmbH & Co. KG 
(Karlsruhe), Clontech (Saint-Germain-en-Laye, France), Eppendorf AG (Hamburg), GE 
Healthcare (München), Greiner Bio-One GmbH (Solingen), Invitrogen (Darmstadt), Merck 
KGaA (Darmstadt), Millipore (Darmstadt), Nerbe plus GmbH (Winsen/Luhe), New 
England Biolabs (Frankfurt am Main), Nunc GmbH & Co. KG (Wiesbaden), Otto Fischar 
GmbH & Co. KG (Saarbrücken), Promega GmbH (Mannheim), Roche Diagnostics 
Deutschland GmbH (Mannheim), Sarstedt AG & Co. KG (Nümbrecht), Sigma-Aldrich 
(Seelze), Thermo Scientific (Langenselbold), TPP Techno Plastic Products AG 
(Trasadingen, Switzerland), VWR International GmbH (Darmstadt) and Whatman GmbH 
(Dassel). All chemicals and consumables were applied according to manufacturers’ 
instructions if not indicated otherwise. Purchase from different suppliers is possible if 
requirements necessary for a successful and reproducible outcome are fulfilled. 
2.2 Equipment and software 
Table 2-1 List of software, its application and corresponding supplier 
Software Application Supplier 
Adobe Photoshop CS4 Image editing Adobe System, München 
AIDA 4.27.039 
Advanced Image Data Analyzer 
Protein concentration 
analysis 
Raytest Isotopenmessgeräte GmbH, Straubenhardt 
ArgusX Agarose gel analysis Argus Software, London, UK 
CellQuest Pro 3.3 Flow cytometry Becton, Dickinson & Co., BD Bioscience, Heidelberg 
Cyflogic 1.2.1 Flow cytometry Perttu Terho & Cyflo Ltd., Turku Finland  
Evoshell 
Confocal microscopy, 
OPERA 
Evotec Technologies, Hamburg 
Geneious 5 DNA sequence analysis Biomatters Ltd., Auckland, New Zealand 
GraphPad Prism 5.01 Statistics GraphPad software, Inc., LaJolla, CA, USA 
i-control Tecan reader Tecan Group Ltd., Männedorf, Switzerland 
Image J 1.42q Image editing National Institues of Health, Bethesda, MD, USA 
MassLynx v4.0 Mass spectrometry Micromass, Water Corporation, Eschborn 
MS Office 2010 Text and statistics Office 2012, Microsoft Corp., Redmont, WA, USA 
Origin 8 Statistics 
ADDITIVE Soft- und Hardware für Technik und  
Wissenschaft GmbH, Friedrichsdorf 
QuantityOne Basic 1-D  
Analysis software v.4.2.1 
Fluorescence 
documentation 
Bio-Rad, Offenbach 
Vector NTI 11 DNA sequence analysis Invitrogen, Darmstadt 
WinMDI 2.9 Flow cytometry Build 2, Joe Trotter, La Jolla, CA, USA 
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Table 2-2 List of hardware with corresponding suppliers  
Equipment/Hardware Supplier/Manufacturer 
Agarose Electrophoresis Device  mini-SUB/SUB-CELL® GT, Bio-Rad, München 
BioLector-like shaking device 
  
self-made at Aachener Verfahrenstechnik (AVT) at RWTH Aachen University,  
adaptation from m2p-Labs, Baesweiler  
Cell washer Dade Serotec, Baxter, Unterschleißheim 
Cytospin centrifuge Cytospin 2 Centrifuge, Shandon, Thermo Scientific, Braunschweig 
Centrifuges  
  
Centrifuge 5804R, Eppendorf AG, Hamburg 
Biofuge Haemo, Heraeus Instruments & Co. KG, Hanau 
Multifuge 3 L-R, Heraeus Instruments & Co. KG, Hanau 
Multifuge 3 S-R, Heraeus Instruments & Co. KG, Hanau 
Confocal microscope Opera HCS System, Evotec Technologies, Hamburg 
Flow cytometer FACScalibur, Becton, Dickinson & Co., BD Bioscience, Heidelberg 
Fluorescence documentation  VersaDoc MP System, Bio-Rad, Offenbach 
Incubator (37 °C) GFL 3031, GFL-Gesellschaft für Labortechnik G mbH, Burgwedel 
Mass spectrometer 
ESI-MS/MS Mass Spectrometer Micromass Electrospray Q-TOF-2, 
Waters Corporation, Eschborn 
MilliQ system MilliQ Synthesis QuantumEX Ultrapure Organex Cartridge, Millipore, Darmstadt 
Orbital shaker  POLYMAX 1040, Heidolph Instruments GmbH & Co. KG, Schwabach 
PCR Thermo Cycler 
GeneAmp PCR System 9700, Applied Biosystems  
by LifeTechnologies Corp., Darmstadt 
96-well plate shaker  TIMIX, Edmund Bühler GmbH, Hechingen 
Power supply  PowerPac® HC, Bio-Rad, München 
2D-scanner FluoreMax-4P, Horiba Jobin Yvon Instruments Inc., USA 
SDS-PAGE + Western blot devices 
BioRad miniProtean III device, additional equipment for gel casting, Bio-Rad, 
München 
Shaking incubator (variable T) Innova Incubator Shaker 4430, New Brunswick Scientific, Wesseling-Berzdorf 
Sonification device 
Sonoplus HD 2070, tip: UW 2070, KE76, Bandelin Electronic GmbH & Co. KG, 
Berlin 
Spectro-photometer BioPhotometer plus, Eppendorf AG, Hamburg 
Tecan reader Tecan Multiplate-Reade Infinite M200, Tecan Group Ltd., Männedorf, Switzerland 
Thermo shaker (variable T) Thermomixer comfort, Eppendorf AG, Hamburg 
Tissue culture clean bench HeraSafe HS18, Heraeus Instruments & Co. KG, Hanau 
Tissue culture incubator (37 °C) HeraCell 150, Thermo Scientific, Braunschweig 
Tube rotator Tube Rotator, VWR International GmbH, Darmstadt 
Ultracentrifuge Aventi Centrifuge J-25i, Beckman Coulter, Krefeld 
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2.3 Bacterial strains and media 
Following E.coli strains (Table 2-3) were used during this thesis. 
Table 2-3 List of E.coli strains, their genotypes and corresponding suppliers 
E.coli strain Genotypes Supplier 
BL21 Rosetta 2 (DE3)  
Supercompetent Cells  
F- ompT hsdSB(rB
- mB
-) gal dcm (DE3) pRARE2 (CamR) Merck KGaA, Darmstadt 
HB2151 K12 ara Δ(lac-proAB)thi/F' proA+B lacIq lacZΔM15 MCR, Cambridge, UK 
TG1 Tr 
K12 Δ(lac-proAB) supE thi hsdD5/F' traD36 proA+B lacIq 
lacZΔM15 MCR, Cambridge, UK 
XL1 Blue  
Supercompetent Cells 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F' proAB lacIqZΔM15 Tn10 (Tetr)] 
Agilent Technologies,  
Waldbronn 
Bacterial growth media and agar (Table 2-4) were prepared with ddH2O (deionized water) 
and autoclaved as 250 mL or 300 mL aliquots in 500 mL bottles, appropriate antibiotics 
and/or sterile glucose were added directly prior to use.  
Table 2-4 List of cultivation media and agars and their exact formulae 
Cultivation media/agar Composition 
2 x TY medium 16 g tryptone, 10 g yeast extract, 5 g NaCl, ad 1 L ddH2O 
2 x TYamp 100 µg/mL ampicillin in 2 x TY medium 
2 x TYamp, 2 x TYkan 100 µg/mL ampicillin or 50 µg/mL kanamycin in 2 x TY medium 
2 x TYgluc,amp 1% glucose, 100 µg/mL ampicillin in 2 x TY medium 
2 x TY induction medium 100 µg/mL ampicillin, 50 µg/mL kanamycin, 0.25 mM IPTG in 2 x TY medium 
Cryo medium 15% (v/v) sterile glycerol, appropriate antibiotic in 2 x TY medium 
Lysogeny Broth (LB) medium 10 g tryptone, 5 g yeast extract, 10 g NaCl, ad 1 L ddH2O 
LBamp, LBkan 100 µg/mL ampicillin or 50 µg/mL kanamycin in LB medium 
LB auto-induction medium 0.5 g/L glucose, 2 g/L lactose, 5 g/L glycerol in LB medium 
Lysogeny broth (LB) agar 5 g yeast extract, 5 g NaCl, 10 g Bacto-Agar, ad 1 L ddH2O 
LBamp, LBkan agar 100 µg/mL ampicillin or 50 µg/mL kanamycin in LB agar 
LBgluc,amp agar 1% glucose, 100 µg/mL ampicillin in LB agar 
M9 minimal agar  
(1 L final volume) 
Solution A: 15 g Bacto-Agar  in 780 mL ddH2O 
Solution B: 2.5 g NaCl, 5 g NH4Cl, 33.9 g Na2HPO4, 15 g KH2PO4 in 1 L ddH2O 
Solution C: 1 M MgSO4 
Solution D: 1 M CaCl2 x 6 H2O 
Solution E: 20% glucose 
Solution F: 0.001 g thiaminhydrochlorid in 10 mL ddH2O 
Autoclave solutions A – D, sterile filtrate solutions E and F 
Mix 780 mL Solution A, 200 mL Solution B, 2 mL Solution C, 100 µL Solution D, 
20 mL Solution E and 400 µL Solution F.  
SOC medium Agilent Technologies, Waldbronn 
Modified Wilms-Reuss medium  
(1 L final volume) [232] 
Solution I: 5 g (NH4)2SO4, 0.5 g NH4Cl, 3 g K2HPO4, 2 g Na2SO4,  
                   41.85 g MOPS (3-(N-morpholino)propanesulfonic acid buffer) 
                   in 947 mL ddH2O (pH 7.5) 
Solution II: 0.027 g ZnSO4 x 7 H2O, 0.024 g CuSO4 x 5 H2O, 0.015 g MnSO4 x H2O,  
                   0.027 g CoCl2 x 6 H2O, 2.088 g FeCl3 x 6 H2O, 0.099 g CaCl2 x 2 H2O,  
                   1.67 g Na2EDTA x 2 H2O in 50 mL ddH2O 
Solution III: 250 g glucose in 500 mL ddH2O 
Solution IV: 5 g MgSO4 x 7 H2O in 100 mL ddH2O 
Solution V: 0.1 g thiaminhydrochlorid in 10 mL ddH2O 
Autoclave solutions I, III, IV and sterile filtrate solutions II and V. 
Mix 947 mL Solution I, 1 mL Solution II, 40 mL Solution III, 10 mL Solution IV, 
1 mL Solution V and add appropriate antibiotic 
 
Material 
 
 
36 
2.4 Eukaryotic cell lines and media 
The EGFR+ and highly metastasizing pancreatic cancer cell line L3.6pl was chosen as 
selection cell line. Thus, the well-published anti-EGFR 425(scFv) single chain antibody 
fragment [159, 164] could be exploited as positive control during characterization 
experiments. The Hodgkins’ lymphoma-derived cell line L540cy over-expressing the 
CD30 surface receptor was used as positive cell line for the Ki-4(scFv) antibody fragment 
[132]. Table 2-5 and Table 2-6 list all cell lines and necessary reagents used for the 
characterization of scFv fragments or W-tagged fusion proteins. 
Table 2-5 List of cell lines, their originating tissue, supplier and cultivation medium 
Cell line Characteristics Supplier/Reference Medium 
A431 Human epidermoid carcinoma ATCC, Manassas, VA, USA RPMI/10/1 
FG Human pancreatic carcinoma Munich, Bruns et al. 1999 [155] RPMI/10/1 
HEK293T Human embryonal kidney ATCC, Manassas, VA, USA RPMI/10/1 
L3.6pl Human pancreatic carcinoma Munich, Bruns et al. 1999 [155] RPMI/10/1 
L540cy Human Hodgkins' Lymphoma ATCC, Manassas, VA, USA RPMI/10/1 
LNCaP Human prostate carcinoma DSMZ, Braunschweig RPMI/10/1 
MCF7 Human breast adenocarcinoma DSMZ, Braunschweig RPMI/10/1 
MDA-MB-231 Human breast adenocarcinoma ATCC, Manassas, VA, USA RPMI/10/1 
MIA PaCa-2 Human pancreactic cancer ATCC, Manassas, VA, USA DMEM/10/1 
PancTuI Human pancreatic carcinoma Kiel University, Prof. Kalthoff [189] RPMI/10 
PancTuI-CBRL Human pancreatic carcinoma Kiel University, Prof. Kalthoff [189] RPMI/10 
PT-46 Human pancreatic carcinoma Kiel University, Prof. Kalthoff RPMI/10 
S2-0028 Human pancreatic carcinoma Ulm University RPMI/10/1 
SiHa-BTH35 Human cervix carcinoma ATCC, Manassas, VA, USA RPMI/10/1 
Su86.86 Human pancreatic carcinoma ATCC, Manassas, VA, USA DMEM/10/1 
(RPMI: RPMI 1640 Glutamax, DMEM: DMEM Glutamax, 10: 10% fetal bovine serum (FBS), 1: 1% penicillin-streptomycin (P/S) 
Table 2-6 List of tissue culture media and supplementary components for tissue culture 
Media and supplementary components Supplier/Manufacturer 
Accutase® PAA Laboratories GmbH, Pasching, Austria 
DMEM (Dulbecco’s Modified Eagle Medium) Glutamax Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
DMSO (99%) for tissue culture Sigma-Aldrich, Seelze 
1 x DPBS (Dulbecco’s Phosphate Buffered Saline), pH 7.4 Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
Fetal bovine serum (FBS) Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
Penicillin-Streptomycin Liquid Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
RPMI (Roswell Park Memorial Institute) 1640 Glutamax,  
containing phenol red 
Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
RPMI 1640 Glutamax,  
without phenol red 
Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
Trypan blue Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
0.25% trypsin-EDTA (1x), containing phenol red Invitrogen/Gibco, Life Technolgies GmbH, Darmstadt 
Zeocin® Invivogen, Toulouse, France 
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2.5 Enzymes and their buffers 
All enzymes (Table 2-7) for restriction digests, dephosphorylation, ligations or DNA 
amplification were applied according to distributor’s manual. Enzyme reaction buffers and 
reaction components essential for enzyme activity were supplied with enzyme purchase. 
Table 2-7 List of enzymes and corresponding suppliers 
Enzymes Supplier/Manufacturer 
Antarctic phosphatase New England Biolabs, Frankfurt am Main 
GoTaq Flexi DNA Polymerase  Promega GmbH, Mannheim 
Pfu DNA polymerase Fermentas, St. Leon-Rot 
DpnI Fermentas, St. Leon-Rot 
HindIII New England Biolabs, Frankfurt am Main 
NcoI New England Biolabs, Frankfurt am Main 
NdeI New England Biolabs, Frankfurt am Main 
NotI New England Biolabs, Frankfurt am Main 
SfiI New England Biolabs, Frankfurt am Main 
T4 DNA Ligase Invitrogen/Gibco, Life Technologies, Darmstadt 
2.6 Reaction kits 
Following kits (Table 2-8) were applied according to the manufacturer’s instructions. 
Table 2-8 List of commercially available kits and corresponding suppliers 
 
2.7 Buffers, solutions and antibiotics 
All buffers and solutions (Table 2-9) were prepared with ddH2O if not indicated otherwise. 
Antibiotics (Table 2-10) were prepared with ultra-pure water (MilliQ) from the MilliQ 
Synthesis System (specifications: 18.2 MΩ/cm at 25 °C, pyrogen content <0.0001 EU/mL 
and bacteria content <1 KBE/mL), sterile filtrated, aliquoted and frozen at -20 °C until use. 
  
Name Supplier/Manufacturer 
ABTS substrate Roche Diagnostics Deutschland GmbH, Mannheim 
FuGene HD Transfection  Roche Diagnostics Deutschland GmbH, Mannheim 
Nucleo Bond PC 100 Kit Macherey & Nagel, Düren 
Nucleo Spin Plasmid Kit Macherey & Nagel, Düren 
QIAquick Gel Extraction Kit Qiagen GmbH, Hilden 
QuikChange® Site-Directed Mutagenesis Kit Agilent Technologies, Waldbronn 
Uptima BC Assay Protein Quantification Interchim, Sankt-Augustin-Buisdorf 
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Table 2-9 List of composition of buffers and solutions 
Buffer Composition 
10 x colony PCR buffer 500 mM KCl, 100 mM Tris-HCl (pH 9.0), 1% (v/v) TritonX100 
Destaining solution 100 mL acetic acid (100% glacial), 200 mL methanol, 700 mL ddH2O 
ELISA coating buffer 
5.3 g Na2CO3 in 900 mL ddH2O, add 4.2 g NaHCO3, 1 g NaAc,  
ad 1 L ddH2O (pH 9.6) 
Homogenization buffer 25 mM Tris-HCl (pH 7.4), 320 mM sucrose, 1 Complete Protease Inhibitor tablet/50 mL 
IPTG solution 1 M IPTG stock solution in MilliQ 
10 x Laemmli running buffer 31 g Tris, 144 g glycine, 10 g SDS, ad 1 L ddH2O (pH 8.6) 
1 x Laemmli running buffer 1 : 10 dilution of 10 x Laemmli running buffer in ddH2O 
Lysis buffer 
50 mM Tris, 300 mM NaCl, 10 mM EDTA (pH 8.0),  
1 Complete Protease Inhibitor tablet/50 mL (pH 7.5) 
Lysis buffer with lysozyme 300 µg/mL lysozyme in lysis buffer 
Lysis buffer with NP-40 10 mM NP-40 in lysis buffer 
2% MPBS, 5% MPBST, 
5% MRPMI 
2% or 5% (w/v) milk powder dissolved in 1 x PBS, 1 x PBST or RPMI Glutamax 
10 x PBS  
(phosphate buffered saline) 
80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 2.4 g KH2PO4 (pH 6.9), ad 1 L ddH2O 
1 x PBS  1 : 10 dilution of 10 x PBS with ddH2O (pH 7.4) 
1 x PBST 1 x PBS, 0.05% (v/v) Tween20 
PEG/NaCl 20% (w/v) PEG6000, 2.5 M NaCl 
4% PFA fixing solution 4 g (w/v) paraformaldehyde, ad 100 mL 1 x PBS  
Phage elution buffer 200 mM glycine-HCl (pH 2.2) 
Phage neutralization buffer 1M Tris-HCl (pH 9.1) 
5 x protein loading buffer 
62.5 mM Tris-HCl (pH 6.8), 30% (v/v) glycerol, 4% (w/v) SDS,  
0.05% (w/v) bromophenol blue, 10% (v/v) ȕ-mercaptoethanol 
Resuspension buffer 50 mM Tris-HCl (pH 7.4) 
4% PAA stacking gel  
(2 gels) 
650 µL Rotiphorese Gel 30, 625 µL 1 M Tris-HCl (pH 6.8), 50 µL 10% (w/v) SDS,  
50 µL 10% (w/v) APS, 5 µL TEMED, 3.645 mL ddH2O 
12% PAA separation gel 
(2 gels) 
4 mL Rotiphorese Gel 30, 3.75 mL 1 M Tris-HCl (pH 8.8), 100 µL 10% (w/v) SDS,  
50 µL 10% (w/v) APS, 10 µL TEMED, 2.11 mL ddH2O 
50 x TAE buffer  
(Tris-Acetate-EDTA) 
242 g Tris, 57.1 mL pure acetic acid, 100 mL 0.5 M EDTA at pH 8.0  
(working pH 8.3) 
4 x TALON wash buffer 0.2 M NaH2PO4, 1.2 M NaCl, ad 1 L ddH2O (pH 7.0) 
1 x TALON wash buffer 1 : 4 dilution of 4 x TALON wash buffer with ddH2O (pH 7.0) 
1 x TALON elution buffer 250 mM imidazole in 1 x TALON wash buffer (pH 7.0) 
TEA buffer 0.1 M TEA in ddH2O (pH 12.0) 
1 x TES buffer 
50 mM Tris, 20% (w/v) sucrose, 1 mM EDTA (pH 8.0),  
1 Complete Protease Inhibitor tablet/50 mL  
0.2 x TES buffer  1 : 5 dilution of 1 x TES buffer with ddH2O, 1 Complete Protease Inhibitor tablet/50 mL 
10 x Western blot transfer buffer 25 mM Tris, 192 mM glycine, ad 1 L ddH2O 
1 x Western blot transfer buffer 100 mL 10 x Western blot transfer buffer, 200 mL methanol, 700 mL ddH2O 
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Table 2-10 List of antibiotics 
Antibiotics Supplier Stock concentration Working concentration
Ampicillin Sigma-Aldrich, Seelze 50 mg/mL 100 µg/mL 
Chloramphenicol Sigma-Aldrich, Seelze 34 mg/mL 34 µg/mL 
Kanamycin Sigma-Aldrich, Seelze 50 mg/mL 50 µg/mL 
Penicillin Invitrogen/Gibco, Life Technologies GmbH, Darmstadt 10 mg/mL 100 µg/mL 
Streptomycin Invitrogen/Gibco, Life Technologies GmbH, Darmstadt 10 mg/mL 100 µg/mL 
Zeocin® Invivogen, Toulouse France 100 mg/mL 100 µg/mL 
2.8 Antibodies and enzyme-conjugated antibodies 
Table 2-11 lists antibodies for specific proteinchemical detection of recombinant 
scFv-phage particles or scFv fusion proteins during ELISA (3.3.9), flow cytometry 
(3.3.10), Western blotting (3.3.2) and immunofluorescence staining (3.3.11.2). 
Table 2-11 List of antibodies for immunological analysis 
Antibodies Host Application Supplier Dilution 
HRP/anti-M13 monoclonal conjugate mouse E GE healthcare, München 1:5000 
Penta-His Alexa Fluor 488 conjugate mouse F Qiagen GmbH, Düren 1:300 
Monoclonal anti-polyHis IgG mouse E, WB Sigma, Seelze 1:2000 
Anti-rabbit Fc specific IgG HRP conjugate goat E, WB Sigma, Seelze 1:5000 
Anti-mouse-peroxidase conjugate goat E, WB Sigma, Seelze 1:5000 
Polyclonal anti-SNAP-tag IgG rabbit E, IF Genescript, Aachen 1:5000 
anti-rabbit IgG (H+L) F(ab)2 Fragment Alexa 
Fluor 647 
goat IF 
Cell Signaling Technology Inc., 
Boston, MA, USA 
1:5000 
E: ELISA, IF: immunofluorescence, F: flow cytometry, WB: Western blot 
2.9 Primer 
All primer sequences (Table 2-12) used for sequencing reactions or PCR amplification 
were ordered from Invitrogen (Darmstadt) as lyophilized powder, reconstituted in MilliQ 
to a concentration of 100 pmol and stored at -20 °C until use. 
Table 2-12 Primer sequences and corresponding vectors for sequencing and PCR 
Primer name Vector Sequence 5‘  3‘ Direction of sequencing 
fdseq1 pIT2 GAA TTT TCT GTA TGA GG reverse down-stream of scFv 
LMB3 pIT2 CAG GAA ACA GCT ATG AC forward up-stream of scFv 
mSNAP forward pMS-SNAPMut CGA CTC ACT ATA GGG AGA CCC AAG C forward up-stream of scFv 
mSNAP reverse I pMS-SNAPMut CCT TTG CCC AGC AGC TTG ATC TCG reverse down-stream of scFv 
mSNAP reverse II pMS-SNAPMut GCA ACT AGA AGG CAC AGT CG reverse down-stream of SNAP 
T7 promoter pMT TAA TAC GAC TCA CTA TAG GG forward up-stream of scFv 
T7 terminator pMT TAC AGG GCG CGT CCC ATT CG reverse down-stream of scFv 
 
Material 
 
 
40 
2.10 Plasmid vectors 
Table 2-13 Plasmid vectors/phagemids, corresponding background information and suppliers 
Vectors Background information Supplier 
pIT2 
Phage display vector of Tomlinson libraries I and J. Phagemid vector for 
pIII-scFv fusion protein production in E.coli TG1F+ or expression of soluble 
scFv proteins in E.coli HB2151. Ampicillin 40ancreati, lac-promoter/IPTG 
controlled.  
MRC, 
Cambridge, UK 
pMT 
Vector for prokaryotic protein expression of soluble scFv proteins or Wx-scFv 
fusion proteins. Derived from pET27b+ vector [171]. Kanamycin resistant, T7 
promoter/IPTG controlled. 
FhG IME, 
Aachen 
pET27b+ 
Vector for prokaryotic protein expression, used as negative control during  
on-line measurements. Kanamycin resistant, T7 promoter/IPTG controlled. 
Merck KgaA, 
Darmstadt 
pMS-SNAPMut 
Vector for eukaryotic soluble protein expression. Bicistronic construct 
combined from vectors pSecTag2 (Invitrogen, Darmstadt) and pIRES2-eGFP 
(Clontech, Saint-Germain-en-Laye, France). Ampicillin and Zeocin® resistant, 
CMV promoter controlled [183]. 
FhG IME, 
Aachen 
pMA Cloning vector for W-tags, ampicillin resistant 
GENEART, 
Regensburg 
pCR4Blunt-TOPO Cloning vector for W-tags, ampicillin and kanamycin resistant 
GENEART, 
Regensburg 
Detailed plasmid maps of pMT and pMS-SNAPMut vectors are illustrated in Figure 2-1 
displaying highlighted coding sequences for the single genetic components. Schematics of 
corresponding expression cassettes are outlined in 4.5 and 5.2 including all restriction sites 
required for cloning. 
 
Figure 2-1 Schemtic drawing of plasmid maps of expression vectors pMT and pMS-SNAPMut.  
(A) pET-derived pMT plasmid for the prokaryotic production of soluble scFv protein in BL21 Rosetta 2 
(DE3) E.coli promoting lac-operon controlled protein expression via T7 promoter and T7 terminator. 
Recombinant proteins are transported into the periplasmic space and eventually secreted via the pelB leader 
peptide. Detection and purification is performed via the His10-tag. Figure 4-9 describes the expression 
cassette in more detail. (B) Bicistronic pMS-SNAPMut vector for eukaryotic expression of recombinant 
proteins after transient transfection into HEK293T cells. Protein expression is CMV-controlled 
(cytomegalovirus promoter) and an Igkappa (immunoglobulin kappa) signal sequence promotes secretion of 
soluble proteins. Detection and purification is achieved with the His6-tag, myc-tag or SNAP-tag. An internal 
ribosomal entry site (IVS/IRES) mediates co-translation of eGFP (enhanced green fluorescent protein) during 
cultivation in Zeocin-supplemented medium. Cloning and prokaryotic expression is carried out duing 
Ampicillin pressure. Figure 4-10 explains the expression cassette in more detail. F1 ori: replication origin f1 
phage, pSV40: SV40 replication origin, SV40 pA: SV40 polyadenylation signal, ColE1: E.coli origin of 
replication, AmpR: Ampicillin resistance, KanR: Kanamycin resistance, ZeoR: Zeocin resistance. 
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2.11 Molecular weight markers 
Table 2-14 Molecular DNA and protein markers and corresponding suppliers 
DNA Ladder/Protein Marker Supplier/Manufacturer 
MassRuler DNA Ladder Mix, 100 – 10,000 bp Fermentas, St. Leon-Rot 
Spectra Multicolor Broad Range Protein Ladder, 10 – 260 kDa Fermentas, St. Leon-Rot 
Novex Sharp Pre-stained Protein Standard, 3.5 – 260 kDa Invitrogen, Darmstadt 
Prestained Protein Ladder Broad Range, 10 – 230kDa New England Biolabs, Frankfurt am Main 
Orange G, 6 x DNA loading dye, 50 bp New England Biolabs, Frankfurt am Main 
2.12 Single chain antibody libraries and helperphage 
Phage display libraries, used for selections during this thesis, were the human single-fold 
scFv Tomlinson Libraries I and J, originally obtained from the Medical Research Council 
(MRC) Center for Protein Engineering in Cambridge (UK). Both are encoded on the pIT2 
phagemid vector as scFv proteins fused to the pIII phage coat protein. Transformed into 
E.coli TG1 Tr (TG1F+), the phagmids were stored as cryo stocks at -80 °C. TG1F+ 
bacteria can be infected by filamentous M13KO7 phage particles to produce scFv-phage 
units. A detailed instruction and description of the Tomlinson Libraries I and J is found in 
1.3.3. Following phage types were used (Table 2-15). 
Table 2-15 Description of different types of phage particles and corresponding suppliers 
Phage Characteristics Supplier 
M13KO7  
helperphage 
It codes for genetic information of all wild-type coat proteins. After 
infecting phagemid-carrying bacteria, pIII-scFv fusion proteins are 
produced as well as unfused pIII coat proteins. During phage assembly, 
the coat proteins are joined at random so that between one and two 
pIII-scFv fusion proteins are presented on the surface of 1 – 10% of all 
produced phage particles. Kanamycin resistant. 
New England Biolabs, 
Frankfurt am Main 
M13 KO7ΔpIII  
hyperphage 
It is a M13KO7-derived gIII-deficient version which misses the pIII 
gene (gIII) completely. During phage assembly, only the scFv-pIII coat 
protein is present, and as a consequence, produced phage particles 
present five incorporated pIII-scFv on their protein coat. Kanamycin 
resistant. 
PROGEN Biotechnik GmbH, 
Heidelberg 
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3 Methods 
3.1 Molecular biological and DNA cloning techniques 
General recombinant DNA techniques, as well as methods for cell cultivation, transfecting 
mammalian cells and transforming bacteria, were based on standard of “Molecular 
Cloning: A laboratory manual” from Sambrook et al., 2001 [233]. Individual components 
for experiments are listed below. Phosphate buffered saline solution, here called PBS was 
used at a concentration of 1 x PBS. Same applies for PBS supplemented with 0.05% 
Tween20, called PBST. Recombinant cloning techniques were used to subclone DNA 
fragments into the plasmid/phagemid vectors pIT2 or pMT for prokaryotic expression, or 
into pMS-SNAPMut for eukaryotic expression (2.10). General cloning was performed with 
E.coli strain XL1 Blue (3.1.2, 3.1.3). 
3.1.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) [233, 234] is an important standard technique in 
molecular biology. DNA fragments were exponentially amplified by PCR, for subsequent 
sequencing (3.1.4) or restriction digest (3.1.2), but also to introduce mutations in a DNA 
fragment (3.4.6) by means of the taq-polymerase from Thermus aquaticus bacterium [234]. 
Besides taq-polymerase, a pfu-polymerase was used with 3’-5’-exonuclease proof-reading 
activity to correct potential sequence errors during DNA assembly of the elongation step. 
PCR products were examined by analytical and preparative agarose gel electrophoresis 
(3.1.5). PCR reaction mixtures were prepared on ice; autoclaved ddH2O was used as 
negative control. 
3.1.1.1 PCR based on DNA template 
A PCR reaction can be started from a DNA template, such as chromosomal DNA or a 
plasmid. PCR reactions were set up in 200 µL tubes of a PCR-strip (25 µL/tube reaction 
volume). It was tested whether positive L3.6pl-binding scFv-phage particles, after 
screening in the monoclonal phage ELISA (3.3.9.2) contained a scFv-insert. Right-sized 
scFv-inserts were excised from the agarose gel (3.1.5), extracted and sequenced (3.1.4). 
Primers LMB3 (forward) and fdseq1 (reverse) attached to the insert template at a distance 
of 134 and 119 base pairs (bp), respectively, resulting in a PCR product 976 bp long. Table 
3-1 states conditions for the thermo cycler and the reagents for the PCR reaction mixture. 
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Table 3-1 Reaction conditions of DNA template-based PCR amplification reaction.  
(A) PCR reaction mixture, (B) thermo cycler program. 
(A) 
 
(B) 
 
 
   
Reagent Volume [µL] Temperature [°C] Time [min] Cycles 
DNA template 1 94 03:00 1 
5 x gotaq buffer 5 94 01:00 
 
DMSO (99%) 2 50 00:45 
 
dNTP mix (25 mM) 0.3 72 02:00 30 
LMB3 (10 pmol) 1 72 10:00 
 
fdseq1 (10 pmol) 1 4 ∞ 
 
50 x gotaq polymerase 0.15 
  
ddH2O ad 25 µL total volume   
DNA fragments for restriction digest were extracted by same PCR procedure. 
3.1.1.2 Bacterial colony PCR 
Instead of a DNA template, PCR can be started from a bacterial colony. Therefore, a single 
colony was picked from an agar plate with a sterile pipet tip, saved on a second agar plate 
by slightly touching and transferred to a 200 µL tube as PCR. Table 3-2 lists the colony 
PCR reaction mix and thermo cycler set-up. 
Table 3-2 Reaction conditions of colony-based PCR amplification reaction.  
(A) PCR reaction mixture, (B) thermo cycler program. 
(A) (B) 
Reagent Volume [µL] Temperature [°C] Time [min] Cycles 
Bacterial colony 1 colony 95 10:00 1 
10 x colony PCR buffer 5 95 01:00 
 
MgCl2 (25 mM) 3 50 01:00 
 
dNTP mix (25 mM) 0.3 72 01:30 30 
LMB3 (10 pmol) 1 72 10:00 
 
fdseq1 (10 pmol) 1 4 ∞ 
 
50 x gotaq polymerase 0.2 
 
ddH2O ad 50 µL total volume  
The colony PCR method was used to check for presence of scFv-inserts or to test whether 
a ligation (3.1.3) during cloning has been successful. 
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3.1.2 DNA restriction digest 
Plasmids or PCR products were digested with restriction endonucleases (2.5) according to 
enzyme concentrations, buffers and temperature given in manufacturers’ manual. 
Typically, 500 – 100 ng DNA material was digested in 50 µL total volume applying one 
unit enzyme/1000 ng DNA, except for supercoiled plasmid DNA where a 4-fold enzyme 
concentration was used to achieve complete digestion. Isolated L3.6pl-specific scFv 
fragments (3.4) were subcloned into pMT and pMS-SNAPMut expression vectors through 
restriction sites SfiI and NotI. Newly designed W-tags (3.1.8) with pelB leader were 
subcloned from GENEART vectors into the pMT expression vector [171] via NcoI and 
HindIII restriction sites, whereas W-tags without pelB leader were transferred using NdeI 
and HindIII. To prevent relegation, vector backbones were additionally dephosphorylated 
at 37 °C for 1 h after digest using Antarctic phosphatase, followed by a 20 min 
deactivation step at 65 °C. Digested DNA fragments were separated by preparative agarose 
gel electrophoresis (3.1.5), gel-purified (2.6) and ligated (3.1.3) into the desired DNA 
vector construct. 
3.1.3 DNA ligation 
To ligate scFv fragments and W-tags into their respective vector backbones, 50 – 100 ng 
vector were ligated to the insert at a molecular ratio of 1 : 3 using the enzyme T4 ligase 
(2.5). Ligation was carried out with T4 ligation buffer at RT for 3 h as instructed in the 
manual. 
3.1.4 DNA sequencing and sequencing analysis 
PCR products, site-directed mutations or correct ligations, as well as DNA fragments or 
plasmids were sequenced at MWG Eurofins (Ebersberg, Germany) by dideoxy chain 
termination according to Sanger et al. [235]. 15 µL of purified PCR product (5 ng/µL) or 
purified plasmid DNA (50 – 100 ng/µL) were transferred to an Eppendorf tube, sent for 
sequencing and subsequently analyzed with the Vector NTI software (Table 2-2). 
3.1.5 Analytical and preparative agarose gel electrophoresis 
For preliminary analysis, 5 – 10 µL samples of undigested plasmid DNA, PCR products or 
restricted DNA were mixed with DNA loading dye and loaded onto an analytical agarose 
gel to check the length of the DNA fragments. Gels were prepared with 0.8 – 1% (w/v) 
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agarose in 1 x TAE buffer (2.7), containing 0.1 µg/mL ethidium bromide, and run at 
80 - 120 V. Size and integrity of a DNA fragment were evaluated with a DNA molecular 
marker (2.11). DNA-embedded ethidium bromide was visualized via a UV transilluminator 
at 312 nm, documented by a black and white camera attached to the top of the 
transillluminator and analyzed using the ArgusX program (2.2). 
For subsequent DNA excision and purification, a preparative agarose gel was run 
separately using the entire DNA solution. No picture was taken to prevent DNA damage 
by UV-light but the desired DNA fragment was quickly excised from the gel (under a UV 
transilluminator lamp) and gel-purified using the QIAquick Gel Extraction Kit (2.6).  
3.1.6 Determination of DNA concentration 
DNA was diluted at 1 : 30 or 1 : 50 in ddH2O and transferred to a UV cuvette to measure 
DNA concentration in a spectro-photometer (2.2) via the extinction at Ȝ = 260 nm. DNA 
purity was evaluated at wavelengths 260 and 280 nm. Whereas the DNA absorbs UV light 
at both wavelengths, residual proteins absorb UV light at 280 nm only. DNA samples free 
of protein contamination have a 260/280 ratio of 1.8, whereas a contaminated sample 
displays a 260/280 ratio <1.8. 
3.1.7  Plasmid DNA isolation from E.coli 
Plasmid DNA was isolated from E.coli cultures using the Macherey & Nagel Kits (2.6) 
NucleoSpin Plasmid (mini-preparation) or NucleoBond PC100 (midi-preparation). Quality 
and quantity of isolated DNA was confirmed by spectrophotometric analysis (3.1.6). 
Isolated plasmid DNA was used for sequence analysis of bacterial clones (3.1.4), control 
digests (3.1.2) or long term storage at -20 °C. To prepare very pure DNA for transfection 
of eukaryotic cells, the eluted DNA was precipitated with isopropanol and washed with 
70% ethanol. The pellet was resuspended in 150 µL ddH2O, and then 1 / 10 volumes 3 M 
NaOAc and 2.5 volumes 100% ethanol were added. The tube was placed at -80 °C O/N 
and thawed at RT for 10 min. Precipitated DNA was spun down (12,000 x g, 4 °C, 
30 min). The supernatant was removed, the transparent pellet washed with 1 mL 
80% ethanol (12,000 x g, 4 °C, 10 min) and dried at RT for 5 – 10 min after the 
supernatant was removed with a pipet. DNA was resuspended in 50 – 100 µL TE-buffer. 
  
Methods 
 
 
46 
3.1.8 Design of tryptophan tag (W-tag) 
Following the expertise of Dr. Heinrich Delbrück from Fraunhofer IME in Aachen, five 
short and optically active tags, called W tags, were modeled by integrating the aromatic 
auto-fluorescent amino acid tryptophan (W) into a naturally occurring ȕ-sheet motif from 
Bacillus caldolyticus cold shock protein (Bc Csp) [236].  
This special ȕ-sheet motif was found by screening the Protein Data Bank (PDB) for small 
motifs with the appropriate distribution of hydrophobic amino acids. Bc Csp [PDB: 1C9O] 
is a small protein (66 amino acids) comprising two ȕ-sheets that form a ȕ-barrel. The first 
ȕ-sheet (30 amino acids) consists of three ȕ-strands connected by two loops, with a 
hydrophobic core and one tryptophan and two phenylalanine residues exposed on the 
surface. Starting from the third residue, the sequence was systematically mutated in silico 
to increase the number of tryptophan residues within the loop using CHARMM 
(http://www.CHARMM.org) in Discovery Studio (http://www.accelrys.com) the free 
energy of each model was minimized and models with the lowest free energy for each 
number of substituted tryptophan residues were selected. 
W-tags were synthesized at GENEART (Regensburg, Germany) with E.coli-compatible 
base triplets as DNA sequence in pMA and pCR4Blunt TOPO cloning vectors containing 
restriction sites NheI, NcoI and HindIII, an His6-tag, a GS-linker and a cleavable 
enterokinase site (EK). W-tags were subcloned into the pMT expression vector upstream 
of the Ki-4(scFv) [237] or M12(scFv) [238] (3.1.3) and transformed into BL21 Rosetta 2 
(DE3) E.coli (3.1.9.3). Untagged Ki-4(scFv) or M12(scFv) were introduced as positive 
expression control (EC), the empty pET-27b+ vector served as negative control (NC). 
3.1.9 Cultivation of E.coli 
Different E.coli strains were used for infection of the Tomlinson libraries I and J, and 
subsequent production of M13KO7-based scFv-helperphage units (3.4.2), for DNA 
amplification and isolation (3.1.9.2), or for the prokaryotic production of proteins (3.1.9.3, 
3.1.9.4). For a list of all bacterial strains, their suppliers and the distinct characteristics see 
chapter 2.3. 
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3.1.9.1 Phage infection and production in TG1F+ 
TG1F+ E.coli (2.3) is an amber stop codon (TAG) suppressor strain, commonly used as 
host strain of filamentous M13KO7 helperphage and M13KO7ΔpIII hyperphage during 
biopanning (3.4.5). These TG1F+ cells have no antibiotic resistance and were grown on a 
M9 minimal media agar plate at 37 °C. For infection, a single TG1F+ colony was picked, 
transferred into 5 mL 2 x TY media (no antibiotics, no glucose) and grown at 37 °C, 
shaking at 250 rpm O/N. The O/N culture was diluted 1 : 100 into fresh 2 x TY medium 
and grown (37 °C, 250 rpm) to an optical density measured at 600  nm (OD600) of 0.4 –
 0.5. This indicates the logarithmical growth phase when the bacterial F-pili are formed and 
efficient infection with M13KO7 phage is possible. After each cultivation step, TG1F+ 
samples were plated on LBamp and LBkan control agar to check for contaminating 
unspecific M13KO7 phage or plasmids. 
3.1.9.2 DNA amplification and isolation in XL-1Blue 
XL1 Blue E.coli (2.3) were employed for general cloning, plasmid DNA amplification and 
isolation. Transformed XL1 Blue clones were picked from an agar plate for cultivation in 
5 mL (mini-preparation) or 25 mL LB medium (midi-preparation) at 37 °C and 250 rpm 
containing the plasmid-appropriate antibiotic. Important: No glucose was added since it 
clogs the membrane during DNA isolation (3.1.7).  
3.1.9.3 Prokaryotic recombinant protein expression in BL21 Rosetta 2(DE3) 
Large-scale expression of Wx-Ki-4(scFv) and Wx-M12(scFv) fusion proteins: Large 
quantities of the W-tag proteins fused to Ki-4(scFv) or M12(scFv) (5.2) as well as the 
negative and positive expression control proteins (5.2) were fermented in BL21 
Rosetta 2 (DE3) using 1L-Erlenmeyer flasks. Clones were inoculated from cryo stocks, 
grown O/N as pre-cultures in 10 mL modified Wilms-Reuss synthetic medium [232] (2.3) 
supplemented with 20 g/L glucose using 250 mL shake flasks sealed with cotton plugs at 
37 °C, a shaking frequency of 350 rpm and 50 mm shaking diameter. 80 mL fresh 
Wilms-Reuss synthetic medium containing 20 g/L glucose and 50 µg/mL kanamycin were 
inoculated at an OD600 adjusted to 0.1 (same culturing conditions as above). After 4 h, the 
bacterial cultures were induced with 1 mM IPTG, cultivated for another 6 h and harvested 
after 10 h (4000 x g, 4 °C, 30 min). 
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Micro-scale expression of Wx-Ki-4(scFv) and Wx-M12(scFv) fusion proteins: W-tagged 
fusion proteins were also expressed in BL21 Rosetta 2 (DE3) E.coli during the on-line 
measurement in microtiter plates (MTPs). Pre-cultures were prepared as described above. 
200 µL main cultures were inoculated at OD600 0.1 and grown in 96-well MTPs (lumox, 
black, µ-clear, Greiner Bio-One, Kremsmünster, Austria) sealed with a gas-permeable 
membrane (AB-0718; Abgene, Epsom, UK) to allow aeration while minimizing 
evaporation. Cultivation took place in a temperature-controlled room (37 °C) under an 
aerated hood with humidified air to minimize evaporation, at 950 rpm and 3 mm shaking 
diameter. When entering the exponential growth phase (t = 3.2 h), cultures were induced 
with 1 mM ITPG. The maximum oxygen transfer rate in Erlenmeyer and MTP system was 
always maintained by a high shaking frequency with an appropriate shaking diameter using 
small culture volumes in a large shaking volume [239, 240].  
5 mL expression of recombinant scFv, Wx-Ki-4(scFv), and Wx-M12(scFv) proteins: 
W-tagged fusion proteins and isolated scFv clones (after amber stop codon mutation 
(3.4.6) and subcloning into the pMT vector) were expressed in BL21 Rosetta 2 (DE3). 
Expression was either performed using a 25 mL flask in 5 mL Wilms-Reuss synthetic 
medium followed by IPTG induction (as described above) or in a special auto-induction 
medium (2.3) [241]. Therefore, a pre-culture of 5 mL LBkan was inoculated from a cryo 
stock, shaken O/N at 37 °C and 250 rpm. Then 100 µL/sample were inoculated into 10 mL 
main culture (LB auto-induction medium, 50 µg/mL kanamycin) and cultivation was 
continued O/N. 
L3.6pl-specific scFv antibodies were also cultivated in BL21 Rosetta 2 (DE3) to produce 
soluble protein for protein ELISA analysis (3.3.9.3). 
3.1.9.4 Prokaryotic recombinant protein expression in HB2151 
Soluble scFv proteins were produced with the non-suppressor strain HB2151 E.coli 
(3.3.9.3) via the pIT2 phagemid vector using the same expression protocol as in 3.3.9.3. 
No subcloning into an expression vector was needed and the scFv fragments were 
expressed at microtiter scale, directly after QuikChange Mutation of the amber stop codons 
in CDR2 (3.4.6). Produced soluble scFv proteins were analyzed for binding activity in a 
protein ELISA (3.3.9.3). 
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3.1.10 Preparation of bacterial cryo stock cultures 
For all bacterial strains and clones, 5 mL cultures were grown O/N at 37 °C shaking at 
250 rpm in LB or 2 x TY medium supplemented with the plasmid-appropriate antibiotic. 
Cells were pelleted (4500 x g, 4 °C, 10 min) and resuspended in 1 mL cryo medium (2.3). 
This bacterial suspension was quickly transferred into a labeled cryo tube, placed on ice 
and frozen at -80 °C for long-term storage. 
3.1.11 Heat shock transformation of E.coli 
Heat-shock transformation was used to introduce genetic material into chemically 
competent bacteria. Competent cells were thawed on ice for 10 min, 25 µL/sample 
bacterial suspension were transferred into a pre-chilled Eppendorf tube and 1 µL plasmid 
DNA (2 µL for ligations) were added. Cells were incubated on ice for 30 min, then 
heat-shocked in a 42 °C water bath for exactly 45 s since the duration of the heat pulse is 
the critical step for maximum transformation efficiency. Tubes were quickly placed back 
on ice for additional 2 min, then filled up with 250 µL SOC medium (pre-warmed to 
42 °C) and incubated at 225 – 250 rpm for 1 h to allow for development of respective 
antibiotic resistance during cell division. Afterwards 50 – 100 µL bacterial suspension 
(250 µL for ligations) were plated out on LB agar plates supplemented with the 
plasmid-appropriate antibiotic to grow cell colonies in an incubator at 37 °C for 12 – 16 h. 
3.2 Tissue culture and cell processing 
3.2.1 Cultivation of eukaryotic cell lines 
All mammalian cells were incubated at 37 °C in a 5% CO2 atmosphere and 95% relative 
humidity using 75 cm
2
 tissue culture flasks. Confluency dependent, cells were passaged 
and supplied with fresh media every three to four days. Dulbecco’s Phosphate Buffered 
Saline (DPBS) (2.4) was used for all cell lines. Depending on the cell line, cells were 
cultivated in RPMI 1640 Glutamax or DMEM Glutamax (2.4) media supplemented with 
10% FBS (fetal bovine serum) and 1% penicillin/streptomycin (P/S). For full list of media 
composition and components for cultivation and passaging see Table 2-5. 
Adherent cell lines were cultivated in the respective media (2.4). For passaging, cells were 
washed with 4 mL DPBS and detached from the bottom of the flask with 2 mL Accutase
®
 
at RT. Cell suspension was filled up with 8 mL medium and centrifuged (1200 rpm, 4 °C, 
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5 min). Pellet was resuspended in fresh medium and diluted to the optimal cell density 
(between 1 : 3 and 1 : 10). 
The Hodgkins’ lymphoma-derived suspension cell line L540cy, expressing the CD30 
receptor for Ki-4(scFv) binding, was grown in complex RPMI/10/1. Cells were cultivated 
at a density of 0.5 – 1.5 x 10
6
 cells/mL in a 10 mL volume. 
Transfected HEK293T cells, used for the production of soluble scFv-SNAP proteins, were 
cultivated in RPMI/10/1, supplemented with 100 µg/mL Zeocin
®
 for selection pressure 
(RPMI/10/1/Zeo). Cells were passaged every 2 weeks at a 1 : 5 dilution. 
3.2.2 Cryopreservation and reactivation of eukaryotic cell lines 
For freezing, cells were grown in 75 cm
2
 flasks until log-phase for several days to reach 
about 60 – 80% confluence. Adherent cells were detached from flask using Accutase
®
 
before counting. Viable cells in a 10 mL cell suspension were counted in a Neubauer 
haemocytometer. A haemocytometer is a thick glass slide with two counting chambers, 
each 0.1 mm deep. Each chamber is divided into nine large squares delineated by triple 
white lines. The center square is divided into 25 squares which are subdivided into 
16 squares. The entire reticulated part has an area of 9 mm
2
. Trypan blue was used to 
determine the vital cell count. Non-viable cells absorb the dye and appear blue and 
asymmetrical under the microscope, while healthy viable cells are refractory to the dye and 
rounded. 10 µL cell suspension were mixed with 10 µL trypan blue and incubated for 
5 min. A cover slip was placed over the two chambers of the haemocytometer and 10 µL 
of the cell mixture with trypan blue were pipetted to one chamber. Viable cells in the four 
squares at the corners were counted, the average was calculated and the cell concentration 
per mL was calculated using the following formula: cells/mL = average number of counted 
cells x dilution factor x 10
4
. 
Then 10 mL cell suspension were pelleted (1,200 x g, 4 °C, 10 min) and cells were 
resuspended in freezing medium, consisting of 70% RPMI 1640 Glutamax or DMEM 
medium containing adequate antibiotics, 20% FBS and 10% DMSO, to a concentration of 
5 x 10
6
 - 1 x 10
7
 cells/mL, depending on the cell line. 1 mL of this suspension was 
transferred into sterile labeled cryo tube, closed tightly and placed on ice immediately. 
After 5 min the cryo tube was placed into the -20 °C freezer for 2 h, then at -80 °C O/N 
and after that into the liquid nitrogen tank for long-term storage. 
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For thawing, a 75 cm
2
 tissue culture flask was prepared with 10 mL respective medium 
(pre-warmed to 37 °C). A tube with the cryo-preserved cells was removed from the liquid 
nitrogen, thawed at 37 °C until cell suspension was free of ice and cells were immediately 
transferred to the flask with the pre-warmed medium. Cells were left to settle for two days, 
then the media was refreshed and cells were passaged as described in 3.2.1. 
3.2.3 Eukaryotic recombinant protein expression in HEK293T cells 
Isolated L3.6pl-specific scFv antibody fragments, after monoclonal phage ELISA 
screening and site-directed mutagenesis of amber stop codons were subcloned into the 
eukaryotic pMS-SNAPMut expression vector (4.5.3) via SfiI and NotI restriction sites. 
Constructs were transfected into HEK293T cells, to produce soluble scFv protein under 
Zeocin
®
 selection pressure. Soluble scFv-SNAP proteins were used for protein ELISA 
analysis (3.3.9.3), flow cytometrical binding analysis (3.3.10) and internalization assays 
(3.3.11.1). 
3.2.3.1 Transfecting HEK293T cells 
All pMS-scFv-SNAPMut DNA constructs were transfected into HEK293T cells via 
lipofection [242] with the lipofection reagent FuGene HD (Roche Diagnostics GmbH, 
Mannheim) according to manufacturers’ instructions. With this method, exogenous DNA 
is introduced into a cell via cationic lipid vesicles. These vesicles complex the negatively 
charged DNA and create large clusters which are internalized through the cell membrane 
by endocytosis. This transfection process is most efficient in the log-phase when the 
mitosis metabolism in the cell is at its peak and DNA is transported to the nucleus and 
taken up. HEK293T cells were split into a 12-well plate at 6 x 10
4
 cells/well and cultivated 
in RPMI/10/1, for about 24 h or to reach 80% confluency. 2.5 µg purified DNA per 
transfection (3.1.7) were mixed gently with 3 µL FuGene transfection reagent, to reach the 
recommended ratio of approximately 1 : 3, and filled up with 100 µL serum-free RPMI 
Glutamax medium. This mixture was incubated at RT for 15 min to allow formation of the 
transfection complex. Meanwhile 1.5 mL/well fresh RPMI/10/1 was transferred into the 
12-well plate. Afterwards the transfection mixture was added dropwise, incubated at RT 
for 5 min. Then plates were incubated at 37 °C for another 48 – 72 h to allow transfection. 
The pMS-425(scFv)-SNAPMut plasmid was used as positive transfection control, ddH2O 
as negative. 
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3.2.3.2 Cultivation of transiently transfected HEK293T for protein production 
Following 48 – 72 h incubation, the transiently transfected HEK293T cells were supplied 
with 1.5 mL fresh RPMI/10/Zeo for selective pressure to remove untransfected cells. Two 
days later, all transfected HEK293T cells were detached from the 12-well plate using 
Accutase
®
, transferred to a 75 cm
2
 tissue culture flask without splitting and placed at 37 °C 
and 5% CO2 to settle and grow for one week under selective pressure. By then, several 
colonies with transfected HEK293T cells had developed which were singularized with 
Accutase
®
 and placed into a fresh 75 cm
2
 flask for passaging and collection of supernatant 
containing soluble scFv-SNAP proteins (3.2.1). Tissue culture supernatant was harvested 
once a week and stored at 4 °C for up to 6 months since the proteins were stabilized by the 
FBS in the medium. 
Protein production of secreted scFv-SNAP proteins was examined via SDS-PAGE (3.3.1) 
and Western blotting (3.3.2). In addition, the pMS-scFv-SNAPMut vector contains an 
eGFP sequence separated from the scFv-SNAP expression cassette by an IVS/IRES 
sequence. As a result, scFv-SNAP protein expression was monitored under a fluorescence 
microscope (data not shown). 
3.2.4 Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats by means of 
density gradient centrifugation, to use for the preparation of membrane fractions (3.2.5), 
for depletion during biopanning (0, 3.4.5.2) or as negative control during flow cytometrical 
analysis (3.3.10). PBMCs were prepared freshly for each experiment. Buffy coats (45 –
 50 mL) were obtained from the Department of Transfusion Medicine at Aachen 
University Hospital. Blood was carefully withdrawn from the transfusion bag using a 
syringe and transferred to a 50 mL falcon tube where it was mixed with PBS (free of Ca
2+
 
and Mg
2+
!!) at a ratio of 1 : 1. Ficoll Paque PLUS (GE healthcare) was mixed thoroughly; 
15 mL were removed with a syringe and placed in 50 mL falcon tube. Ficoll Paque is an 
aqueous solution of a high molecular weight polysaccharide adjusted to a density of 
1.077 ± 0.001. Next, 30 mL of the blood-PBS mixture were carefully transferred onto the 
Ficoll Paque without disturbing the lower layer forming two phases. The falcon was 
centrifuged (800 x g, 18 – 20 °C, 30 min, brakes switched off). Ficoll-Paque acts as a 
separation medium and during centrifugation cells migrate to form layers containing 
different cell types. Erythrocytes and granulocytes aggregate at the bottom of the flask 
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together with cell debris. At the interface between plasma and Ficoll-Paque layer, 
mononuclear cells are found beside slowly sedimenting particles, such as platelets. After 
separation, the mononuclear ring containing the PBMCs was collected from the falcon. 
Cells were washed three times with 10 mL PBS (200 x g, RT, 5 min) to remove 
contaminations of platelets and cell material. Clean PBMCs were resuspended in PBS or 
homogenization buffer (2.7). 
3.2.5 Preparation of membrane fractions 
Biologically active membrane fragments were produced from different cell lines as a 
source for undefined antigen during solid-phase panning and as coating antigen on 96-well 
plates during screening and ELISA experiments. Cell lines were cultivated, sonicated and 
membrane fractions were isolated using ultra centrifugation [134].  
Cell lines were cultivated in 75 cm
2
 flasks using the appropriate media. About 10 flasks per 
cell line were harvested and 1.8 x 10
7
 cells/preparation/cell line were processed to 
membrane fractions. Adherent cells were detached from the flask with 2 mL Accutase
®
. 
Cells were washed with 3 x 10 mL PBS (200 x g, 4 °C, 10 min). Cells were resuspended in 
8 mL ice-cold homogenization buffer (2.7), counted and incubated on ice for 10 min. This 
cell suspension was sonicated twice for 60 s with intensity of maximum 70% or until the 
cell suspension appeared clear (depending on morphological properties of cell line). The 
clear suspension was centrifuged (1,000 x g, 4 °C, 12 min). The supernatant was 
transferred to ultra-centrifuge tubes and centrifuged (100,000 x g, 4 °C, 20 min). Pelleted 
membrane fractions were taken up in 10 mL ice-cold resuspension buffer (50 mM Tris HCl 
(pH 7.4)) and were ultra-centrifuged again under the same conditions. Finally, the 
membrane fraction pellet was resuspended in 1.2 mL/tube PBS and stored as 300 µL 
aliquots at -80 °C. For L3.6pl and FG membrane fractions ELISA coating buffer was used 
instead of PBS. 
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3.3 Protein chemical and immunological methods 
3.3.1 SDS-PAGE 
Denaturing discontinuous sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) was performed for protein analysis, detection and size separation [233]. 
Protein samples were mixed with 5 x protein loading dye containing ȕ-mercaptoethanol, 
heated to 99 °C for 5 – 10 min for complete denaturation, centrifuged and loaded on a 12% 
polyacrylamide gel next to a pre-stained protein marker for size comparison. Protein 
separation was carried out in a BioRad MiniProtean III Electrophresis chamber at 100 –
 150 V for 1 – 2 h. Then glass plates were removed and separated protein bands were 
stained with Coomassie Brilliant Blue (SERVA, Heidelberg, Germany). The gel was 
destained until protein bands became clearly visible using Destaining Solution (2.7) and a 
sponge. For buffer compositions, stacking and separating gel mixtures see 2.7. Completed 
Coomassie-stained gels were scanned for documentation and subsequent automatic 
imaging data analysis (AIDA) (3.3.3.1). 
3.3.2 Western blot analysis 
Proteins from a duplicate SDS-PAGE (3.3.1) were transferred and immobilized onto a 
nitrocellulose membrane (GE healthcare, UK) with a cooled BioRad Mini Trans-Blot 
device. This method specifically verifies proteins by means of immunochemical 
visualization. Following protein transfer, the membrane was blocked with 2% MPBS for 
2 h at RT, washed 3 x 5 min with PBST and incubated with a penta-anti-His IgG mouse 
primary antibody (2.8) (dilution: 1 : 2000 in PBS) for 1 h at RT. Washing was repeated as 
above and the secondary goat-anti-mouse peroxidase conjugated antibody (2.8) was 
incubated (dilution: 1 : 5000 in PBS) for 1 h at RT. The signal was developed with 3,3′-
diaminobenzidine tetrahydrochloride (DAB) activated with 30% H2O2. Several washing 
steps with PBS stopped the substrate reaction and the blot was scanned for documentation 
and AIDA analysis (3.3.3.1). 
3.3.3  Determination of protein concentration 
Protein concentrations were determined using two different methods: (1) Densitometric 
analysis of protein bands on Coomassie-stained gels by the AIDA Image Analyzer 
software (3.3.3.1) and (2) colorimetric determination with a BC-assay (3.3.3.2). 
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3.3.3.1 AIDA analysis 
Protein samples on the Coomassie-stained gel (3.3.1) were analyzed against a BSA 
standard dilution series (10 µg/mL – 500 µg/mL) run in parallel. AIDA visually compares 
staining density of protein bands and protein concentrations were calculated in relation to 
the BSA standards. Thus, overall protein concentrations as well as the concentration of a 
certain target protein can be calculated. 
3.3.3.2 BC-Assay 
Total protein concentration of purified scFv-SNAP proteins was determined 
colorimetrically with a BC-assay (2.6). In this method, Cu
2+
 ions are reduced to Cu
+
 ions 
and proteins are quantitatively chelated to the monovalent copper ions in presence of 
bicichoninic acid to form a purple and water soluble complex. The color signal was 
developed for 1 h at 60 °C and its absorption was measured at Ȝ = 562 nm. The result was 
interpreted and calculated in Excel based on a straight calibration line from a BSA protein 
standard dilution series (2 – 500 µg/mL). The reaction protocol was carried out in a 
microtiter plate according to the manufacturers’ instructions for the “enhanced protocol”. 
3.3.4 Immobilized metal-ion affinity chromatography 
Eukaryotically expressed soluble scFv-SNAP proteins, as well as prokaryotically 
expressed Wx-Ki-4(scFv) proteins, were purified via the C-terminal His6-tag using 
immobilized metal-ion affinity chromatography (IMAC) [243]. This method facilitates 
small-scale purification of non-denatured prokaryotic and eukaryotic proteins by means of 
batch preparation with a suspended matrix. Its principle is based on the reversible 
interaction between various amino acid side chains (e. g. present in His6-tag) and bivalent 
immobilized metal-ions, such as Co
2+
, Ni
2+
 or Zn
2+
, usually embedded into pockets of an 
iminodiacetic acid (IDA) matrix. His-tagged proteins act as electron donor and transition 
metal ions as electron acceptor, thus forming a reversible ionic bond. Nickel-based resins 
tend to bind host proteins with histidine residues, having an adverse effect on protein 
purity. Instead, cobalt-based TALON resin was employed here to purify the His6-tagged 
proteins under native conditions. Competitive elution with excess imidazole recovers resin-
bound proteins by replacing all His6-tagged proteins on the TALON resin. 
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3.3.4.1 IMAC purification protocol 
Collected tissue culture supernatant (TCSN) containing eukaryotically expressed 
scFv-SNAP proteins (3.2.3) or bacterial crude lysate from prokaryotic expression after cell 
disruption with a combination of TES buffer lysis (3.3.5.2) and sonication (3.3.5.4) were 
processed during IMAC. Cell debris was removed from solutions (4,500 x g (15,000 x g 
for crude lysate), 4 °C, 30 min). Moreover, EDTA was removed from bacterial lysate in an 
additional dialysis step (3.3.6) to prevent it from disturbing the IMAC purification set-up. 
The whole purification process was carried out at RT. For purification, 9 mL TCSN or 
dialyzed crude lysate were mixed with 4 mL 4 x Equilibration buffer (2.7) in a 15 mL 
falcon tube. 150 – 200 µL TALON resin were transferred to a 1.5 mL Eppendorf tube, 
centrifuged (6,000 rpm, 1 min) and washed with 1 mL 1 x Equilibration buffer. 
Supernatant was always removed by dunking the pipet tip into the resin pellet and carefully 
aspirating the liquid. Equilibrated matrix and TCSN or dialyzed lysate were mixed and 
incubated for 1 h on a rotator to allow the His6-tagged proteins to attach to the Co
2+
 ions on 
the TALON matrix. This suspension was centrifuged (1,000 x g, 5 min), and after 
discarding the supernatant the resin was washed twice with 1 mL 1 x Equilibration buffer 
as above. To elute matrix-bound proteins, the matrix was incubated with 150 µL Elution 
buffer containing 250 mM imidazole (2.7) for 20 min on a rotator. The matrix was pelleted 
(6,000 rpm, 2 min), the supernatant containing the eluted protein transferred to a fresh 
Eppendorf tube and stored at 4 °C. 
Purified proteins were analyzed via SDS-PAGE (3.3.1) and Western blotting (3.3.2) to 
determine protein purity and concentration for following protein ELISA (3.3.9.3) and flow 
cytometric binding analysis (3.3.10) as well as internalization assays (3.3.11.1, 3.3.11.2). 
3.3.4.2 SNAP-tag labeling of scFv-proteins with fluorophore dyes 
For subsequent fluorescence-based binding and internalization experiments scFv antibody 
fragments were genetically fused to an engineered version of the human DNA-repair 
enzyme O6-alkylguanine DNA alkyltransferase (hAGT), known as SNAP-tag (1.5.3), by 
subcloning into the pMS-SNAPMut vector [209, 210, 212, 213]. Substrates containing 
O6-benzylguanine derivates can be covalently linked to SNAP fusion proteins providing a 
strategy to equip scFv antibodies with various fluorescent dyes or other imaging reagents 
[209, 211, 215]. The SNAP-tag labeling reaction is highly specific and efficient 
(stochiometrically 1 : 1) but independent of the label’s nature. Substrates BG-Vista Green 
(BG-VG), BG-Alexa Fuor 488 (BG-AF488) and BG-Alexa Fluor 647 (BG-AF647) were 
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purchased from New England BioLabs as lyophilized products, resuspended in 50 µL 
DMSO (stock concentration: 1 nmol/µL) and stored at -20 °C protected from light. For the 
labeling reaction scFv-SNAP proteins were IMAC-purified as described in 3.3.4.1. Right 
before the elution step, matrix-bound proteins were additionally incubated with 150 µL 
1 x Equilibration buffer containing 1.5 µL BG-dye for 1 h at RT on a rotator protected 
from light. Afterwards the resin was washed with 3 x 1 mL 1 x Equilibration buffer, eluted 
and analyzed as described in 3.3.4.1. Successful fluorescence labeling was checked on the 
SDS-PAGE before Coomassie staining under a VersaDoc device. Fluorescence-labeled 
proteins always have to be protected from light to avoid fading of fluorescence intensity. 
3.3.5 Extraction of recombinant protein after prokaryotic expression 
Bacteria-produced periplasmic recombinant proteins were released from the cells by 
application of several methods. Recovered proteins were used for soluble protein ELISA 
(3.3.9.3) or flow cytometric binding analysis (3.3.10), or 2D scans of Wx-Ki-4(scFv) 
proteins (3.5.2).  
3.3.5.1 Lysozyme extraction 
One method for protein extraction after prokaryotic expression was the enzyme-based 
lysozyme extraction. Lysis buffer (2.7) was freshly mixed with 300 µg/mL lysozyme 
(stock solution: 10 mg/mL in 10 mM Tris-HCl, pH 8.0) and the bacterial pellet was 
resuspended. This mixture was incubated at 37 °C for 30 min, then the suspension was 
centrifuged (15,000 x g, 4 °C, 30 min) and the lysate was transferred to a fresh tube. 
3.3.5.2 TES buffer extraction 
Osmotic shock extraction uses the sudden change of solute concentration from high to low 
around the cells. Due to the lower salt concentration, large amounts of water enter the cell 
very rapidly, causing it to swell and burst, thereby releasing the proteins contained in the 
periplasmic space. To release periplasmic proteins from 50 mL pelleted bacterial culture 
(3.1.9.3), they were resuspended in 8 mL 1 x Tris-EDTA-sucrose (TES) buffer (2.7). The 
suspension was incubated for 15 min on ice, then 12 mL 0.2 x TES buffer at RT were 
added and the mixture was incubated for 15 min shaking at RT to keep suspension intact. 
Osmotic lysate with periplasmic proteins was recovered after centrifugation (15,000 x g, 
4 °C, 30 min), transferred to a fresh 15 mL falcon tube. 
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3.3.5.3 Extraction with NP-40 
As third method, the non-denaturing detergent Nonidet-P40 (Applichem, A1694 0250, 
99% pure), normally a detergent for recovery of cytoplasmic proteins was tested. 
Therefore, lysis buffer (2.7) was supplemented with 10 mM of NP-40, the bacterial pellet 
was resuspended and the mixture was incubated on ice for 5 – 10 min. The lysate was spun 
down (15,000 x g, 4 °C, 30 min) and the lysate was collected in a clean tube. 
3.3.5.4 Extraction via sonication 
Harvested bacteria were resuspended in lysis buffer (2.7) and the suspension was sonicated 
five times for 60 s at 70% amplitude (Sonoplus, Bandelin, Berlin, Germany) until the 
solution appeared transparent. The mixture was kept on ice to prevent protein degradation. 
The solution was centrifuged (15,000 x g, 4 °C, 30 min) and released proteins were 
transferred to a fresh tube. 
3.3.6 Dialysis of scFv-protein solutions and crude lysate 
To remove salts, EDTA or imidazole, protein samples and crude cell lysates were passed 
through PD10-desalting columns (GE Healthcare, Munich) thus exchanging the buffer 
with PBS prior to down-stream analysis. This method is based on gravity-flow gel 
filtration for collecting size-sorted molecules. For dialysis, sample volume was adjusted to 
2.5 mL, then columns were calibrated with 2 x 10 mL ddH2O and samples were loaded 
onto the column. The flowthrough with the low-molecular contaminants was discarded and 
protein was eluted from gel filter with 3 – 3.5 mL PBS, whereas salts remain on the 
column. 
3.3.7 Concentrating protein solutions 
Samples of large volume and low protein content were concentrated by means of 
Vivaspin 6 (15 mL) or Vivaspin 20 (50 mL) ultrafiltration spin columns with a protein 
cut-off at 5 or 30 kDa depending on protein size. Molecules below cut-off pass the 
polyethersulfon membrane in the concentration centrifugators. A large volume of a protein 
solution was transferred to the upper compartment of the spin columns and centrifuged 
according to the manufacturers’ instructions at 4 °C to the desired volume and 
concentration. Contaminants were removed efficiently by refilling the protein solution with 
PBS to 5 or 10 mL and repeated centrifugation. Final protein concentrate was recovered 
directly from the spin column and transferred to a fresh tube to determine protein content. 
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3.3.8 Mass spectrometrical analysis 
As analytical method to determine molecules and molecule fragments mass spectroscopy 
was employed to verify the identity of W-tagged and non-tagged scFv antibody fragments. 
A protein band was excised from a Coomassie-stained SDS-PAGE (3.3.1), shredded and 
decolorized by adding ammonium hydrogen carbonate (NH4HCO3) and acetonitrile. After 
denaturation with dithiothreitol (DTT) and alkylation with iodine acetamide, mass 
spectrometric analysis was performed by Michael Küpper from Fraunhofer Institute IME 
(Aachen). Molecules were analyzed with an ESI-MS/MS mass spectrometer (Micromass 
Electrospray Q-TOF 2, Waters Corporation, Eschbor) after proteolytic cleavage with 
trypsin and gel extraction in a nanoHPLC (Dionex, Germering). Identified molecule 
fragments were evaluated using the protein data base MASCOT (Matrix Science, London, 
UK). 
3.3.9 Enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay (ELISA) is a common antibody-dependent 
detection assay based on an enzymatic color change reaction, thus identifying binding 
activity to an immobilized antigen on an MTP. ELISA was used to show enrichment of 
L3.6pl-binding scFv-phage particles (3.3.9.1), to screen for sequence-unique 
L3.6pl-specific scFv-phage particles (3.3.9.2) and to test cross reactivity to other cell lines 
(3.3.9.2). Moreover, specific binding activity of soluble scFv-SNAP proteins after 
eukaryotic expression was documented (3.3.9.3) by ELISA. Membrane preparations 
(3.2.5) of L3.6pl and PBMC cells were coated as antigen, as well as membrane 
preparations of several other cell lines during cross reactivity testing (4.3.2). 
General information for all ELISA experiments: (a) All blocking and incubation steps were 
performed out on an orbital shaker (400 rpm), (b) bacterial MTP cultures were covered 
with a semi-permeable membrane to ensure sufficient oxygen supply for bacterial growth 
and (c) MTPs with phage-containing solutions or bacterial cultures were covered with an 
air-tight plastic seal to avoid phage-related cross-contamination to neighboring wells or the 
incubator. 
3.3.9.1 Polyclonal phage ELISA 
After each selection round, polyclonal phage pools were analyzed for enrichment of 
L3.6pl-specific scFv-phage fragments. The scFv-phage pools of all three selection rounds, 
as well as the original Tomlinson Libraries, were precipitated with PEG/NaCl (2.7) and 
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resuspended in PBS to reach a phage concentration (3.4.4) of 1 x 10
11
 pfu/mL. A 96-well 
MTP was coated with 100 µL/well L3.6pl membranes (dilution: 1 : 100 in ELISA coating 
buffer) and 100 µL/well FG or PBMC membranes, respectively, at the same antigen 
dilution. Antigen was immobilized on MTPs by incubation at 4 °C for 12 – 16 h without 
shaking. Then the antigen was quickly washed with 3 x 200 µL/well PBS and blocked with 
200 µL/well 2% MPBS for 2 h at RT. In parallel, the polyclonal scFv-phage pools were 
blocked with 2% MPBS at a ratio of 1 : 1. Afterwards, wells were washed as above and 
100 µL/well blocked scFv-phage solution was added to the respective wells. After 
incubation of the scFv-phage solution for 1 h at RT unbound scFv-phage particles were 
removed with 3 x 200 µL/well PBST and 100 µL/well secondary HRP/anti-M13 
monoclonal conjugated antibody (dilution: 1 : 5,000 in 2% MPBS) were incubated for 1 h 
at RT. Then wells were washed as before and 100 µL/well fresh ABTS (2,2'-azino-bis(3-
ethyl-benzothiazoline-6-sulphonic acid) substrate solution were added and incubated at RT 
for 15 – 60  min. ABTS absorbance was measured in a Tecan Reader (2.2) at 405 nm 
(reference wavelength 490 nm) every 15 min. 
To verify results, all polyclonal scFv-phage pools were analyzed as triplicates. Moreover, 
every assay was performed twice with M13KO7 helperphage and repeated once with 
M13KO7ΔpIII hyperphage. 
3.3.9.2 Monoclonal phage ELISA 
After biopanning a population of scFv-phage particles was screened by a monoclonal 
phage ELISA to identify unique scFv-phage clones with L3.6pl-specific binding activity. 
A 5 mL 2 x TYgluc,amp culture was inoculated from TG1F+ E.coli glycerol stocks resulting 
from the third selection round and grown for 8 h at 37 °C and 250 rpm. 1 : 100 dilutions 
ranging from 10
-2
 to 10
-8
 were prepared with 2 x TYgluc,amp medium, then 10 µL/dilution 
was plated on an LBamp agar plate and incubated O/N at 37 °C. Single colonies carrying the 
information for one unique phagemid were picked to produce a single scFv-presenting 
clone for monoclonal phage ELISA analysis. Individual clones were each inoculated into a 
96-well MTP with 150 µL/well 2 x TYgluc,amp medium and grown at 37 °C and 250 rpm 
O/N. A cryo stock was prepared from this original 96-well MTP (3.1.10) from which a 
small inoculum (~1 – 2µL/well) was transferred to a fresh 96-well MTP containing 
200 µL/well 2 x TYgluc,amp medium. Cultures were grown at 37 °C and 250 rpm for 2 h to 
reach an approximate OD600 of 0.4 – 0.5, then 25 µL/well 2 x TYgluc,amp medium were 
added containing 1 x 10
9
 pfu/well M13KO7 helperphage. Wells were infected at 37 °C 
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without shaking for 30 min and another 30 min shaking at 37 °C and 250 rpm. Then the 
MTP was centrifuged (1,800 x g, 4 °C, 10 min), the supernatant was discarded and the 
bacterial pellet resuspended in 200 µL/well 2 x TY induction medium (2.3) to induce 
phage production. The MTP was placed at 30 °C and 250 rpm for 18 – 20 h to promote 
phage production. Next, scFv-phage cultures were centrifuged as above and the 
supernatant containing the scFv-phage was blocked with 2% MPBS (ratio 1 : 1) for 2 h 
before monoclonal phage ELISA analysis. For the monoclonal ELISA procedure the same 
protocol was used as for the polyclonal phage ELISA (3.3.9.1). 
One sample was analyzed per well, and thus each monoclonal phage ELISA was repeated 
three times to ensure reproducibility of the results. 
Antigen coating: Membrane fractions of L3.6pl and other cell lines were coated on the 
96-well MTP in 100 µL/well (dilution: 1 : 100 in ELISA coating buffer or PBS) and 
immobilized at 4 °C O/N. Living cells were coated 24 h previous to the ELISA 
experiment. 100 µL/well cell suspension, at 20,000 cells/well, were seeded out in 
RPMI/10/1 and grown. PBMCs were isolated (3.2.4), diluted to a concentration of 
20,000 cells/well and centrifuged to the MTP bottom, first at 500 x g for 5 min, then with 
increased centrifugation force for 30 min at 4,500 x g. The supernatant covering all cells 
was discarded and wells were air-dried for 2 min. Then 100 µL/well of ice-cold EtOH 
(-20 °C) were incubated on ice (under a hood) for 10 min to fix cells onto MTP.  
3.3.9.3 Protein ELISA 
After monoclonal phage ELISA screening (3.3.9.2) and site-directed mutagenesis of amber 
stop codons (3.4.6), L3.6pl-specific scFv antibodies were analyzed as soluble protein 
expressed in: (1) A prokaryotic system via pIT2 vector in HB2151 or pMT vector in BL21 
Rosetta 2 (DE3) E.coli, or (2) via the eukaryotic pMS-SNAPMut vector transfected into 
HEK293T cells (3.2.3). Binding activity and specificity without an attached phage 
particles, possibly interfering with the specific scFv-binding, was tested on L3.6pl 
membrane fractions (antigen coating as in 3.3.9.2). Samples were analyzed in triplicates 
and the soluble protein ELISA was repeated twice to confirm reproducibility of binding 
results. 
Prokaryotic expression: Soluble scFv proteins were expressed as 5 mL cultures as 
described in 3.1.9.3. Bacteria were pelleted (4,500 x g, 4 °C, 15 min) and periplasmic 
proteins were recovered via TES buffer lysis (3.3.5.2). The lysate was analyzed via 
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SDS-PAGE (2.7) before performing the ELISA experiment. Blocking, washing and 
incubation steps were analogous to the polyclonal phage ELISA (3.3.9.1), but different 
antibodies were applied. Specific L3.6pl-binding scFv antibodies were detected with a 
monoclonal anti-poly His mouse IgG antibody (dilution: 1 : 2500 in PBS) against His6-tag 
which was then bound by a goat-anti-mouse peroxidase-conjugated IgG secondary 
antibody (dilution: 1 : 5000 in PBS). ABTS substrate was added to develop a signal 
(3.3.9.1). The W-tagged Ki-4(scFv) proteins, after dialysis (3.3.6) and Vivaspin 
concentration (3.3.7), were treated likewise. 
Eukaryotic expression: TCSN containing scFv-SNAP proteins (3.2.3) was collected and 
the protein concentration analyzed via SDS-PAGE. Blocking, washing and incubation 
steps were analogous to the polyclonal phage ELISA (3.3.9.1). Bound scFv-SNAP proteins 
were captured with a commercial polyclonal anti-SNAP-tag rabbit IgG (dilution: 1 : 5,000 
in PBS). For specific detection a goat-anti-rabbit HRP-conjugated IgG antibody (dilution: 
1 : 5,000 in PBS) was applied followed by signal development with 100 µL/well fresh 
ABTS (3.3.9.1). 
3.3.10 Flow cytometric analysis 
Binding activity of L3.6pl-specific scFv-SNAP proteins and Wx-Ki-4(scFv) fusion 
proteins on a native antigen conformation was analyzed via flow cytometry. PBMCs were 
used as negative control. Samples were centrifuged at 1,200 x g at 4 °C for 5 min. Mean 
fluorescence intensity values (MFI) and geometrical mean values (%G mean) of the flow 
cytometry measurements were displayed as percent changes in relation to 425(scFv) 
positive control or Ki-4(scFv) expression control (100%). MFI was calculated by 
CellQuest Pro or WinMDI 2.9 software (Table 2-1). All measurements were performed 
with a FACScalibur flow cytometer (Table 2-2). 
3.3.10.1 Binding analysis of scFv-SNAP proteins 
50 µL L3.6pl and PBMC cell suspensions (2 x 10
5
 cells/mL) were transferred into FACS 
tubes and washed with 1 mL ice cold PBS. 300 µL/tube unpurified TCSN containing 
scFv-SNAP proteins (3.2.3) or 2 µg IMAC-purified protein (3.3.4) were added and 
incubated on ice for 1 h. Cells were washed once with 1 mL PBS, incubated on ice with 
100 µL/tube penta-anti-His Alexa Fluor 488 conjugated antibody (dilution: 1 µg/mL) for 
30 min and washed again twice. Cell pellet was resuspended in 500 µL/tube ice cold PBS 
containing 1 µg/mL propidium iodide to sort out dead cells. The fluorescence signal of 
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bound proteins was measured and analyzed. The same conditions were employed during 
flow cytometric cross-reactivity testing to other cell lines. 
3.3.10.2 Binding analysis of BG-coupled scFv-SNAP proteins 
L3.6pl and PBMC cells were transferred into FACS tubes and treated as in 3.3.10.1. Then 
2 µg IMAC-purified BG-coupled protein (3.3.4) were added and incubated on ice for 1 h. 
Used scFv-SNAP proteins were either coupled to BG-VG or BG-AF488 for measurement 
of green fluorescence or to BG-AF647 for red fluorescence documentation. Cells were 
washed twice with 1 mL PBS and resuspended in 500 µL/tube ice-cold PBS containing 
1 µg/mL propidium iodide to sort out dead cells (propidium iodide staining was not used 
for measurement of BG-AF647 coupled scFv proteins since the signal of propidium iodide 
interfered with the measurement). The fluorescence signal of bound proteins was measured 
and analyzed as in 3.3.10.1. 
3.3.10.3 Binding analysis of Wx-Ki-4(scFv) fusion proteins 
L540cy and PBMC cell suspensions (2 x 10
5
 cells/mL) were transferred into FACS tubes 
and treated as described in 3.3.10.1. Then 2 µg of each Wx-Ki-4(scFv) fusion protein, 
present in bacterial crude extract after TES-lysis (3.3.5.2) were incubated on ice for 1 h. 
Binding of Wx-Ki-4(scFv) fusion proteins to L540cy cells was detected via the His6-tag as 
described in 3.3.10.1. 
3.3.11 Fluorescence-based internalization assays 
When developing therapeutic treatment options it is essential to isolate scFv antibodies 
with internalizing properties. Internalization into a diseased target cell after binding to its 
cellular surface is a very basic requirement for cytolytic cancer therapeutics (e. g. 
immunotoxins) to unfold their full effect within the cell. Moreover, rapid degradation of 
the medicine in the body is prevented leading to better treatment results. Newly isolated 
scFv antibodies isolated from the Tomlinson Libraries I and J were characterized for 
internalization behavior by means of flow cytometry (3.3.11.1) and OPERA-based 
confocal microscopy on living cells (3.3.11.2) as well as on immunofluorescence-stained 
fixed and permeabilized cells (3.3.11.2). The well-documented and rapidly internalized 
EFGR-binding 425(scFv) antibody fragment [158, 159] was used as positive control 
throughout all internalization experiments. 
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3.3.11.1 Flow cytometry-based internalization testing 
All incubations at 4 °C were performed in 1% NaN3 to prevent too rapid internalization. 
Incubations at 37 °C were carried out in serum-free RPMI medium to create a most viable 
environment encouraging internalization. For washing, cells were resuspended in 1 mL 
ice-cold PBS and pelleted (1,200 rpm, 4 °C, 5 min). To test for surface binding and 
internalization, 1 x 10
6
 L3.6pl cells/tube were incubated for 1 h with 300 µL NaN3 or 
RPMI 1640 Glutamax medium, containing 3 µg AF647-coupled scFv-SNAP protein. 
Incubation was conducted at 4 °C to allow cell surface attachment only, and another in 
parallel at 37 °C to promote internalization of 647-labeled scFv-SNAP proteins. Then cells 
were washed with 1 x 2 mL PBS and the red fluorescence signal of 4 °C and 37 °C 
incubations was measured using a FACScalibur device. For measurements, cells were 
always resuspended in 500 µL/tube 0.5% PFA. Afterwards surface-bound scFv-SNAP 
proteins were digested off with 500 µL/tube 0.25% trypsin-EDTA at 37 °C for 5 – 10 min. 
Trypsin reaction was stopped by addition of 500 µL/tube RPMI medium supplemented 
with 20% FBS. Then, cells were washed once and the fluorescence signal was measured 
again. For 4 °C incubations, no fluorescence signal was expected after trypsinization. 
However, for 37 °C incubations the fluorescence signal should still be present from inside 
the cells if the internalization process has been successful. As additional control, L3.6pl 
cells before and after trypsinization were incubated with a penta-anti-His Alexa Fluor 488 
conjugated IgG as secondary detection antibody to confirm removal of all surface-bound 
scFv-SNAP proteins by trypsinization. Therefore, cells were resuspended in 100 µL/tube 
NaN3 containing 1 µg/mL secondary antibody, incubated on ice for 30 min., washed twice, 
measured and analyzed as described in 3.3.10. This protocol has been adapted from Xiao et 
al., 2008 [244]. 
3.3.11.2 OPERA-based confocal microscopy 
Real-time observation of living L3.6pl cells: All scFv-SNAP fusion proteins with a 
positive internalization outcome in 3.3.11.1 were examined further during live cell imaging 
with OPERA-based confocal microscopy at Fraunhofer IME (Aachen). The OPERA 
measurement device is a fully automated system for confocal microscopy able to measure 
several samples and their replica wells in parallel and to visualize internalization kinetics 
for several hours in real-time under cell cultivating conditions. The laser analysis system 
was able to focus on different layers throughout the cell and to stack the pictures for 
subsequent documentation and analysis. L3.6pl cells were split onto a 96-well MTP 
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(Greiner, black, µ-clear) at 20,000 cells/well, and placed at 37 °C to settle and adhere O/N 
in RPMI/10/1. Afterwards, culture medium was exchanged with serum-free medium for 
2 – 4 h. Then, wells were washed twice with 200 µL ice-cold PBS and 3 µg scFv-SNAP 
protein labeled with BG-AF647 were incubated at 4 °C in 50 µL/well RPMI medium 
without phenol red (color would disturb measurement) for 30 – 60 min to visualize binding 
to the cell surface. Again wells were washed with 3 x 200 µL PBS to remove excess dye or 
unbound proteins. The MTP was then placed at 37 °C to induce internalization. 
Internalization was observed and measured with the OPERA system after 30, 60 and 
80 min via AF647 fluorescence. To remove background fluorescence related to free AF647 
dye, wells were washed repeatedly with PBS. AF647-labeled Ki-4(scFv)-SNAP protein, 
without internalizing properties on L3.6pl cells, served as negative control. Samples were 
measured as triplicates and pictures were taken of surface-bound as well as internalized 
scFv-SNAP proteins. 
Immunofluorescence staining: L3.6pl cells were seeded into a 96-well MTP (Greiner, 
black, µ-clear) at 20,000 cells/well and grown O/N in full media. Medium was exchanged 
to serum-free and cells were incubated for another 3 – 4 h. Wells were washed twice with 
200 µL PBS and 150 µL/well unpurified TCSN containing soluble scFv-SNAP proteins 
were added. Proteins incubated at 37 °C for different time periods (4 h, 3 h, 2 h and 1 h) to 
examine internalization behavior. In parallel, the same scFv-SNAP proteins were incubated 
at 4 °C for 1 h to confirm cell surface binding. Next, wells were washed twice with 200 µL 
ice-cold PBS, fixed with 200 µL 4% PFA for 10 min at RT and washed again with PBS 
(2 x 5 min and 3 x fast). Half of the wells were permeabilized with 100 µL 
0.1% TritonX100 in PBS for 10 min at RT and washed with PBS (3 x 5 min). Unspecific 
sites were blocked with 200 µL/well 3% BSA/PBS (BSA: IgG-free fraction V) for 1 h at 
RT or at 4 °C O/N. Wells were cleaned with PBS (3 x fast) and the polyclonal anti-SNAP-
tag rabbit IgG secondary antibody (dilution: 1 : 5,000 in 1% BSA/PBS) was incubated for 
1 h at RT or at 4 °C O/N. Afterwards, cells were washed again with PBS (2 x fast, 
3 x 5 min.). Next, the anti-rabbit IgG (H+L), F(ab)2 Fragment (Alexa®647) tertiary 
detection antibody (dilution: 1 : 1,000 in 1% BSA/PBS) was incubated for 1 h at RT. Wells 
were washed using same washing conditions as above and 100 µL/well DAPI solution 
(dilution: 1 : 10,000 in PBS) were added for counter-staining of nuclei. Fluorescence 
intensity of bound scFv-SNAP proteins was detected via the OPERA system. Measurement 
parameters were adjusted with the OPERA software Evoshell with the help of Dr. Stefano 
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Di Fiore at Fraunhofer IME (Aachen). Figures were evaluated and edited using the ImageJ 
1.42q software. 
3.4 Phage Display Technology 
In this work, the naïve human and semi-synthetic Tomlinson Phage Libraries I and J 
(1.3.3) were used for the isolation of L3.6pl-specific scFv antibody fragments using phage 
display technology. To avoid confusion between clones selected from the two libraries, 
biopanning was performed separately. 
3.4.1 Cultivation of Tomlinson Libaries I and J 
Each library was received as a 500 µL cryo stock containing phagemid-carrying TG1F+ 
E.coli. 200 mL pre-warmed 2 x TYgluc,amp medium (2.3) were inoculated with it and grown 
O/N at 37 °C and 250 rpm. Bacteria were pelleted (4,000 x g, 4 °C, 10 min), resuspended 
in 10 mL 2 x TY cryo medium (2.3), aliquoted (500 µL/tube) and stored at -80 °C (3.1.10). 
Tomlinson library cultures for phage display selection were inoculated from these stocks 
and grown O/N as 5 mL 2 x TYgluc,amp medium pre-culture at 37 °C and 250 rpm. 25 mL 
fresh 2 x TYgluc,amp medium were inoculated with 500 µL pre-culture and grown in a sterile 
250 mL Erlenmeyer flask at 37 °C and 250 rpm to OD600 of 0.5. This optical density 
indicates the logarithmic growth phase of TG1F+ E.coli when phage infection via extended 
F-pili is possible (1.3.1). 
3.4.2 Phage infection and production 
5 mL of this culture (3.4.1) were infected with M13KO7 helperphage or M13KO7ΔpIII 
hyperphage, at a multiplicity of infection (MOI) ≥ 20, and incubated for 30 min at 37 °C 
without shaking followed by 30 min shaking at 37 °C and 250 rpm. The infected culture 
was centrifuged (4,000 x g, 4 °C, 5 min), the supernatant discarded and the infected 
bacterial pellet was resuspended in 25 mL 2 x TY induction medium (2.3) to promote 
phage production. The suspension was sealed in air-tight Erlenmeyer plastic flasks and 
incubated at 30 °C and 250 rpm for 18 – 20 h. As infection control, 50 µL of this 
suspension were also plated on LBkan agar and incubated at 37 °C O/N. Phage pools were 
prepared freshly before each selection round. 
Methods 
 
 
67 
3.4.3 Phage precipitation 
The bacterial culture (3.4.2) was spun down (4,500 x g, 4 °C, 30 min), the phage-
containing supernatant transferred to a 50 mL falcon tube and 1/5 volume ice-cold 
PEG/NaCl (2.7) was added. At low temperatures, the presence of PEG shifts the solubility 
constant of the phage particles in solution, thus precipitating phage particles during 
incubation on ice for 1 h. Precipitated phage were pelleted (12,000 x g, 4 °C, 30 min) and 
the phage pellet was resuspended in 200 – 1000 µL PBS (depending on the selection round 
and strategy). Phage solutions were stored at 4 °C until use. 
3.4.4 Titer determination 
Before and after each selection round, the phage input and output titer was determined with 
the colony method, where ampicillin-resistant TG1F+ cultures were counted after infection 
with a dilution series of M13KO7 helperphage. Therefore, 10 mL 2 x TYgluc,amp medium 
were inoculated with a single uninfected TG1F+ colony from an M9 minimal agar plate 
(2.3) and grown at 37 °C and 250 rpm to an OD600 of 0.5. Then phage suspensions, either 
after PEG-precipitation or elutions after panning, were diluted 1 : 100 in 200 µL PBS 
(dilutions: 10
-2
 to 10
-16
) and used to infect fresh TG1F+ E.coli by incubation for 1 h at 
37 °C and 250 rpm. 10 µL of each dilution were spotted on an LBgluc,amp agar plate and 
incubated at 37 °C for 12 – 16 h. Plaque forming units (pfu), i. e. resistant bacterial 
colonies, were counted and phage concentration was calculated as follows: 
phage concentration [pfu/mL] = 
୬	ሾ୮୤୳ሿ	ൈ	ହሻሺୈ୊	ൈ	୴୭୪୳୫ୣ	ሾ୫୐ሿ 
(n = counted number of ampicillin-resistant colonies on one plate (e.g. plate with 10-6 dilution); DF = dilution factor of 
phage suspension from plate with counted colonies (e.g. at 10-6 dilution); volume = plated volume of phage-bacteria 
mixture of 10 µL; 5 =  dilution of phage-bacteria mixture; pfu = plaque forming units) 
3.4.5 Biopanning 
L3.6pl-specific scFv antibody fragments were selected via three panning strategies:  
(1) Solid-phase panning on adherent viable cells under internalizing conditions (3.4.5.1),  
(2) suspension panning on living cells under internalizing conditions (3.4.5.2) and  
(3) solid-phase panning on membrane fractions for selection of surface-binding scFv 
fragments (3.4.5.3). 
Each complete selection consisted of three panning rounds. First selection rounds were 
always performed with the polyvalent M13KO7ΔpIII hyperphage. This particular phage is 
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missing the gene coding for the pIII coat protein (ΔpIII), hence displaying five copies of a 
specific scFv fragment fused to pIII when produced in TG1F+ E.coli. It shows a much 
stronger binding affinity to a specific surface protein than phage particles with only one 
copy. By this a maximum amount of scFv fragments with unspecific binding to the 
depletion antigens were removed whereas the ones displaying L3.6pl-specific binding were 
rescued to the next selection round. Second and third selection rounds were carried out 
with the monovalent M13KO7 helperphage carrying one scFv-pIII protein on its surface. 
Antigen concentrations were reduced with continuing selection rounds along with 
increasing washing stringency to eliminate scFv-phage particles with unspecific binding 
properties. For detailed instructions to phage display technology, the Tomlinson libraries 
and a general panning schematic see Figure 1-3. 
3.4.5.1 Panning on adherent L3.6pl cells under internalization conditions 
Two days prior to panning 1 x 10
6
 L3.6pl cells were split into a 25 cm
2
 tissue culture flask 
with RPMI/10/1 medium. The same was done for the FG cell line. To avoid cell loss 
during panning, cells had to be adhered to the bottom of the flask. The same cell 
concentration was used for each selection round.  
Throughout selection rounds, 1 mL precipitated scFv-phage particles (3.4.3) were blocked 
with 5% MRPMI (ratio 1 : 1). This mixture was transferred to an empty 25 cm
2
 tissue 
culture flask and incubated at RT for 2 h on a shaker to block the unspecific binding sites 
and to eliminate plastic binders. Simultaneously, FG and L3.6pl cells were washed three 
times with 2 mL PBS and were each blocked with 2 mL 5% MRPMI for 2 h at RT. 
Cross-reactive scFv-phage particles were separated from L3.6pl-specific binders via 
depletion on FG cells, before selection on L3.6pl cells. Therefore, blocked phage solution 
was transferred onto the FG cells and incubated for 1 h at RT shaking slightly.  
This solution containing the non-bound phage after subtractive selection on FG cells was 
transferred onto the L3.6pl cells for positive selection. The phage mixture was incubated at 
37 °C for 1 h shaking slightly. The supernatant was discarded and L3.6pl cells were 
washed with PBS and PBST according to washing steps listed in Table 3-3. 
Table 3-3 Washing steps with increasing stringency applied during solid phase selection on 
adherent whole cells. 
 Selection round 1 Selection round 2 Selection round 3 
Washing steps 
3 x PBST quick 
2 x PBST 5 min on shaker 
3 x PBS quick 
2 x PBS 5 min on shaker 
1 x PBST quick 
4 x PBST 5 min on shaker 
1 x PBS quick 
4 x PBS 5 min on shaker 
1 x PBST quick 
4 x PBST 5 min on shaker 
1 x PBS quick 
4 x PBS 5 min on shaker 
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Phage were collected via proteolytic elution with 600 µL 0.2 M glycine HCl (pH 2.2) 
incubated on L3.6pl cells for 10 min at RT shaking slightly. The eluate was neutralized 
with 1500 µL 1 M Tris-HCl (pH 7.4), transferred to a fresh tube. L3.6pl cells were 
dissolved in 600 µL 0.1 M TEA (pH 12) by incubation for 10 min at RT and subsequently 
neutralized with 1500 µL 1 M Tris-HCl (pH 7.4). Output titers of phage eluate and lysate 
were determined (3.4.4) and two falcons with 14 mL E.coli TG1F+ suspension at an OD600 
of 0.5 were infected with the phage eluate and lysate, respectively. Infected cultures were 
centrifuged (4,000 x g, 4 °C, 10 min) and the pellet was resuspended in 600 µL 2 x 
TYgluc,amp medium. The bacterial suspension was plated on four LBamp agar plates and 
incubated at 37 °C for 12 – 16 h. Afterwards ampicillin-resistant colonies were scraped 
from the plate with 1.5 mL 2 x TY cryo medium and 1 mL/tube bacterial suspension were 
placed at -80 °C for long term storage. 
Figure 3-1 visualizes the selection strategy for the isolation of specific scFv fragments on 
adherent L3.6pl cells. 
 
Figure 3-1 Schematic for phage display selection on adherent whole L3.6pl cells.  
(A) Complete phage pool is incubated on the adherent L3.6pl cells for binding and internalization at 37 °C, 
(B) unbound phage particles are washed away in several washing step of differing stringency, (C) surface-
bound phage particles are eluted from the cells via a pH shift and I the eluted phage particles are amplified 
again so that they can be used for the next selection round starting again with (A) or for further 
characterization. (D) Phage particles that have been internalized during incubation at 37 °C are recovered via 
cell lysis. I Phage particles from lysis fraction are amplified again. 
3.4.5.2 Suspension panning on L3.6pl cells under internalizing conditions 
1 x 10
6
 L3.6pl cells and same amount of PBMC cells were harvested, washed twice with 
5 mL PBS and transferred to a 15 mL falcon tube. PBMCs were freshly isolated before 
each selection round (3.2.4). The same cell concentration was used for all three selection 
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rounds, all centrifugation steps were carried out at 200 x g at 4 °C for 2 min. To ensure that 
the cells were able to survive shear stress implied by repeated centrifugation, the third 
selection round was simulated previous to this panning strategy (Table 3-4).  
Table 3-4 Washing steps with increasing stringency used for selection rounds one, two and three 
during suspension panning with whole L3.6pl cells 
 Selection round 1 Selection round 2 Selection round 3 
Washing steps 
3 x PBST quick 
2 x PBST 5 min on shaker 
3 x PBS quick 
2 x PBS 5 min on shaker 
1 x PBST quick 
4 x PBST 5 min on shaker 
1 x PBS quick 
4 x PBS 5 min on shaker 
1 x PBST quick 
4 x PBST 5 min on shaker 
1 x PBS quick 
4 x PBS 5 min on shaker 
The same protocol as described in 3.4.5.1 was used for panning, internalization, lysis and 
re-infection of scFv-phage fragments with the only difference that the phage-scFv particles 
were not eluted from the cells but lysis was performed right away. Figure 3-2 shows a 
schematic of the applied suspension panning strategy. 
 
Figure 3-2 Schematic for phage display selection on L3.6pl cells in suspension.  
(A) Complete phage pool is incubated on L3.6pl cells in suspension for binding and internalization at 37 °C, 
(B) unbound phage particles are washed away in several washing step of differing stringency, (C) surface-
bound and internalized phage particles are recovered at the same time via total cell lysis without previous 
elution and (D) the recovered phage particles are amplified again so that they can be used for the next 
selection round starting again with (A) or for further characterization. 
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3.4.5.3 Panning on membrane fractions 
100 µL/well PBMC and L3.6pl membrane fractions were coated on a 96-well MaxiSorb 
MTP at 4 °C for 12 – 16 h to immobilize the depletion and selection antigens. Antigen 
concentration was decreased during the panning process as well as the number of coated 
wells ( 
Table 3-5). L3.6pl membrane fractions were diluted in ELISA coating buffer (pH 9.6), 
PBMC membrane fractions in PBS (pH 7.4). 
Table 3-5 Dilution of membrane fraction antigen used for selection rounds one, two and three. 
 Selection round 1 Selection round 2 Selection round 3 
Antigen dilution Undiluted 1 : 10 1 : 100 
Number of coated wells 4 3 2 
Precipitated phage solutions were resuspended in 600 µL for the first, 400 µL for the 
second and 200 µL PBS for the third selection round. The precipitated phage pools were 
blocked with 5% MPBST (ratio 1 : 1). 200 µL/well 5% MPBST-phage mixture was 
transferred to empty wells (number of wells according to selection round) on the MTP and 
incubated at RT for 2 h on a shaker to block the unspecific binding sites as well as to sort 
out plastic-binding scFv-phage units. Simultaneously, wells coated with PBMC and L3.6pl 
antigen were washed with 3 x 200 µL PBS and were blocked with 200 µL 5% MPBST for 
2 h at RT. 
Cross-reactivity to healthy human cells was eliminated by negative selection on PBMC 
membranes. Therefore, blocked phage solutions were transferred to the PBMC-coated 
wells and incubated for 1 h at RT on a shaker before positive selection on L3.6pl antigen. 
The depleted phage solution was transferred onto the L3.6pl membranes and incubated on 
a shaker for 1 h at RT. Afterwards the supernatant containing unbound scFv-phage 
particles was discarded and the antigen was washed with PBS and PBST at RT according 
to the washing steps listed in Table 3-6. 
Table 3-6 Washing steps with increasing stringency applied during selections rounds one to three 
for all modes of selection. 
 Selection round 1 Selection round 2 Selection round 3 
Washing steps 
3 x PBST quick 
2 x PBST 5 min on shaker 
3 x PBST quick 
2 x PBST 5 min on shaker 
1 x PBST quick 
4 x PBST 5 min on shaker 
1 x PBST quick 
4 x PBST 5 min on shaker 
10 x PBST quick 
5 x PBST 5 min on shaker 
10 x PBST quick 
5 x PBST 5 min on shaker 
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Surface-bound scFv fragment antibodies were eluted via a pH shift. 200 µL/well 
0.2 M glycine-HCl (pH 2.2) were added to each antigen-coated well, incubated for 10 min 
at RT on a shaker and neutralized with 500 µL/well 1 M Tris-HCl (pH 7.4). The titer of 
each eluate was determined by drawing a 2 µL aliquot (3.4.4) and the phage were 
transferred to 14 mL TG1F+ suspension grown to an OD600 of 0.5. In parallel, 200 µL/well 
of the same TG1F+ culture were transferred into each phage-containing well on the MTP 
and both were incubated for 1 h at 37 °C without shaking to allow infection. Infected 
cultures were pooled and panning was finished as described in 3.4.5.1. Panning strategy on 
membrane fractions is illustrated in Figure 3-3. 
 
Figure 3-3 Schematic for phage display selection on L3.6pl membrane fractions.  
(A) Complete phage pool is incubated on the membrane fractions for binding, (B) unbound phage particles 
are washed away in several washing step of differing stringency, (C) bound phage particles are eluted from 
the membrane fractions via a pH-shift and (D) the eluted phage particles are amplified again so that they can 
be used for the next selection round starting again with (A) or for further characterization. 
3.4.6 Site-directed mutagenesis 
The Tomlinson Library J has been artificially diversified by introduction of NNK triplets. 
As a consequence, about 3% of the scFv clones statistically contain a TAG triplet coding 
for the amber stop codon (1.3.3) within CDR2. E.coli suppressor strains, such as TG1F+, 
translate the TAG stop codon to the amino acid glutamine. To obtain fully functional scFv 
clones for soluble protein expression in non-suppressor strains or eukaryotes, the amber 
stop codon was mutated using the “QuikChange Site-Directed Mutagenesis Kit” (2.6). A 
point mutation exchanged the amber stop codon TAG to the triplet CAG directly coding 
for the neutral amino acid glutamine. The kit is based on a PCR reaction performed with 
the proof-reading PfuTurbo DNA polymerase from Pyrococcus furiosus and a temperature 
cycler. PfuTurbo DNA polymerase replicates both plasmid strands without misplacing the 
mutant oligonucleotide primers. Instead of the usual ssDNA template, the basic procedure 
makes use of the supercoiled dsDNA vector containing the insert of interest and two 
synthetic oligonucleotide primers containing the desired mutation. Primers were especially 
Phage Binding Washing Steps Phage Elution Phage Amplification
L3.6pl
membranes
CA B D
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designed for the mutation of each CDR2. The oligonucleotide primers, each 
complementary to opposite strands of the vector, were extended during temperature 
cycling and create a new and mutated circular dsDNA plasmid. The PCR product was 
digested with DpnI, which is an endonuclease specific for methylated and hemimethylated 
DNA. Thus the parental bacteria DNA template was removed without damaging 
synthesized and mutated DNA not displaying methyl groups. 
3.4.6.1 QuikChange Mutation primers 
Due to the high degree of variation within each CDR2 sequence, a different primer pair 
was designed for each mutation process using the QuikChange Primer Design software 
from Agilent Technologies Genomics. Primers were between 25 and 45 bases long with a 
melting temperature Tm ≥ 78 °C and an optimal GC-content of at least 40%. Tm was 
calculated according to the following formula Tm = 81.5+0.41(%GC)-675/N-%mismatch 
(N=length of primer). Primers had to anneal at exactly the same sequence on opposite 
strands of the plasmid with the desired mutation in the middle of the primers and ~10 – 15 
bases of correct sequence on both sides. Primers (10.1) were ordered from Invitrogen and 
delivered as lyophilized powder. 
3.4.6.2 QuikChange Mutation protocol 
Lyophilized primers were restored with sterile ddH2O to a final concentration of 10 pmol 
and mixed for the PCR mutagenesis reaction with double-stranded phagemid DNA, 
reaction buffer, dNTPs and the PfuTurbo DNA polymerase on ice. Table 3-7 shows the 
mutagenesis mix and thermo cycler set-up. 
Table 3-7 Reaction conditions of site-directed mutagenesis of amber stop codons using the 
QuikChange Site-Directed Mutagenesis Kit. 
(A) PCR reaction mixture, (B) thermo cycler program. 
(A) (B) 
Reagent Volume [µL] Temperature [°C] Time [min] Cycles 
Phagemid DNA (~20 ng/µL) 0.5 95 00:30 1 
10 x Pfu reaction buffer 5 95 00:30 
 
dNTP mix (25 mM) 1 55 01:00 
 
Forward primer (10 pmol) 1 68-72 06:00 12 
Reverse primer (10 pmol) 1 72 10:00 
 
PfuDNA polymerase 1 4 ∞ 
 
ddH2O ad 50 µL total volume   
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The PCR product was placed on ice for 10 min, then 1 µl DpnI restriction enzyme was 
added to each amplification reaction and immediately incubated at 37 °C for 1 h to digest 
non-mutated parental DNA. Mutated plasmids were transformed into XL1Blue E.coli 
(3.1.11) and plated on LBamp agar. Single colonies were picked and tested for presence and 
correct size of the scFv-insert via colony PCR (3.1.1.2) using primers LMB3 and fdseq1 
and subsequent agarose gel electrophoresis (3.1.5). Correct scFv-inserts were gel-purified 
with the QIAquick Gel Extraction Kit (2.6), sequenced with same primers (2.9, 3.1.4) and 
evaluated via alignment with non-mutated sequences (Vector NTI software). Successfully 
mutated scFv-clones were stored as cryo stocks at -80 °C (3.1.10). 
3.5 Methods of bioengineering 
The bioengineering part of this thesis was performed in cooperation with Esther Gartz at 
the Institute for Biochemical Engineering (AVT) at RWTH Aachen University lead by 
Prof. Dr. – Ing. Jochen Büchs. The modified BioLector [223, 224, 245] device, used for 
this thesis, has originally been developed at the AVT and is now commercially distributed 
by m2pLabs GmbH (Baesweiler). All continuous on-line measurements with the 
BioLector-like device were exclusively performed at the AVT by Esther Gartz. It was used 
to monitor product formation of a target protein fused to the short auto-fluorescent W-tag 
designed in this thesis [246]. 
3.5.1 Micro-scale on-line measurement 
Continuous non-invasive micro-scale on-line measurement was performed on micro-scale 
cultures expressing the W-tagged Ki-4(scFv) and M12(scFv) fusion proteins (3.1.9.3). 
Biomass and product formation of induced and non-induced cultures were measured with 
the modified BioLector device containing an added fiber optical measurement moiety [223, 
224]. The adapted device included a modified orbital shaker (Kühner, Basel, Switzerland), 
an x-y linear motion unit (BMG, Lab Technologies, Offenburg), a fluorescence 
spectrophotometer with filter wheels (Fluostar, BMG, Lab Technologies, Offenburg) and a 
computer. All filters had an optical band width of 10 nm. Biomass formed during 
fermentation was quantified using 180° back-scattered light at 620 nm. Increase in product 
formation during the fermentation process was observed via fluorescence intensity of the 
accumulated tryptophan residues within the designed W-tags which were fused to the Ki-
4(scFv) or M12(scFv) target proteins. The auto-fluorescent W-tags were excited at 280 nm 
and detected at an emission wavelength of 350 nm. Both measurement variables were 
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obtained while the cultures were shaken continuously and without disturbing the 
fermentation system. 
3.5.2 2D-scan analysis 
After large scale protein production (3.1.9.3), the fluorescence intensity of 200 µL 
bacterial crude extract was analyzed in 96-well MTPs (lumox, black, µ-clear, Greiner 
Bio-One) using two dimensional (2D) fluorescence scanning. Bacterial cultures were 
centrifuged (4,500 x g, 4 °C, 30 min) and proteins were released with combined 
application of TES buffer lysis (3.3.5.2) and sonication (3.3.5.4). Buffer of the lysates was 
exchanged to PBS (3.3.6) to remove EDTA and colored bacterial contaminations to reduce 
disturbing factors during 2D-scan analysis. Then samples were concentrated (3.3.7) and 
fluorescence intensity of 3 µg/mL W-tagged proteins was measured at excitation 
wavelengths of 250 – 300 nm and emission wavelengths of 300 – 400 nm using a modified 
FluoreMax-4P (Horiba Jobin Yvon, USA) with a Y-shaped optical fiber and an inlet for 
the MTP to measure from below. Integration time was set to 100 ms and the gap width was 
2 nm for excitation as well as for emission. 
3.6 Analytical and statistical software 
All on-line fermentation and 2D-scan data was analyzed and statistically evaluated by 
Esther Gartz using Microsoft Office Excel 2010. Final data was obtained from the wells 
and the statistical mean was calculated of a 4-fold verified set of measurements. The 
relative percentage deviation was also calculated from this set of data. All results were 
proven to be reproducible in different experiments. Curve diagrams from this data were 
created with Origin. Calculation of the fitted power function in 5.3.1 was performed with 
MATLAB. ELISA data was statistically evaluated using Microsoft Office Excel 2010 or 
GraphPad Prism 5.0. Flow cytometric evaluation of mean fluorescence intensities and the 
geometrical mean was performed with the CellQuest Pro software (BD Biosciences, NJ). 
3.7 Documentation and image editing 
SDS-PAGE and Western blots were digitalized with a commercially available standard 
scanner. Photographs, scans and other pictures were edited and adapted in Adobe 
Photoshop CS4, with Microsoft Power Point 2010 or ImageJ. Both programs were used to 
optimize colors, black, white and grey shades or variations and intensities. Moreover, they 
were applied to sharpen contrast or adjust light intensities as well as to ensure sufficient 
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image resolution and the appropriate format of the filed pictures. Results were neither 
changed nor manipulated. 
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4 Results: Antibodies against pancreatic cancer 
Treatment of cancer with antibody-based immunotherapy holds high potential as 
alternative adjuvant therapeutic approach. Since currently no recombinant antibodies are 
approved for treatment of pancreatic cancer [77] or adequate early diagnosis, the aim of 
this thesis was to isolate novel and sequence-unique scFv antibody fragments from the 
Tomlinson phage libraries I and J using phage display technology. The highly 
metastasizing pancreatic cancer cell line L3.6pl was exploited as target antigen to generate 
highly specific scFv binders against unknown tumor-associated antigens expressed on 
pancreatic cancer cells. The following chapter provides isolation results of three different 
panning strategies applied for scFv antibody selection and the screening of sequence-
unique L3.6pl-specific scFv antibody fragments. Moreover, it states the in vitro 
characterization of isolated scFv antibodies, cross-reactivity data to other pancreatic cancer 
cell lines, native protein structure binding data on living cells and internalization 
properties. 
4.1 Experiments prior to phage display selection 
4.1.1 Quality assessment of Tomlinson Libraries I and J 
Selection of highly specific scFv antibodies was performed using the naïve and 
semi-synthetic human Tomlinson phage libraries I and J (1.3.3) obtained from the Medical 
Research Council (MRC) Center for Protein Engineering (Cambridge, UK).  
To assess infection rate and quality of phagemid-carrying bacteria, both libraries were 
infected separately with monovalent M13KO7 helperphage to produce scFv-presenting 
phage particles under antibiotic pressure with ampicillin and kanamycin (3.4.2). Titer 
determination (3.4.4) of precipitated phage molecules (3.4.3) showed a scFv-phage particle 
concentration of at least 4.9 x 10
11
 pfu/mL for the library I and 5 x 10
12
 pfu/mL for the 
library J. The minimum phage concentration necessary for successful selection is 
1 x 10
11
 pfu/mL. Successful analysis of phagemid-carrying and infected bacteria allowed 
subsequent high-quality production of scFv-phage units for phage display selection with 
different panning strategies (0, 3.4.5.1, 3.4.5.2). As continuous quality controls, input and 
output titrations were performed throughout all panning processes to ensure sufficient 
infection rates and scFv-phage concentrations. 
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4.1.2 Testing of blocking and washing conditions 
To observe potentially adverse effects of cell lysis and shear stress on living L3.6pl cells 
during suspension panning, the third selection round with the most stringent washing 
protocol (3.4.5.2) was simulated with five blocking/washing reagents (Table 4-1) prior to 
panning. 
Table 4-1 Five different blocking/washing reagents tested for their adverse effects on L3.6pl cells 
 
Reagent pH Manufacturer 
(a) 1 x PBS 7.4 lab stock (2.7) 
(b) 1 x DPBS 7.4 Invitrogen/Gibco, Life Technologies GmbH, Darmstadt 
(c) 1 x PBST 7.2 lab stock (2.7) 
(d) RPMI 1640 Glutamax 7 – 7.4 Invitrogen/Gibco, Life Technologies GmbH, Darmstadt 
(e) 0.9% (w/v) NaCl isotonic solution 7 – 7.5 VWR, Darmstadt 
The reagent with the least negative effect on L3.6pl cells was subsequently chosen for 
selection. Pellet size was documented after each step by marking the pellet border on the 
falcon tube resulting in Table 4-2.  
Table 4-2 Documentation of negative effects for five different washing reagents tested on the cell 
line L3.6pl using panning conditions of third selection round. 
Washing step (a) (b) (c) (d) (e) 
1 complete complete complete complete complete 
2 complete complete complete complete complete 
3 complete complete complete complete complete 
4 complete complete complete 50% 75% 
5 50% complete complete 25% 25% 
6 0% 50% complete 0% 0% 
7 
 
50% complete 
8 
 
25% complete 
9 
 
0% 50% 
10 
  
50% 
Reagents (a), (d) and (e) had the strongest adverse effect on L3.6pl cells resulting in a 
complete cell loss caused by lysis after 6 washing steps, followed by reagent (b) with total 
cell loss after 9 washing cycles. The best cell yield was reached with 1 x PBST (reagent 
(c)) with 50% remaining cells after completed third panning round. PBST was 
consequently applied for all selection rounds with L3.6pl cells in suspension. 
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4.2 Isolation of L3.6pl-specific scFv-phage particles 
This work employed the scFv-based Tomlinson libraries I and J to generate specific 
L3.6pl-binding scFv-phage units with the phage display technology. Successful isolation of 
specific binders depends on the scFv-phage library, the antigen source and the selection 
strategy. The next chapter describes the scFv-phage enrichment and selection results of 
three different panning strategies:  
(1) on adherent L3.6pl whole cells (3.4.5.1), 
(2) on L3.6pl cells in suspension (3.4.5.2), 
(3) on L3.6pl membrane fractions (3.4.5.3). 
A general panning schematic applied to all three panning strategies is diagrammed in 
Figure 1-3. L3.6pl-binding scFv-phage molecules were isolated during three consecutive 
panning rounds. Unspecific particles binding to ubiquitous surface proteins or the MTP 
surface were eliminated via negative selection on FG or PBMC antigen. Enrichment of 
scFv-phage binders after each panning cycle was assessed by input and output titration 
(3.4.4) as well as via polyclonal phage ELISA analysis (3.3.9.1). 
4.2.1 Enrichment of scFv-phage particles on adherent cells 
Solid-phase panning on adherent L3.6pl cells (3.4.5.1) was performed exclusively with 
Tomlinson library J. All subtractive selection steps were carried out on FG cells and the 
hyperphage M13KO7ΔpIII was applied for the first selection round. After phage rescue, 
eluted scFv-phage proteins were used for subsequent selection by elution only, whereas 
each lysis fraction was used for subsequent selection by elution and lysis. Elution fractions 
after the same selection rounds were combined before output titration. Sensitivity of L3.6pl 
cells towards the alkaline elution buffer and shear stress led to cell loss during washing and 
elution. Hence, to obtain complete titration result documented in Table 4-3, selection round 
two was repeated three times, and selection round three was repeated once for satisfying 
elution and lysis outcomes. The final lysis fraction showed a very low output titer but the 
infected culture on the harvest plate had enough colonies to stop the selection process. 
Based on input and output titrations, the enrichment factor (EF) (EF = output [pfu/mL] / 
input [pfu/mL]) was calculated for specifically binding scFv-phage units after elution and 
lysis for each selection round. Accordingly, the actual enrichment (AE) was calculated by 
dividing enrichment factors of two successive selection rounds (AE =  EFx / EFx-1) as 
displayed in Table 4-3. For the elution fractions, practically no enrichment (AE = 0.005) 
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was documented from the first to the second panning round but an 11-fold enrichment of 
L3.6pl-binding scFv-phage particles was found after the third selection round. No 
significant enrichment of scFv-phage particles was documented for the lysis fractions, 
neither after the second (AE2 = 0.0004), nor the third panning round (AE3 = 0.004). 
Table 4-3 Input and output titer of elution and lysis fractions during three consecutive panning 
rounds on adherent L3.6pl cells. 
The input titer was over 1 x 1011 pfu/mL and output titers ranged from 6 x 108 pfu/mL after selection round 
one to 1.2 x 102 pfu/mL after the third round. In addition, calculations of enrichment factors (EF) and 
resulting actual enrichments (AE) after each selection round are stated. (A) Enrichment documentation of 
elution fractions, (B) enrichment documentation of lysis fractions. 
(A) 
Selection round 
Elution 
EF AE 
 Input [pfu/mL] Output [pfu/mL] 
 1 5 x 1012 4.2 x 107 8.4 x 10-6 - 
 2 8 x 1011 3.3 x 104 4.1 x 10-8 0.005 
 3 5.2 x 1011 2.4 x 105 4.6 x 10-7 11 
      
(B) 
Selection round 
Lysis 
EF AE 
 Input [pfu/mL] Output [pfu/mL] 
 1 5 x 1012 6 x 108 1.2 x 10-4 - 
 2 1 x 1012 4.8 x 104 4.8 x 10-8 0.0004 
 3 5.7 x 1011 1.2 x 102 2.1 x 10-10 0.004 
In addition, enrichment of L3.6pl-binding scFv-phage particles was examined by means of 
polyclonal phage ELISA analysis (3.3.9.1) of scFv-phage pools from the original library J 
as well as from scFv-phage pools after each selection round. This allowed a comparison of 
the number of specific scFv-phage binders via their binding activity. For this panning 
strategy FG membrane fractions (subtractive antigen) were coated together with L3.6pl 
membrane fractions (selective antigen) diluted 1 : 100. The scFv-phage pools of eluate and 
lysis fractions after each selection round were precipitated separately, but mixed together 
for titer determination and subsequent polyclonal phage ELISA analysis. Figure 4-1 
depicts a strong absorption signal for the unselected library J on L3.6pl and FG membranes 
alike, indicating a large number of potential binders. In contrast to that, a significantly 
higher binding signal, i. e. 150% increased absorption signal (p = 0.0016) was observed for 
L3.6pl-binding scFv-phage units after the first selection round. Compared to this, binding 
activity decreased by 59% after the second (p = 0.0464) and 150% after the third selection 
round. Absorption after the final selection round was not significantly different from the 
value documented for naïve library J. ABTS signals on L3.6pl membrane fractions were 
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not significantly higher  than FG absorption values even though phage pools had been 
depleted on FG cells before each positive selection. 
 
Figure 4-1 Polyclonal phage ELISA after three panning rounds on adherent L3.6pl cells. 
Combined phage pools of elution and lysis fractions after each selection round were analyzed for binding 
activity on membrane fractions of the L3.6pl selection antigen (black) and the FG depletion antigen (grey). 
Binding activity is displayed via average of ABTS absorption values of three independently performed 
experiments including error bars for standard deviation. Significant increase/decrease of absorption values 
between the unselected library J and the selection rounds is indicated by asterisks (**: medium significant 
difference, *: low significant difference). NC: average absorption value of negative controls, no AG: average 
absorption value of controls without antigen coating, SR1 – SR3: selection rounds one to three. 
Considering the significant increase in binding activity after the first selection round, 
scFv-phage molecules resulting from the first and third selection round were screened by 
monoclonal phage ELISA analysis (3.3.9.2, 4.2.4.1). 
4.2.2 Enrichment of scFv-phage by suspension panning 
For suspension panning of L3.6pl cells the Tomlinson library I was used (3.4.5.2). All 
subtractive selection steps were executed on freshly isolated PBMC cells (3.2.4) and the 
polyvalent M13KO7ΔpIII hyperphage was used for the first selection round. After 
internalization at 37 °C no elution was performed but surface-bound and incorporated 
scFv-phage particles were simultaneously recovered by cell lysis. Table 4-4 presents input 
and output titrations, performed for all panning rounds, thus evaluating enrichment of 
L3.6pl-binding scFv-phage units. Based on input and output titrations, the enrichment 
factors (EF) and the actual enrichment (AE) were calculated according to chapter 4.2.1 
(Table 4-4). Enrichment factors resulted in an actual enrichment of L3.6pl-binding scFv-
phage units of 250-fold after selection round two and an additional 1.5-fold increase after 
selection round three. 
Tomlinson J SR1 SR2 SR3 no AG NC
0
1
2
3
L3.6pl
FG
L3.6pl‐specific scFv‐phage enrichment
E
4
0
5
 nm
**
*
Results: Antibodies against pancreatic cancer 
 
 
82 
Table 4-4 Input and output titrations of selections on Tomlinson library I on L3.6pl cells in 
suspension as well as enrichment factors (EF) and actual enrichment (AE) after each selection round. 
All input titers showed sufficient scFv-phage concentrations, output titers ranged from 105 after the first and 
second selection round to 106 after the third. Enrichment of L3.6pl-binding scFv-phage units was shown. 
Based on titrations, enrichment factors and actual enrichments were calculated for each panning round. 
Selection round Input [pfu/mL] Output [pfu/mL] EF AE 
1 3.1 x 1012 1.2 x 105 3.9 x 10-8 - 
2 1 x 1011 9.6 x 105 9.6 x 10-6 250 
3 2.6 x 1011 3.6 x 106 1.4 x 10-5 1.5 
Even though titrations and resulting actual enrichment indicated an increase of 
L3.6pl-specific scFv-phage particles, no significant increase in binding activity was 
documented during polyclonal phage ELISA analysis (3.3.9.1) of consecutive selection 
rounds (Figure 4-2). For this experiment PBMC membrane fractions (depletion cells) were 
coated as antigen together with L3.6pl membranes. Despite a slight increase in binding 
activity of 15% after the first selection round, absorptions values decreased during 
continued panning rounds. The unselected library I displayed 10% higher ABTS 
absorption signals on L3.6pl membranes than the phage pool after the third selection 
round. This indicates a loss of L3.6pl-binding scFv-phage particles. Statistical evaluation 
showed neither significant increase nor decrease of L3.6pl-specific scFv-phage units 
throughout all three selection rounds. Compared to absorption values on L3.6pl membrane 
fractions, signals on PBMC membranes were found to be significantly lower (p = 0.0424). 
 
Figure 4-2 Polyclonal phage ELISA after three selection rounds on L3.6pl cells in suspension. 
Overall ABTS absorption signals were very weak (< 0.25). Signals on PBMC membranes (grey) were 
considerably weaker than on L3.6pl antigen (black). Binding activity increased after first selection round and 
then decreased again until the third. Binding activity is displayed as average of ABTS absorption values of 
three independently performed experiments including error bars for standard deviation. No significant 
difference was found for binding activities of selection rounds. NC: average absorption value of negative 
controls, no AG: average absorption value of controls without antigen coating, SR1 – SR3: selection rounds 
one to three, *: low significant difference. 
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Based on the titration results, single clones were picked after the third selection round for 
analysis in a monoclonal phage ELISA (3.3.9.2, 4.2.4.2). 
4.2.3 Enrichment of scFv-phage particles on membrane fractions 
Solid-phase panning on L3.6pl membrane fractions (3.4.5.3) was performed on both 
Tomlinson libraries in parallel. Depletion was carried out on PBMC membrane fractions 
and the polyvalent M13KO7ΔpIII hyperphage was used for the first selection round. 
Surface-bound scFv-phage particles were eluted from the membrane antigen, and input and 
output titers were determined of all three panning rounds for both libraries (Table 4-5). 
Enrichment factors (EF) and actual enrichment (AE) were calculated from titrations as 
described in 4.2.1, and are also listed in Table 4-5. All selection rounds showed a constant 
output of 10
5
 for L3.6pl-binding scFv-phage proteins. Actual enrichment of library I was 
0.32-fold after panning round two and only 0.07-fold after round three (Table 4-5 A). For 
library J a 2.3-fold increase of L3.6pl-binding scFv-phage units was observed after 
selection round two, a 0.02-fold increase after round three (Table 4-5 B). 
Table 4-5 Input and output titers as well as enrichment factors (EF) and actual enrichment (AE) of 
panning rounds with Tomlinson Library I and J on L3.6pl membranes fractions. 
All input titers were over the necessary value of 1 x 1011 pfu/mL for a successful selection, output titers 
reached various values of 105 after all selections rounds. (A) Enrichment results of Tomlinson Library I, (B) 
enrichment results of Tomlinson Library J. A slight enrichment of L3.6pl-binding scFv-phage units was 
shown for both libraries within three consecutive panning rounds.  
(A) 
Selection round 
Tomlinson I 
EF AE 
 Input [pfu/mL] Output [pfu/mL] 
 1 1.2 x 1011 2.4 x 105 2 x 10-6 - 
 2 7.6 x 1011 4.8 x 105 6.3 x 10-7 0.32 
 3 1.1 x 1013 5.2 x 105 4.7 x 10-8 0.07 
      
(B) 
Selection round 
Tomlinson J 
EF AE 
 Input [pfu/mL] Output [pfu/mL] 
 1 2.5 x 1011 2.8 x 105 1.1 x 10-6 - 
 2 3.8 x 1011 9.6 x 105 2.5 x 10-6 2.3 
 3 9.3 x 1012 4 x 105 4.3 x 10-8 0.02 
Polyclonal phage ELISA experiments (3.3.9.1) displayed results for increase of 
L3.6pl-binding scFv-phage units analogous to titration-based enrichment calculations. For 
polyclonal phage ELISA, scFv-phage pools of both libraries and of the three continuous 
selection rounds were tested for binding activity on PBMC (subtractive antigen) and 
L3.6pl membranes previously used for positive selection.  
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Tomlinson Library I: In Figure 4-3A, ABTS absorption signals after panning of library I 
are illustrated after 15 min incubation. A very high binding capacity was measured for the 
unselected I library on L3.6pl membranes indicating a large amount of potential binders. 
After the first panning round, absorption values on L3.6pl membranes decreased by 57% 
when cross-reactive and weak binders had been sorted out via depletion on PBMC 
membranes. From the first to the second selection round, absorption signals increased 
again by 88%; after completion of selection round three, an additional increase of 18% was 
documented. In summary, a low but significant enrichment of L3.6p-specific binders was 
denoted after panning round two (p = 0.0287) and three (p = 0.0137) in comparison to the 
first selection round. Absorption values measured on PBMC membranes after selection 
round one, were 425% higher than for the naïve library I, and slightly higher (but not 
significantly) than the values on L3.6pl membranes. Nevertheless, PBMC absorption 
values decreased after panning rounds two and three indicating the successful elimination 
of scFv-phage molecules with cross-reactivity towards PBMC membranes. 
Tomlinson Library J: Figure 4-3B indicates ABTS absorption values after selection of 
library J measured after 60 min incubation. A very high binding capacity on L3.6pl 
membranes was documented for the naïve library J, indicating a large amount of potential 
binders. After the first selection round, absorption values on L3.6pl membranes decreased 
by 90% when cross-reactive and weak binders had been sorted out via depletion on PBMC 
membranes. From the first to the second selection round, absorption signals increased 
again by 800% but after finishing selection round three only a slight additional increase of 
L3.6pl-specific binders was found. In summary, a low but significant enrichment was 
denoted after panning round two (p = 0.0287) and the absorption values after round three 
showed medium significance (p = 0.0137) in comparison to the first selection round. 
Absorption values measured on PBMC membranes were similar throughout the panning 
process. 
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Figure 4-3 Polyclonal phage ELISA after three consecutive panning rounds with Tomlinson libraries 
I and J on L3.6pl membrane fractions. 
(A) Absorption signals for library I measured after 15 min ABTS incubation (signals too strong for TECAN 
measurement after longer incubation period), (B) absorption signals for library J measured after 60 min 
ABTS incubation. Absorption values on L3.6pl membranes are illustrated in black, values for PBMC 
membranes are indicated in grey. For both libraries, binding activity decreases after the first selection round 
and continuously increases again afterwards. Binding activity is displayed as average of ABTS absorption 
values of three independently performed experiments including error bars for standard deviation. NC: 
average absorption value of negative controls, no AG: average absorption value of controls without antigen 
coating, SR1 – SR3: selection rounds one to three, *: low significant difference, **: medium significant 
difference. 
Based on the assumption that the low increase of L3.6pl-binding scFv-phage particles 
represented strong binders, as shown during polyclonal phage ELISA experiments, 
pannings after round three were used for monoclonal phage ELISA analysis (4.2.4.3). 
4.2.4 Identification of unique L3.6pl-specific scFv-phage binders 
Phage pools with enriched L3.6pl-binding scFv-phage particles were screened for 
sequence-unique binders via measurement of binding activity in a monoclonal phage 
ELISA experiment (3.3.9.2). Depending on enrichment results after titration and 
polyclonal phage ELISA analysis (4.2.1, 4.2.2, 4.2.3), single clones were picked from 
LBamp,gluc agar plates, transferred into 96-well MTPs and analyzed on immobilized 
membrane fractions (diluted 1 : 100 in ELISA coating buffer or PBS). All monoclonal 
phage ELISA experiments were repeated three times to show reproducibility of results. A 
clone was defined as positive binder when its average absorption value was at least 
2.5-times stronger than the negative control (NC) values and background signals measured 
in reference wells without antigen coating. This defined value, here called NC-reference 
value, was calculated for every experiment and is graphically indicated by a black vertical 
line. Following monoclonal phage ELISA analysis, L3.6pl-positive clones were tested for 
presence of the scFv-insert (length ~950 bp) via colony PCR (3.1.1.2), then the scFv-insert 
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PCR product was extracted from a preparative agarose gel (3.1.5) and its DNA sequence 
was analyzed (3.1.4). 
4.2.4.1 Monoclonal phage ELISA after selection on adherent cells 
Based on results in 4.2.1, scFv-phage pools after the first and third selection round were 
screened in a monoclonal phage ELISA (3.3.9.2). Figure 4-4A and Figure 4-4B illustrate 
the screening results of: (a) Two master plates (144 clones) analyzed after the first 
selection round and (b) two master plates (144 clones) after the third selection round. 
Resulting from the first selection round, ten L3.6pl-binding clones displayed binding 
activity above the NC-reference value of 0.329 and were defined as positive (Figure 4-4A). 
Three of these clones (A6, B5, and F10) displayed ABTS absorption values twice the 
NC-reference value. Clone B7 exceeded it even three times. 
After the third selection round, only three L3.6pl-binding clones were classified as positive 
via binding activity above the NC-reference value of 0.509 (Figure 4-4B). All three binders 
displayed an absorption reading not significantly stronger than the NC-reference value. 
Clone F7 presented 50% stronger binding on FG than on L3.6pl membranes.  
 
Figure 4-4 Monoclonal phage ELISA after first and third selection round on adherent L3.6pl cells. 
(A) Ten L3.6pl-positive binders with absorption signals > 0.329 were detected after the first selection round 
(SR1), (B) three L3.6pl-positive binders with absorption values > 0.509 were identified after the third 
selection round (SR3). Black bars represent absorption measurements on L3.6pl membranes (positive 
selection), grey bars show absorption signals on FG membranes (subtractive selection), and the NC-reference 
value is indicated by the black vertical line. Binding activity is displayed as average of ABTS absorption 
values of three independently performed experiments including error bars for standard deviation. NC: 
average absorption value of negative controls, no AG: average absorption value of control wells without 
antigen coating. 
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All L3.6pl-positive clones exhibited binding activity above the NC-reference value on FG 
membrane fractions as well, but except for clones B9, E10 and F10, FG binding activity 
was weaker than on L3.6pl membranes. High binding activity on FG membranes was 
expected since the L3.6pl cell line was developed from FG and thus both cell lines share 
high similarity of surface proteins. Colony PCR and agarose gel electrophoresis revealed 
that all isolated clones were false-positive binders and none of the 13 positive clones 
contained a scFv-insert. As a conclusion all clones were discarded. 
4.2.4.2 Monoclonal phage ELISA after suspension panning 
After the third selection round, 216 single clones were picked onto three master plates to 
isolate sequence-unique scFv-phage binders. Following the calculation of the NC-reference 
value of 0.194, a total of three L3.6pl-positive clones were identified. They all displayed 
very weak overall absorption values (not significantly different from the NC-reference 
value). PBMC signals were between 50% and 75% of the L3.6pl signals. 
 
Figure 4-5 Monoclonal phage ELISA after three panning rounds on L3.6pl cells in suspension. 
Three L3.6pl-positive binders with absorption values > 0.129 were identified after the third selection round 
(SR3). Black bars represent absorption measurements on L3.6pl membranes (positive selection), grey bars 
show absorption signals on PBMC membranes (subtractive selection), and the NC-reference value is 
indicated by the black vertical line. Binding activity is displayed as average of ABTS absorption values of 
three independently performed experiments including error bars for standard deviation. NC: average 
absorption value of negative controls, no AG: average absorption value of control wells without antigen 
coating. 
L3.6pl-positive clones were checked by colony PCR (3.1.1.2), and after DNA analysis 
clone D4 was the only one identified with an intact insert sequence. Clone B1 had no 
insert, clone A11 carried a frame shift in CDR2 of the scFv-insert. Hence, both clones were 
not investigated further. 
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4.2.4.3 Monoclonal phage ELISA after panning on membrane fractions 
Succeeding completed panning and enrichment analysis (4.2.3), eight master plates (576 
clones) were picked from the selected Tomlinson library I and another eight master plates 
from selected Tomlinson library J. After monoclonal phage ELISA analysis, a total of 193 
clones was defined as L3.6pl-positive binders. To illustrate this large number of clones, 
false positive binders and clones containing a frame shift were sorted out by colony PCR 
and DNA sequence analysis. Only positive clones containing an intact insert sequence are 
displayed in Figure 4-6. 
Figure 4-6A shows eight truly L3.6pl-positive clones were isolated from library I with an 
absorption value higher than the NC-reference value of 0.210. While clones B12, C5, D8, 
D12 and F3 showed low absorption values that were 3-times higher than the background, a 
strong binding activity was measured for clones E5, E7 and F11 exceeding the background 
by 4-times and more. Clone C1 displayed an absorption value slightly below the 
NC-reference value but was analyzed exemplary as non-binding control for comparison. 
DNA sequencing revealed that clones B12 and D12 had the same sequence. Since stronger 
binding activity was measured for clone D12, it was kept for further experiments, clone 
B12 was discarded. 
Figure 4-6B illustrates absorption values of eleven L3.6pl-positive clones isolated from 
library J displaying binding activity above the NC-reference value of 0.172. While clones 
D1, E1 and E3 had low binding activity of twice the background, clones E2, E5 and F1 
displayed medium absorption values between twice and 5-times higher than the 
background. Binders D9 and E8 range between 5 and 10-times over the background 
whereas the remaining binders (A3 and D5) were measured to have a binding activity over 
10-times greater the NC-reference value. DNA sequence analysis revealed that clones E1, 
E2, E3 and E5 had the same sequence. Based on its high absorption value, clone E3 was 
applied for all further experiments and clones E1, E2 and E5 were discarded. 
Overall ABTS absorption signals on the PBMC membranes were low, displaying values 
similar to that of the negative controls and wells without coated antigen. The only 
exception was clones A3 which showed only 20% less binding activity on PBMC than on 
L3.6pl membranes. 
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Figure 4-6 Monoclonal phage ELISA after three panning rounds with Tomlinson Library I and J on 
L3.6pl membrane fractions. 
(A) Eight L3.6pl-positive binders isolated from Tomlinson library I, (B) eleven L3.6pl-positive binders 
isolated from Tomlinson library J. The black columns represent binding on L3.6pl membranes and the grey 
columns on PBMC membranes whereas the black line marks the NC-reference value defining a clone as 
positive binder. Binding activity is displayed as average of ABTS absorption values of three independently 
performed experiments including error bars for standard deviation. NC: average absorption value of negative 
controls, no AG: average absorption value of control wells without antigen coating. 
4.2.5 Monoclonal phage ELISA of 14.1(scFv) 
In addition to the Tomlinson-derived clones, monoclonal phage ELISA analysis was 
performed with the murine single chain antibody 14.1(scFv) isolated by Beate Stadler from 
a self-made phage display library originated from immunized mice (1.3.7). Prior to this 
work, the 14.1(scFv) has already been identified as L3.6pl-positive binder on membrane 
fractions. During this thesis, it was applied to characterization experiments to verify its 
binding activity on the L3.6pl antigen and to obtain additional characterization data. 
During the monoclonal phage ELISA, 14.1(scFv) displayed strong binding activity on 
L3.6pl membrane fractions with an absorption value 8.5-fold over the NC-reference value 
of 0.210 (Figure 4-7). Absorption readings on PBMC membranes ranged on the level of 
the negative controls. 
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Figure 4-7 Monoclonal phage ELISA of 14.1(scFv) on L3.6pl membrane fractions isolated from the 
murine self-made from immunized mice after multiple selection rounds on L3.6pl antigen. 
The black column represents binding on L3.6pl membranes and the grey column on PBMC membranes. The 
black line marks the NC-reference value identifying the 14.1(scFv) as L3.6pl-positive binder. Binding 
activity is displayed as average of ABTS absorption values of three independently performed experiments 
including error bars for standard deviation. NC: average absorption value of negative controls, no AG: 
average absorption value of control wells without antigen coating. 
4.3 Sequence analysis of isolated L3.6pl-specific scFv 
After completion of three consecutive panning rounds performed with three different 
selection strategies, 16 L3.6pl-specific and sequence-unique binders were isolated from 
Tomlinson libraries I and J, in addition to the already existing 14.1(scFv) antibody 
fragment from a self-made murine library (1.3.7). During monoclonal phage ELIA analysis 
many positive binders were identified as false-positive, projecting a positive absorption 
signal but were either missing the scFv-insert, had an incomplete sequence or a frame shift 
in FWR2. 
In summary, 23 master plates, containing a total number of single 1656 clones, were 
picked for screening by monoclonal phage ELISA analysis (Table 4-6). 13 L3.6pl-positive 
binders were detected after selection on adherent cells, three after panning in suspension 
and 193 positive clones after membrane selection of both libraries combined. This added 
up to a total number of 209 L3.6pl-binding clones (12.6% of all picked clones). 
Table 4-6 Overview of number of master plates and clones analyzed via monoclonal phage ELISA 
after three consecutive panning rounds with three different selection strategies, as well as number of 
resulting L3.6pl-positive binders 
Panning strategy Number of master plates Number of picked clones Number of L3.6pl-positive clones 
Adherent 4 288 13 (4.5%) a) 
Suspension 3 216 3 (1.4%) a) 
Membranes 16 1152 193 (16.8%) a) 
Total 23 1656 209 (12.6%) a) 
a) Percentage of L3.6pl-positive clones based on number of picked clones 
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Only 20 clones (9.6% of all ELISA-positive clones) contained an intact insert sequence, 
meaning that 91.4% of the ELISA-positive clones were false-positive (Table 4-7). 
Panning on adherent L3.6pl resulted in 100% false-positive clones. From panning in 
suspension one sequence-correct clone (33.3% of ELISA-positive clones) was isolated, 
whereas 19 clones (9% of L3.6pl-binding clones) were identified with an intact DNA 
sequence after panning on membrane fractions. 
Table 4-7 Overview of number and proportion of L3.6pl-positive clones identified with an intact 
DNA insert sequence with respect to different selection strategies.  
Panning strategy Number of sequence-intact clones Number of false-positive clones 
Adherent 0 (0%) b
) 
13 (100%) b
)
 
Suspension 1 (33.3%) b
)
 2 (66.6%) b
)
 
Membranes 19 (9%) b
)
 174 (91%) b
)
 
Total 20 (9.6%) b
)
 189 (91.4%) b
)
 
b) Percentage of sequence intact and false-positive clones based on number of 209 ELISA-positive clones 
DNA sequencing revealed that two clones from Tomlinson library I and four clones from 
library J had identical sequences. This resulted in a total of 16 L3.6pl-positive binders 
with a unique sequence (Table 4-8). After subtraction of identical clones, eight 
sequence-unique binders were defined for both libraries.  
Table 4-8 Overview of number of L3.6pl-binding clones with intact, identical and unique DNA 
sequence 
Library Sequence-intact clones Sequence-identical clones Sequence-unique clones 
I 9 2 8 
J 11 4 8 
I and J 20 6 16 
Unwanted stop codons were located in 14 clones, which corresponds to 87.5% of all 
sequence-unique clones (Table 4-9). Amber stop triplets (TAG) were found in the 
complementarity determining regions CDR2 or CDR3 of eight clones. An additional six 
clones contained the ochre stop codon triplet TGA in frame work region FWR2. Clones 
D4 (library I) and E3 (library J) did not carry any stop codon. 
Table 4-9 Overview of number and percentage of sequence-unique L3.6pl-postive clones contain 
amber or ochre stop codons.  
Library Number of clones with stop codon Amber stop codons Ochre stop codons No stop codon 
I 7 (87.5%) c
) 4 3 1 
J 7 (87.5%) c
)
 4 3 1 
I and J 14 (87.5%) c
)
 8 6 2 
c) Percentage of clones containing an amber/ochre stop codons based on number sequence-intact clones 
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Amino acid sequences of all 16 L3.6pl-positive clones marked according to the distribution 
of amber or ochre stop codons are listed in Table 4-10. 
Table 4-10 Amino acid sequences of complementarity determining regions (CDRs) in VH and VL of 
16 scFv antibodies identified as L3.6pl-positive binders during monoclonal phage ELISA analysis.  
CDRs were defined using the KABAT database [100, 101]. Clones marked with an asterisk contain an ochre 
stop codon (TGA) in FWR2, clones marked with an x contain an amber stop codon in CDR2 or CDR3, 
whereas clones D4 and E3 lack a stop codon. 
 
Heavy chain variable region (VH) light chain variable region (VL) 
 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
A3x 
SYAMS 
QINPNG*PTKYADSVKG NKRKFDYS
RASQSISSYLN
RASALQS QQAKKNPTT 
C5x AICNYGSSTS*ADSVKG TDACFDYS AASDLQS QQSSANPTT 
D1* SISNYGSTTSYADSVKG YYGDFDY SASALQS QQTYTAPYT 
D4 NISTLGAGTDYADSVKG NATAFDY AASWLQS QQCYSTPKT 
D5x NIYREG*RTSYADSVKG GAALFDY VASHLQS QQVAVTPVT 
D6* TIGYQGTHTMYADSVKG VPYAFDY SASSLQS QQSYSTPNT 
D8x YISAAGSNTDYVDSVKG ANSSFDY TAS*LQS QQNSAGPGT 
D9x NIYREG*RTSYANSVKG GAALFDY VASHLQS QQVAVTPVT 
D12x GIS*RGSTTAYVDSVKG NYTAFDY RASRLQS QQRPPRPRT 
E3 SIIGSQGSLTIYADSVKG HVVAFDY SASILQS QQFTRAPPT 
E5* DISTAGATTTYADSVKG DGYSFDY ASSLQS QQTYSAPAT 
E7* NICCGGSSTTYADSVKG STTSFDY NASSLQS QQADNSPTT 
E8* VIGSQGSRTAYADSVKG HVLAFDY SASILQS QQYRQSPPT 
F1x SIYS*GNLTIYADSVKG RPDSFDY TASTLQS QQLSRAPST 
F3x SITAYGDTTSYADSVKG SAT*FDY ASALQS QQCCDSPYT 
F11* AISTSGTSTNYADSVKG NYTSFDY TASALQS QQDASSPDT 
Except clone A3, none of the L3.6pl-positive clones showed any significant ABTS 
absorption signal on the PBMC negative control antigen during monoclonal phage ELISA. 
But all L3.6pl-positive clones depicted positive binding on the FG cell line. 
4.3.1 Whole cell ELISA 
Screening of sequence-unique L3.6pl-specific binders was performed on membrane 
fractions which present the still functional antigen on small membrane vesicles [134]. A 
major drawback of membrane fractions is the formation of vesicles to compensate surface 
tension. Approximately 50% right-side-out vesicles and 50% inside-out particles, exposing 
the inner cell membrane during selection and screening, are formed. To ensure binding 
activity on native surface protein conformations, the isolated binders were tested in a 
monoclonal phage ELISA on living L3.6pl cells (3.3.9.2). A positive binding signal was 
measured for some clones but absorption results could not be verified in repeated 
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experiments. Six repetitions of the monoclonal phage ELISA on whole cells resulted in 
very inconsistent binding data; different clones displayed positive binding activity with 
each ELISA repetition (data not shown). To obtain more reproducible binding results, 
100% ice-cold EtOH, acetone and 4% PFA were tested as alternative fixation methods. 
Nevertheless, binding results were dissenting for 100% ice-cold EtOH and acetone, 
whereas on 4% PFA high and unspecific background was measured after addition of 
scFv-phage particles. Fixed L3.6pl cells were viewed under a microscope and a substantial 
cell loss was documented independent of the fixation reagent. It was concluded that L3.6pl 
cells were very sensitive and difficult to handle during a whole cell ELISA, and 
consequently the resulting data was not significant. To confirm binding activity on whole 
L3.6pl cells, positive scFv antibodies were tested as soluble proteins via flow cytometry 
(3.3.10.1, 4.6.2). 
4.3.2 Cross-reactivity analysis 
L3.6pl-positive clones were examined for cross-reactive binding to other human pancreatic 
cancer cell lines by means of monoclonal phage ELISA analysis (3.3.9.2). Binding 
capacity of 17 clones, tested positive in 4.2.4, was analyzed on membrane fractions of FG, 
Su86.86, S2-0028 and PT-46 cell lines (Figure 4-8). Cross-reactivity testing was performed 
in triplicates and repeated three times for each clone and antigen to confirm reproducibility 
of binding data. A clone was defined as positive binder when its average absorption value 
was at least 2.5-fold stronger than the mean negative control (NC) and background 
absorption signals measured in reference wells without antigen coating. This calculated 
value, here called NC-reference value, was adjusted for each experiment. Weak binding 
was defined as absorption values up to 2-fold, medium binding activity as 3 to 5-fold, and 
strong binders as 5 to 10-fold higher than the background.  
With the exception of clones D8, 16 binders exhibited positive binding capacity on FG 
membranes (Figure 4-8A) with absorption signals higher than the NC-reference value of 
0.313. Clones D1 and E3 showed weak binding whereas medium absorption readings were 
recorded for seven clones (C5, D12, F1, F11, D4, E5 and E8). Clones D6, E7, F3, 14.1, 
D9, A3 and D5 were defined as strong binders. Moreover, Figure 4-8A illustrates positive 
absorption readings on Su86.86 antigen for eleven clones. Weak absorption values were 
measured for 6 clones (14.1, D6, D12, E3, E5 and F3), and medium binding activity was 
demonstrated for clones F1, F11 and D9. Strong absorption readings (up to 6-fold over 
NC-reference) were recorded for clones D5 and A3. 
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Figure 4-8B shows binding activity of isolated clones on S2-0028 and PT-46 antigen. 
Weak binding activity was recorded for clones C5, D5 and D9 on S2-0028 antigen. The 
remaining clones displayed no binding. On PT-46 antigen, two clones did not demonstrate 
binding (14.1 and E7), whereas all other clones displayed weak absorption values except 
for clone D9 which was denoted with medium binding activity. Overall background noise 
was very high for measurements on S2-0028 and PT-46 antigen. 
 
Figure 4-8 Cross-reactivity data of isolated clones and 14.1(scFv) obtained by means of monoclonal 
phage ELISA analysis on FG, Su86.86, S2-0028 and PT-46 membrane fractions. 
(A) Cross-reactivity data towards FG and Su86.86 antigen. The light grey bars present binding data on FG 
membranes, the bars with left-tilted lines indicate absorption readings on Su86.86 antigen and the NC-
reference value of 0.313 is marked by the black line. 16 clones were found with positive binding results on 
FG membranes and eleven clones displayed binding activity on Su86.86 antigen. (B) Cross-reactivity data 
towards S2-0028 and PT-46 membrane fractions. The grey dotted bars present binding data on S2-0028 
membranes, bars with right-tilted lines indicate absorption readings on PT-46 antigen and the NC-reference 
value of 0.515 is marked by the black line. 15 clones demonstrated positive absorption signals on the PT-46 
antigen but only 3 clones had positive ABTS measurement on S2-0028 membranes. Binding activity is 
displayed as average of ABTS absorption values of three independently performed experiments including 
error bars for standard deviation. NC: average absorption value of negative controls, no AG: average 
absorption value of control wells without antigen coating. 
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4.4 QuikChange Mutation of stop codons 
In order to characterize the isolated L3.6pl binders as soluble proteins, the scFv antibody 
fragments were expressed without the pIII phage coat protein fusion. Normally, soluble 
protein expression without pIII is achieved by transformation of pIT2 phagemids into the 
non-suppressor strain HB2151 E.coli. This bacterial strain recognizes the amber stop 
codon and terminates protein translation after the scFv right before the pIII phage coat 
protein (4.5.1). Here, the artificial NNK triplet diversification of CDRs in the Tomlinson 
library J (1.3.3) is problematic for the expression of soluble protein, since 3% of the 
diversifications result in the formation of the amber stop codon TAG. Phage display with 
the amber-suppressor strain TG1F+ E.coli allowed mistranslation of the amber stop codon 
as glutamine (CAG). Yet, expression of soluble proteins in prokaryotic non-suppressor 
strains or eukaryotes would result in truncated and non-functional proteins. In this work, 
eight of 16 positive clones included an amber stop codon in their DNA sequence. 
Moreover, seven clones displayed an abnormal point mutation in FWR2 where the amino 
acid tryptophan was mutated from triplet TGG to the ochre stop codon TGA. Introduction 
of a stop codon within the scFv sequence leads to an early termination of protein 
translation ending in an incomplete and non-functional scFv protein. Consequently, all stop 
codons were eliminated by site-directed mutagenesis with the QuikChange® Site-Directed 
Mutagenesis Kit (2.6). The amber triplet TAG was mutated to CAG, which encodes the 
amino acid glutamine, and the ochre TGA triplets were changed back to the regular 
framework triplet TGG, coding for tryptophan. As a result, the scFv antibodies could be 
expressed as soluble prokaryotic protein in E.coli HB2151 (3.1.9.4). After subcloning, 
soluble protein prokaryotic expression in E.coli BL21 Rosetta 2 (DE3) (3.1.9.3) and 
eukaryotic protein expression in HEK293T was feasible as well (3.2.3).  
Clone D8 was sorted out during site-directed mutagenesis since the stop codon could not 
be removed after 10 mutation attempts. Binding activity of mutated clones expressed in 
TG1F+ E.coli on phage level was not tested; instead soluble protein characterization was 
started directly after site-directed mutagenesis. 
4.5 Production and purification of soluble scFv antibodies 
After screening of L3.6pl-positive binders by monoclonal phage ELISA (4.2.4), DNA 
sequencing of unique binders (4.3) and site-directed elimination of stop codons (4.4), 15 
remaining binders, in addition to the 14.1(scFv) (1.3.7), were characterized on protein 
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level. Therefore, scFv antibody fragments were expressed without pIII phage coat protein 
fusion by means of three different expression methods: (a) Prokaryotic expression in 
HB2151 E.coli using the pIT2 phagemid (4.5.1), (b) prokaryotic expression in Rosetta 2 
(DE3) E.coli using the T7 promoter-controlled pMT plasmid (4.5.2) [171] and (c) 
eukaryotic expression in HEK293T cells via the CMV-operated pMS-SNAPMut plasmid 
(4.5.3) [183]. Expression of soluble scFv protein offers a huge advantage during scFv 
characterization since the phage coat protein in the original scFv-phage fusion protein may 
interfere with binding properties on L3.6pl cells or membranes due to protein interactions. 
The inexact titer determination (all phage particles in a solution are counted including the 
ones without scFv) is an additional problem during binding analysis on phage level. It is 
known that only up to 10% of the phage particles in a solution are fused to a scFv [247]. 
This renders exact quantitative evaluation of the binding activity on phage level 
impossible. Soluble scFv proteins will be characterized by protein ELISA (4.6.1), flow 
cytometry (4.6.2) and internalization assays (4.6.3). 
4.5.1 Prokaryotic expression in HB2151 E.coli via pIT2 phagemid 
After stop codon removal by site-directed mutagenesis, the pIT2-phagemids (2.10) were 
re-transformed into the non-suppressor strain HB2151 E.coli (2.3, 3.1.11) for soluble 
protein expression. Protein expression was initiated via the pHEN-derived lac-operon 
controlled pIT2 phagemid (Figure 1-4A) by means of IPTG or lactose induction. While 
still containing the genetic information for the pIII phage coat protein, the unsuppressed 
amber stop codon actively terminated protein translation, thus separating the scFv 
fragment from pIII. Figure 1-4B shows the expression cassette for production of soluble 
scFv proteins according to 3.1.9.4. 
Due to the low amount of scFv protein secreted into the medium, protein recovery from the 
bacterial pellet via TES buffer lysis (3.3.5.2) was necessary. Protein yield was analyzed by 
SDS-PAGE (3.3.1) and Western blot (3.3.2). Several clones displayed protein expression, 
whereas others did not express any protein. Huge variations in protein concentration were 
observed for all single clones in consecutive experiments. Each repetition featured 
different clones with strong protein yield, while others depicted no protein expression 
despite correct DNA sequence and intact open reading frame (ORF) (data not shown). This 
inconsistent protein production rendered binding analysis via protein ELISA impossible 
since absorption results mirrored the non-reproducible protein concentrations which 
resulted in varying binding activities (data not shown). To obtain more consistent protein 
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expression, some of the cultivation and experimental parameters were changed: (a) 
Different IPTG concentrations 0.5, 1, 2, 5 and 10 mM in LBamp medium to induce protein 
expression, (b) bacterial lysis with lysozyme (3.3.5.1) or sonication (3.3.5.4) for protein 
recovery instead of TES buffer, (c) LBamp medium and 2 x TYamp medium for cultivation 
instead of auto-induction medium, (d) use of different detection antibodies directed against 
His6-tag and myc-tag, and (e) use of different blocking reagents (Chemiblock, 
3% BSA/PBS, varying concentrations of milk powder dissolved in PBS (between 1 and 
10%)). None of these parameters succeeded in improved protein production and 
reproducible ELISA results. Only clones A3, D5 and D9 exhibited enough protein yield for 
repeatedly positive binding analysis in every performed protein ELISA. 
4.5.2 Prokaryotic expression in BL21 Rosetta 2 (DE3) via pMT plasmid 
As a consequence of 4.5.1, soluble scFv proteins for evaluation of protein binding activity 
were expressed with a different strategy. Therefore, scFv inserts were subcloned into the 
pET-27b+-derived pMT vector (2.10) via the compatible restriction sites SfiI and NotI 
(Figure 4-9) and transformed into BL21 Rosetta 2 (DE3) E.coli (2.3). This bacterial strain 
carries the lac-operon controlled gene for the T7 RNA polymerase (T7 promoter). 
Induction by IPTG or lactose, guarantees a stringent periplasmic expression of the 
recombinant scFv protein via a pelB leader peptide. 
 
Figure 4-9 Schematic of pMT expression cassette for prokaryotic production of soluble scFv protein 
in BL21 Rosetta 2 (DE3). 
A pelB signal peptide and the His10-tag are located up-stream of the scFv sequence. Within the scFv, the 
heavy chain VH is connected to the light chain VL through a glycine-serine (GS) linker peptide. scFv 
expression is controlled by a T7 promoter inducible with IPTG or lactose. A TAA stop codon terminates the 
protein translation down-stream of the scFv sequence. The scFv DNA sequence was inserted into the pMT 
vector through enzymatic restriction sites SfiI and NotI. 
Recombinant scFv protein was expressed as described in 3.1.9.3. Despite high potential for 
secretion, only small concentrations of soluble scFv protein were detected in the culture 
medium. Again the bacterial pellet was lysed using TES buffer (3.3.5.2), then protein yield 
was investigated by means of SDS-PAGE (3.3.1) and Western blot (3.3.2). Protein 
expression results displayed similar inconsistency of protein concentrations as in 4.5.1. 
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Same parameters were changed as variables for the expression in HB2151 to improve 
expression results; nevertheless, protein yield and ELISA binding results were not 
reproducible. As a consequence, prokaryotic expression of soluble recombinant scFv 
antibody fragments was not pursued further. 
4.5.3 Eukaryotic expression in HEK293T via pMS-SNAPMut plasmid 
To approach eukaryotic expression of soluble scFv antibodies, L3.6pl-positive scFv inserts 
were transferred into the pSecTag2-based pMS-SNAPMut vector (2.10) via restriction 
sites SfiI and NotI (Figure 4-10). 15 L3.6pl-positive clones were successfully transfected 
into HEK293T cells (3.2.3.1) along with the 14.1(scFv, and 425(scFv) antibody fragments 
as positive control. Eukaryotic expression was conducted as described in 3.2.3.2. 
 
Figure 4-10 Schematic of pMS-SNAPMut expression cassette for eukaryotic expression of soluble 
scFv-SNAP proteins in transiently transfected HEK293T. 
Protein expression is regulated with a CMV promoter. Recombinant scFv proteins, consisting of a heavy 
chain VH and light chain VL connected via a glycine-serine (GS) linker, are secreted into the culture medium 
via a Igkappa signal sequence up-stream of the scFv. The scFv is genetically fused to a SNAP-tag as well as 
a His6-tag and a myc-tag used for detection or fluorescent labeling. Protein expression is terminated by a 
TGA stop codon. Down-stream of this, the internal ribosomal entry side (IRES) promotes co-translation of 
enhanced green fluorescent protein (eGFP) in parallel to expression of scFv-SNAP. Visible green 
fluorescence in transfected HEK293T cells indicates successful scFv-SNAP protein production.  
In successfully transfected cells, the bicistronic pMS-SNAPMut vector promotes 
expression of soluble scFv-SNAP proteins in HEK293T cells simultaneously with eGFP. 
This fluoresces under the microscope, thus visualizing protein expression. Transfected 
cells were cultivated under selective pressure of Zeocin for two weeks until 80 ± 10% of 
all viable cells featured eGFP as well as scFv-SNAP protein expression; untransfected 
HEK293T control cells died completely. Produced scFv-SNAP proteins were secreted into 
the culture medium via an IgG kappa signal sequence and the tissue culture supernatant 
(TCSN) was examined by SDS-PAGE and Western blot (Figure 4-11). The coomassie-
stained SDS-PAGE is not displayed here since the high FBS concentration in the 
cultivation medium resulted in a protein band at 66 kDa overlaying the scFv-SNAP protein 
band at 42 kDa. All scFv-SNAP proteins, except E3(scFv)-SNAP, were successfully 
expressed at the expected protein size. Protein concentrations slightly differed between 
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clones but all bands were clearly visible, indicating a sufficient scFv-SNAP protein 
concentration for subsequent experiments. 
 
Figure 4-11 Western blot analysis of tissue culture supernatant containing transiently expressed scFv-
SNAP proteins.  
A protein band at ~42 kDa indicates successful expression of all scFv-SNAP proteins, here detected via a 
penta-anti-His primary and a GAM-PO secondary antibody followed by signal development with DAB. Lane 
2: Expression of the positive control protein 425(scFv)-SNAP, lane 3: protein band of 14.1(scFv)-SNAP 
expression. No protein band was detected for the E3(scFv)-SNAP protein (lane 12) which despite correct 
DNA sequence and ORF could not be expressed in HEK293T cells. 
Harvested TCSN, containing the scFv-SNAP proteins, was utilized for flow cytometric 
binding analysis (4.6.2), internalization assays (4.6.3) and IMAC purification combined 
with SNAP-labeling (4.5.4). 
4.5.4 IMAC purification and SNAP-tag labeling with fluorescent dyes 
Eukaryotically produced scFv-SNAP proteins were purified by means of immobilized 
metal-ion affinity chromatography (IMAC) via the C-terminal His6-tag and if necessary 
were additionally labeled at the SNAP-tag with benzylguanine(BG)–coupled fluorescent 
dyes. IMAC purification and fluorescent labeling was exclusively performed with 
ELISA-positive clones (3.3.4). By this, one set of unlabeled scFv-SNAP antibodies and 
one labeled with BG-Alexa Fluor 647 (AF647) fluorescent dye was generated. Proteins 
14.1(scFv)-SNAP and 425(scFv)-SNAP were purified and labeled likewise. Figure 4-12 
illustrates an SDS-PAGE (Figure 4-12A) and Western blot analysis (Figure 4-12B) of 
successfully purified and AF647-labeled scFv-SNAP proteins. Each purification eluate 
analysis featured a protein band at approximately 49 kDa. Successful AF647-labeling was 
verified via image analysis in a VersaDoc device (Figure 4-12C). The presence of the 
scFv-SNAP antibody within the protein band at 42 kDa was verified via mass spectrometry 
after comparison to the MASCOT protein data base (data not shown, 3.3.8). Recombinant 
scFv-SNAP proteins were specifically detected via the His6-tag or SNAP-tag with DAB 
during Western blot analysis (Figure 4-12B). Protein concentration of IMAC-purified 
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scFv-SNAP proteins was calculated by means of densitometric AIDA-based analysis 
(3.3.3.1) using several BSA protein standard dilutions (50 – 1000 µg/mL) for evaluation. 
Resulting protein yield of 40 mL TCSN was between 103 µg/mL (A3(scFv)-SNAP) to 
1078 mg/mL (425(scFv)-SNAP). While AF647-labeling was successfully documented 
(Figure 4-12C), presence of free fluorescent dye (<10 kDa) was not observed on the SDS-
PAGE. 
 
Figure 4-12 SDS-PAGE and Western blot analysis of IMAC-purified scFv-SNAP proteins with 
subsequent AF647 labeling. 
(A) SDS-PAGE after coomassie-staining of all proteins with visible protein band for the scFv-SNAP proteins 
at 49 kDa and  additional protein bands at 66 kDa for the BSA protein standard (lane 12: 50 µg/mL, lane 13: 
200 µg/mL, lane 14: 1000 µg/mL).Additional contaminating protein bands are visible around 70 kDa. (B) 
Western blot with scFv-SNAP proteins at 49 kDa specifically detected via penta-anti-His primary and 
GAM-PO secondary antibody, developed with DAB substrate. (C) Photograph of scFv-SNAP proteins 
successfully labeled with AF647 fluorescent dye. 
4.6 Characterization of soluble scFv antibodies 
Biological functionality of soluble scFv-SNAP proteins was characterized by means of 
soluble protein ELISA (3.3.9.3), flow cytometry (3.3.10.1) and internalization assays 
(3.3.11). Binding activity of unpurified, purified, and AF647-labeled scFv-SNAP protein 
was tested on the pancreatic cancer cell line L3.6pl in combination with internalization 
behavior. Additional cross-reactive flow cytometric binding analysis was performed on 
other pancreatic and non-pancreatic cell lines. The EGFR-binding 425(scFv)-SNAP 
antibody fragment [164] served as a positive control during scFv-SNAP characterization 
(1.3.6). 
4.6.1 Protein ELISA 
Binding activity against pancreatic tumor-associated antigen was examined via soluble 
protein ELISA on L3.6pl, FG and PBMC membrane fractions (3.3.9.3), by applying 
2 µg/well purified but non-labeled scFv-SNAP protein. All clones featuring absorption 
signals of at least twice the ABTS background value (NC-reference value) of 0.129, were 
Results: Antibodies against pancreatic cancer 
 
 
101 
defined as positive. Figure 4-13 displays positive ABTS absorption values on L3.6pl 
membranes for eleven scFv-SNAP proteins. Even stronger absorption values were 
observed on FG membranes but none on PBMC negative control membranes. Clone 
14.1(scFv)-SNAP behaved likewise. A3(scFv)-SNAP showed weak but non-significant 
cross-reaction on PBMC membranes, although this particular absorption value on PBMC 
antigen was much weaker than during monoclonal phage ELISA analysis (4.2.4.3). Clones 
C5(scFv)-SNAP, D12(scFv)-SNAP, E3(scFv)-SNAP, E8(scFv)-SNAP and 
F3(scFv)-SNAP did not bind to L3.6pl membranes on protein level, and were not 
investigated further. Repetition of the protein ELISA, using TCSN instead of 
IMAC-purified protein, verified the tendency of results in Figure 4-13; but variations in 
absorption signals were observed due to differing protein concentrations in the TCSN (data 
not shown). Overall, stronger ELISA signals were measured with unpurified proteins. 
Clones D5(scFv)-SNAP and D9(scFv)-SNAP exhibited strong binding (absorption >10-
fold of background), clones 14.1(scFv)-SNAP and A3(scFv)-SNAP displayed medium 
binding between 5- and 10-fold over background, whereas all other L3.6pl-positive clones 
only showed weak binding activity (2- to 5-fold above background. 
 
Figure 4-13 Protein ELISA analysis with soluble scFv-SNAP proteins produced in HEK293T cells.  
Recombinant scFv-SNAP proteins were tested on L3.6pl, FG and PBMC membrane fractions. Bound 
scFv-SNAP antibodies were detected via polyclonal anti-SNAP-tag primary antibody, a GAM-PO secondary 
antibody and signal development with ABTS substrate. The average background value was 0.129, defining 
clones as positive when displaying ABTS absorption signals twice that value and higher. 
4.6.2 Flow cytometric analysis 
Besides binding analysis on membrane fractions, all eleven positive scFv-SNAP proteins 
(4.6.1) were tested for binding on living L3.6pl and PBMC cells via flow cytometry. 
Histograms in Figure 4-14A clearly document binding activity on viable L3.6pl cells, 
compared to the background fluorescence of the cells. Nine scFv-SNAP proteins, plus the 
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14.1(scFv)-SNAP, depicted positive binding on the L3.6pl target cell line but none on the 
PBMC negative control cells (Figure 4-14B). A3(scFv)-SNAP did not bind to the living 
PBMCs despite positive absorption measurements during ELISA analysis. Figure 4-14C 
states the percentage of L3.6pl target cells bound by scFv-SNAP antibodies and compares 
the mean fluorescent intensities (MFI) of each clone against the 425(scFv)-SNAP positive 
control. Clones E5(scFv)-SNAP and F11(scFv)-SNAP did not bind to living L3.6pl cells 
during flow cytometry and were discarded. Even though clones D5(scFv)-SNAP and 
D9(scFv)-SNAP featured very strong ELISA-binding, only very weak binding potential 
was observed here. Both clones will be discussed separately in 6.1.6. During flow 
cytometry, it was observed repeatedly that purified and fluorescence-labeled scFv-SNAP 
proteins depicted weaker binding activity than the unpurified TCSN (data not shown). 
 
Figure 4-14 Flow cytometric binding activity data of scFv-SNAP proteins on L3.6pl and PBMC cells. 
(A) Incubation of unpurified TCSN or 2 µg/sample scFv-SNAP fusion protein. The right-shifted grey curve 
represents bound scFv-SNAP proteins detected with an anti-His AF488-conjugated antibody. The black 
curve indicates the background fluorescence in comparison. Positive binding was shown for scFv-SNAP 
clones 14.1, A3, D1, D4, D6, E7 and F1. Clones D5 and D9 showed almost no binding. (B) None of the 
clones depicted binding on PBMC cells, (C) percentage of cells bound by scFv-SNAP proteins and the 
corresponding mean fluorescence values (MFI). 
D5(scFv) and D9(scFv) both exhibited very strong binding activity on membrane fractions 
during ELISA analysis on phage (4.2.4.3) and protein level (4.6.1) but merely featured 
weak binding (39% shifted cells) during flow cytometry (4.6.2). Closer investigations 
revealed a positive shift of 2.5% (D5(scFv)) and 2% (D9(scFv)) respectively (Figure 4-15), 
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indicating the possible existence of a certain cell subpopulation within the highly 
metastasizing L3.6pl cell line . 
 
Figure 4-15 Flow cytometric analysis of binding activity of D5(scFv) and D9(scFv) indicating a 
possible subpopulation within the L3.6pl cell line.  
Bound scFv proteins were detected with an anti-His IgG conjugated to AF488 fluorescence dye emitting in 
fluorescence channel FL-1. The black curve represents the background fluorescence of the detection antibody 
on the L3.6pl cells, the filled red curve displays the binding activity of D5(scFv) and D9(scFv) on L3.6pl. 
M1 indicates the area marked for shifted cells. 
4.6.2.1 Flow cytometric cross-reactivity analysis 
Since scFv-phage particles binding to healthy PBMC cells had already been depleted 
during panning, no binding was detected on living PBMC cells during flow cytometry. 
Nevertheless, cross-reactive properties of the L3.6pl-positive scFv-SNAP antibodies was 
investigated on other pancreatic cancer cell lines as well as on carcinoma cell lines 
originated from different tissue types (2.4). Existing cross-reactivity might indicate a 
tumor-associated antigen present on more than one type of cancer.  
Cross-reactivity to pancreatic cancer cell lines: Surface binding was examined on the 
pancreas-derived cell lines FG, Su86.86, MiaPaCa2, PancTuI and PancTuI-luc (Table 
4-11). All clones displayed positive binding on the PancTuI and PancTuI-luc but binding 
activities differed from the values measured on L3.6pl. For instance, clone 
D6(scFv)-SNAP bound 25% more PancTuI/PancTuI-luc cells, whereas clone 
14.1(scFv)-SNAP displayed approximately 50% less binding to PancTuI/PancTuI-luc than 
on L3.6pl. Recombinant scFv-SNAP antibodies 14.1, D1, D4, D6 and F1 also showed 
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binding activity to the non-metastasizing precursor cell line FG. Moreover, scFv-SNAP 
clones D1, D4, D6 and F1 bound to MiaPaCa2 and Su86.86, whereas 14.1(scFv)-SNAP 
did not feature any binding on the latter two cell lines. 
Table 4-11 Results of flow cytometric cross-reactivity testing with L3.6pl-positive scFv-SNAP 
antibody fragments on other pancreatic carcinoma cell lines. 
Clone L3.6pl FG MiaPaCa2 Su86.86 PancTuI/PancTuI-luc
14.1(scFv) +++ +++ - - + 
A3(scFv) +++ - - - ++ 
D1(scFv) ++ + + + ++ 
D4(scFv) +++ + + + + 
D5(scFv) + - - - + 
D6(scFv) ++ + + + +++ 
D9(scFv) + - - - + 
E7(scFv) ++ - - - +++ 
F1(scFv) ++ + + + +++ 
Definition of percentage of shifted cells: +++ = 100 – 75%, ++ = 75 – 50%, + = 50 – 25%, - = 25 – 0% 
Cross-reactivity to non-pancreatic cell lines: Different degrees of cross-reactive binding 
results on cell lines A431 (human epidermoid carcinoma), LNCaP (human prostate 
carcinoma), MDA-MB-231 (human breast carcinoma) and SiHa-BHT35 (human cervix 
carcinoma) are summarized in Table 4-12. All clones except D5(scFv)-SNAP and 
D9(scFv)-SNAP bound to A431 and MDA-MB-231. Cell line SiHa-BTH35 was tested 
positive for binding of six scFv-SNAP clones (14.1, D1, D4, D6, D9 and F1), but only four 
scFv-SNAP proteins (D1, D4, D6 and F1) displayed slightly positive binding on the 
prostate cancer cell line LNCaP.  
Table 4-12 Results of flow cytometric cross-reactivity testing with L3.6pl-positive scFv-SNAP 
antibodies on cell lines derived from several different cancer types. 
Clone A431 LNCaP MDA-MB-231 SiHa-BTH35
425(scFv) 
 
+ 
 
14.1(scFv) + - + ++ 
A3(scFv) + - + - 
D1(scFv) ++ + ++ + 
D4(scFv) + + ++ + 
D5(scFv) - - - - 
D6(scFv) ++ + ++ ++ 
D9(scFv) - - - + 
E7(scFv) + - + - 
F1(scFv) ++ + ++ ++ 
Definition of percentage of shifted cells: +++ = 100 – 75%, ++ = 75 – 50%, + = 50 – 25%, - = 25 – 0% 
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None of the scFv-SNAP antibodies showed unspecific binding to the eukaryotic expression 
cell line HEK293T (data not shown). 
4.6.3 Internalization assays 
Recombinant scFv antibodies isolated in this work are potential candidates for the 
generation of immunotoxins for application during targeted immunotherapeutic cancer 
treatment. It is essential for therapeutic antibodies to be transported into the cytosol of a 
target cell after surface binding. Internalization of fundamentally improves the metabolic 
uptake and therapeutic effectiveness of recombinant immunotoxins. Based on positive 
binding activity on viable cells during flow cytometry (4.6.2.1), flow cytometric 
internalization experiments [244] (4.6.3.1)  were performed with scFv-SNAP proteins of 
clones 14.1, A3, D1, D4, D5, D6, D9, E7 and F1. Candidates with positive internalization 
behavior during flow cytometric internalization were then further investigated by means of 
immunofluorescence staining and confocal microscopy in the OPERA live cell imager 
(4.6.3.2). 
4.6.3.1 Internalization analysis via flow cytometry 
IMAC-purified scFv-SNAP proteins were labeled with red AF647 fluorescent dye and 
incubated with L3.6pl cells at 37 °C to induce internalization. In parallel, the identical 
AF647-labeled scFv-SNAP proteins were incubated at 4 °C to document surface binding 
instead of internalization. Bound and internalized scFv antibodies marked with AF647 
were measured in fluorescence channel FL-4 of a FACScalibur device (Figure 4-16). 
Positive AF647-binding signals were detected at both temperatures. To distinguish 
internalized from surface-bound scFv antibodies, the exterior cell proteins were removed 
by digestion with trypsin. This eliminated the AF647 signal of surface-attached 
scFv-SNAP proteins, while keeping the internalized fluorescence signal intact. Afterwards 
fluorescence signals were still measured for clones 14.1, A3, D4 and F1, when previously 
incubated at 37 °C. Remaining clones did not display a positive fluorescence signal after 
incubation at 37 °C and trypsination. Following 4 °C incubation, none of the clones 
depicted a positive AF647 signal after trypsin treatment. Concluding, positive fluorescence 
signals after trypsin digest were only emitted by AF647-coupled and internalized 
scFv-SNAP antibodies. Figure 4-16 illustrates, a positive internalization process was 
measured for clones 14.1, A3, D4 and F1. A positive right-shift (black curve) was shown 
after incubation at 4 °C as well as 37 °C. Trypsin treatment of L3.6pl cells, after incubation 
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at 4 °C, resulted in a negative flow cytometric signal. To prove successful internalization, 
binding of scFv-SNAP proteins at 4 °C and successful trypsinization after internalization 
were verified by co-incubation with an anti-His-AF488 conjugated detection antibody. 
 
Figure 4-16 Flow cytometric documentation of internalization and binding properties of 14.1(scFv)-
SNAP, A3(scFv)-SNAP, D4(scFv)-SNAPand F1(scFv)-SNAP labeled with AF647 on L3.6pl cells.  
Binding and successful trypsination was detected via the His6-tag and an anti-His-AF488 conjugated 
detection antibody. (A) and (B) demonstrate binding at 4 °C; (C) and (D) prove elimination of red 
fluorescence after incubation at 4 °C and trypsination due to successful removal of surface-bound 
scFv-SNAP protein; (E) depicts the combined fluorescence signal of surface-bound and internalized 
scFv-SNAP at 37 °C; (F) shows surface-bound proteins after 37 °C incubation, detected with 
anti-His-AF488; (G) positive signal of AF647-labeled scFv-SNAP proteins after removal of surface-bound 
protein after incubation at 37°C; (H) proves that trypsination of cells measured in (G) has been successful 
because there is no measurable AF488 signal.  
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Measurements of trypsinated cells after incubation at 37 °C rendered positive 
red-fluorescent signals, indicating internalization of AF647-labeled proteins into L3.6pl 
cells but no signal for the AF488-conjgated detection antibody. Non-trypsinated cells 
featured an AF488-related fluorescence signal for all clones. Fluorescence intensity of 
internalized scFv-SNAP antibodies following trypsin treatment was weaker than the signal 
before trypsination. This was attributed to the removal of surface-bound scFv antibodies 
from the measurement. In summary, four scFv-SNAP clones (14.1, A3, D4 and F1) 
depicted a positive internalization signal during flow cytometric internalization analysis. 
Clones D1, D5, D6, D9 and E7 showed a similar binding performance as in Figure 4-14, 
but their fluorescence signal was completely eliminated by trypsin treatment after 
incubation at 37 °C. This led to the conclusion that for said clones merely exterior binding 
occurred but no internalization.  
4.6.3.2 Internalization via OPERA confocal microscopy 
Following flow cytometry (4.6.3.1), the four internalization-positive scFv-SNAP proteins 
14.1, A3, D4 and F1 were examined by immunofluorescence staining using the OPERA 
live cell imaging system. In a first experiment, IMAC-purified unlabeled scFv-SNAP 
proteins were detected via a polyclonal anti-SNAP-tag antibody and an AF647-labeled 
detection antibody. As second analysis, kinetic measurements were performed with the 
OPERA device by means of live cell imaging in order to document the internalization 
process of the AF647-labeled 14.1(scFv)-SNAP antibody fragment into L3.6pl cells. 
Immunofluorescence staining of scFv-SNAP proteins: 2 µg/well of IMAC-purified 
unlabeled scFv-SNAP protein were incubated on L3.6pl cells in a 96-well plate (µ-clear, 
black, greiner) at 4 °C for 1 h and at 37 °C for different time periods (1, 2, 3, 6 and 12 h) to 
observe internalization behavior. Since adhesive L3.6pl cells were not detached or treated 
with trypsin, differently shaped cells were observed to adhere to the bottom of the 96-well 
plate. Figure 4-17 illustrates the internalization of 14.1(scFv)-SNAP after one to two hours 
incubation at 37 °C at two different locations in a well.  
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Figure 4-17 Immunofluorescence staining of 14.1(scFv)-SNAP protein incubated on L3.6pl cells at 
4°C and 37°C.  
Half of the cells were permeabilized with Triton X100 before staining and after fixation with 4% PFA. After 
1 h incubation at 4 °C, surface binding was observed. After 1 h at 37°C, binding to cell surface was increased 
and vesicle formation started in the permeabilized cells. Internalization of vesicles with 14.1(scFv)-SNAP 
occurred after 1-2 h at 37°C. Vesicles inside the cell became larger and more with time. Non-permeabilized 
cells do not display the internalization very clearly but the permeabilized cells give a very good impression of 
the vesicles transported into the L3.6pl cells. Nucleus staining was performed with DAPI, scFv-SNAP 
detection via a polyclonal anti-SNAP-tag secondary and an AF647-labeled tertiary antibody. 
Non-permeabilized cells show excellent binding of the AF647-labeled 14.1(scFv)-SNAP 
protein, but hardly any internalized antibody. Permeabilized cells, on the other hand, show 
a large number of internalized vesicles after two hours. In contrast to the other antibodies 
with internalizing properties, 14.1(scFv)-SNAP bound to the cell surface continuously 
indicating recognition of a tumor associated target antigen with high expression density. 
Figure 4-18 depicts binding and internalization of clone A3(scFv)-SNAP. Binding after 1 h 
at 4 °C was very weak but binding increased during incubation at 37 °C. In contrast to 
14.1(scFv)-SNAP, binding was located in defined spots on the cell surface. Repeatedly, 
non-permeabilized cells only featured surface binding but permeabilized cells showed 
visible internalized vesicles three hours incubation at 37 °C. 
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Figure 4-18 Immunofluorescence staining of A3(scFv)-SNAP on L3.6pl cells at 4°C and 37°C.  
Half of the cells were permeabilized with Triton X100 before staining and after fixation with 4% PFA. After 
1 h incubation at 4 °C, surface binding was observed. After 1 h at 37°C, binding to cell surface was increased 
and vesicle formation started in the permeabilized cells. Internalization of vesicles with A3(scFv)-SNAP 
protein occurred after 1-2 h at 37°C. Vesicles inside the cell became larger and more with time. 
Non-permeabilized cells do not display the internalization very clearly but the permeabilized cells give a very 
good impression of the vesicles transported into the L3.6pl cells. Nucleus staining was performed with DAPI, 
scFv-SNAP detection via a polyclonal anti-SNAP-tag secondary and an AF647-labeled tertiary antibody. 
For clones D4(scFv)-SNAP and F1(scFv)-SNAP, binding as well as starting internalization 
were only observed after three to six hours incubation at 37 °C. Both were visualized by a 
growing number of vesicles with longer incubation time, in parallel to an enlargement of 
these vesicles over time. The actual internalization process of these two clones took 
between six and twelve hours. This is clearly documented in Figure 4-19 by the defined 
and internalized vesicles inside the cell.  
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Figure 4-19 Immunofluorescence staining of D4(scFv)-SNAP and F1(scFv)-SNAP incubated on L3.6pl 
cells at 4°C and 37°C.  
Half of the cells were permeabilized with Triton X100 before staining and after fixation with 4% PFA. 
Binding of both scFv proteins to cell surface was clearly visible after 3 – 6 h incubation at 37 °C. After 12 h 
at 37 °C binding to cell surface was increased and vesicle formation started. Starting internalization of 
vesicles with D4 and F1 proteins took place around 12 h at 37°C. Vesicles inside the cell became larger with 
time. Non-permeabilized cells do not show the internalization very clearly but the permeabilized cells give a 
very good impression of the vesicles that were transported into the L3.6pl cells. Again both scFv antibodies 
do not bind to the cell surface continuously but only on certain spots of the cell surface. Starting from theses 
spots, they start to internalize into the cells. Nucleus staining was performed with DAPI, scFv-SNAP 
detection via a polyclonal anti-SNAP-tag secondary and an AF647-labeled tertiary antibody. 
Binding of proteins A3(scFv)-SNAP, D4(scFv)-SNAP and F1(scFv)-SNAP located in 
small spots on the cell surface indicates that the bound surface antigen is not over-
expressed to the same extent of the antigen bound by 14.1(scFv)-SNAP antibody. 
Internalization kinetics of 14.1(scFv)-SNAP-AF647: Featuring the fasted internalization 
rate, IMAC-purified and AF647-labeled 14.1(scFv)-SNAP protein was applied during a 
kinetic experiment and measured with the OPERA system. Because living L3.6pl cells 
were very sensitive to any kind of unusual treatment, and tended to detach after two to 
three hours, fast internalization was essential for this experiment. Sensitivity was observed 
by rounding of L3.6pl cells which slightly influenced the focus of the OPERA confocal 
microscope, resulting in blurred photographs. Figure 4-20 documents a kinetic illustration 
of the internalization process of 14.1(scFv)-SNAP-AF647 at 37°C (concentrated 2 µg/well) 
at the same position in four wells at different time points (60 min at 4 °C (t = 0), 30 min at 
37 °C (t = 30), 60 min at 37 °C (t = 60 min), and 80 min at 37 °C (t = 80 min)). After 
surface binding, 14.1(scFv)-SNAP-AF647 was internalized via small vesicles. After 
80 min incubation at 37 °C, most cells were swimming freely in the wells and the 
experiment was stopped. No DAPI counter-staining was performed to avoid eventual 
interference with the AF647 signal and cell sensitivity. 
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Figure 4-20 Internalization kinetics of 14.1(scFv)-SNAP-AF647 into L3.6pl cells at 37°C at different 
time points.  
A, B, C and D show the internalization behavior of 4 different positions at 37°C. Pictures were taken after 1 h 
incubation at 4°C (t = 0) and after 30 min (t = 30), 60 min (t = 60) as well as 80 min (t = 80) incubation at 
37°C. All positions show the process of binding to the cell surface and the internalization of the 14.1(scFv)-
SNAP-AF647 protein into the L3.6pl cells. AF647 fluorescence in cells was photographed at 
40 x magnification with the confocal OPERA microscope. 
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5 Results: Design of novel fluorescent W-tag 
Efficient production of recombinant therapeutic proteins is another current major area of 
research. Prospectively, pancreas-specific scFv antibody fragments isolated from the 
Tomlinson libraries I and J characterized in the work, are promising candidates to serve as 
binding domain within an immunotoxin. Similar therapeutic results, based on the anti-
EGFR single chain 425(scFv) as binding moiety fused to a truncated version of the 
bacterial toxin Pseudomonas Exotoxin A’ (ETA’), have previously been described [157, 
159]. Being potentially toxic to eukaryotic organisms, such cytotoxic constructs are 
primarily produced in prokaryotic expression systems, such as E.coli. To evaluate the 
production of such recombinant target constructs more easily, research during the last 
decade has focussed on non-invasive on-line monitoring systems to observe bacterial 
cultures during fermentation. One system, called BioLector
®
, was developed at the 
Department of Biochemical Engineering at RWTH Aachen University. It is able to monitor 
bacterial cultures for product formation through a green fluorescent protein (GFP) reporter 
tag, measures pH or oxygen content. As an alternative to the commonly used reporter tag 
GFP, a new protein tag was developed, exploiting the auto-fluorescent characteristics of 
the aromatic amino acid tryptophan (W) by means of tryptophan clustering. This 
W-enriched tag, called W-tag, is much shorter than GFP. It offers a possibly advantageous 
approach for the on-line measurement of protein formation in real-time. Five W-tags with 
various numbers of tryptophan residues were designed and exemplarily fused to the 
anti-CD30 receptor single chain Ki-4(scFv) [237]. The anti-Muc1 receptor single chain 
M12(scFv) [238] was used as a second proof-of-concept protein for the on-line monitoring. 
The following chapter presents the results of cloning, expression, as well as on-line and 
off-line analysis regarding those novel W-tags. Additionally, the relation between product 
formation and tryptophan fluorescence intensity was investigated, followed by the analysis 
of binding specificity of W-tagged and untagged recombinant protein. 
5.1 Generation of W-tag constructs 
5.1.1 Sequence design and cloning 
Five different W-tag sequences, containing between one and five tryptophan residues 
(W1 – W5), were developed in co-operation with Dr. Heinrich Delbrück (Fraunhofer IME, 
Aachen). Accumulated tryptophan residues were embedded into the structure of a naturally 
occurring protein loop originated from a Bacillus caldolyticus cold shock protein 
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(GenBank accession numbers are: W1-tag – JN107996, W2-tag – JN120907, W3-tag – 
JN120908, W4-tag – JN120909, W5-tag – JN120910). Table 5-1 gives an overview of the 
number of tryptophan residues (and other aromatic amino acids) within the W-tags, 
additionally comparing the lengths of the W-tags and the W-tagged single chain fusion 
proteins. 
Table 5-1 Five different W-tag variations stating the number of tryptophan residues per construct, 
the construct name, the total number of aromatic amino acids (tryptophan, tyrosine and 
phenylalanine) as well as the size of the tag region and fusion protein in kDa. [246] 
Name Aromatic amino acids in W-tag Fusion protein in kDa W-tag in kDa
EC 0 24.16 1.73 
W1 1W 1Y 1F 25.79 3.36 
W2 2W 3Y 0F 27.44 5.01 
W3 3W 2Y 0F 27.46 5.03 
W4 4W 1Y 0F 27.49 5.06 
W5 5W 3Y 0F 28 5.57 
W-tags were synthesized at GENEART (Regensburg, Germany) and delivered as DNA 
sequences in plasmids pMA(amp) and pCR4Blunt-TOPO(amp,kan), containing the necessary 
restriction sites (NcoI, NdeI, HindIII and XbaI).  
Table 5-2 displays the DNA and protein sequence data of the W-tags. DNA triplets of the 
ordered DNA sequences were optimized for the protein expression in E.coli. 
Table 5-2 DNA and protein sequences of all five W-tags.  
The DNA sequences were ordered from GENEART with E.coli-optimized triplets. They were delivered in 
the vector backbones pMA and pCR4Blunt-TOPO containing all the restriction sites necessary for 
subsequent cloning into a prokaryotic or eukaryotic expression system. 
W-tag DNA sequence Protein sequence Delivery vector 
W1 
AAA TGG AGC AAC AAC GAA 
AAA GGC TAT GGC TTT AGC 
KWSNNEKGYGFS pMA 
W2 
CGC GGC AAA GAA AAA TGG 
AAA AAC AAC GAA AAA GGC 
TAT GGC TAT CAG GAA GAT 
GAA GGC GGC AGC TAT AAA 
TGG GAA GAT 
RGKEKWKNNEKGYGYQEDEGGSYKWED pMA 
W3 
CGC GGC AAA GAA AAA TGG 
AAA AAC AAC GAA AAA GGC 
TGG GGC TAT CAG GAA GAT 
GAA GGC GGC AGC TAT AAA 
TGG GAA GAT 
RGKEKWKNNEKGWGYQEDEGGSYKWED pMA 
W4 
CGC GGC AAA GAA AAA TGG 
AAA AAC AAC GAA AAA GGC 
TGG GGC TAT CAG GAA GAT 
GAA GGC GGC AGC TGG AAA 
TGG GAA GAT 
RGKEKWKNNEKGWGYQEDEGGSWKWED pCR4Blunt-TOPO 
W5 
CGC GGC AAA TAT AAA TGG 
AAA AAC AAC GAA AAA GGC 
TGG GGC TAT TGG GAA GAT 
GAA GGC GGC AGC TGG TAT 
TGG AAA GAT 
RGKYKWKNNEKGWGYWEDEGGSWYWKD pMA 
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During W-tag design, the protein sequences were analyzed with the CHARMM software 
(http://www.CHARMM.org) in Discovery Studio (http://www.accelrys.com) to minimize 
the free energy of each model and to create 3D-models for each W-tag protein loop (Figure 
5-1). Moreover, all protein sequences were arranged with the same program to ensure that 
tryptophan residues were positioned on the outside of the protein loop. 
 
Figure 5-1 3D-models of amino acid sequence structures of all five W-tags.  
(A) W1-tag, (B) W2-tag, (C) W3-tag, (D) W4-tag and I W5-tag; all structures display the amino acid residues 
on molecular basis featuring the calculated in- and outward orientation of the amino acids in the protein loop 
used for the W-tag design. 
5.1.2 Vector assembly of W-tag constructs 
All five W-tags were successfully subcloned from the pMA and pCR4Blunt-TOPO 
delivery vectors into the pET-27b+-derived pMT plasmid (2.10, Figure 2-1) used for 
prokaryotic protein expression in E.coli. The pMT expression vector contained a gene 
encoding the CD30-specific murine single-chain antibody fragment Ki-4(scFv) [237] or 
the human single chain M12(scFv) [238], supposed to bind against the MucI receptor. Two 
different constructs were prepared for each W-tag and each recombinant scFv antibodies: 
(a) One construct carrying a pelB leader peptide to produce periplasmic target protein 
(subcloned via restriction sites NcoI and HindIII), and (b) one construct without pelB 
leader peptide to produce cytoplasmic protein (transferred through enzymes NdeI and 
HindIII). 
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DNA fragments were ligated into the pMT plasmid to create the expressional vector series 
pMT-Wx-Ki-4(scFv) and pMT-Wx-M12(scFv), where x refers to the number of 
tryptophan residues in the W-tag. The complete expression cassette (Figure 5-2) comprised 
a pelB leader (or no pelB leader respectively), W-tags (W1–W5), a His6-tag, GS-linkers 
and a cleavable enterokinase site (EK-site). Recombinant scFv genes were introduced as an 
in-frame fusion down-stream of the W-tag region exchangeable within the expression 
cassette via restriction enzymes SfiI and NotI. 
 
Figure 5-2 Expression cassette for pMT-Wx-Ki-4(scFv) and pMT-Wx-M12(scFv) fusion protein 
constructs.  
The target protein is genetically linked to the W-tag region together forming the target fusion protein. The 
schematic structure of the Wx-Ki-4(scFv)/M12(scFv) insert in the expression cassette consists of the pelB 
signal peptide inducible with IPTG via the lac operator (periplasmic construct), W-tag fused to a His6-tag by 
a GS-linker and the scFv target protein linked to the His6-tag through a potentially cleavable EK-site. The 
cytoplasmic construct has no pelB leader peptide. Restriction sites for constructs with pelB leader are NcoI 
and HindIII, restriction sites for constructs without pelB leader NdeI and HindIII. The recombinant scFv can 
be exchanged through SfiI and NotI restriction sites. [246] 
All W-tag constructs were equipped with a His6-tag for immunodetection and affinity 
purification as well as an EK-site for potential cleavage of the target protein from the 
W-tag and His6-tag. Since all proteins naturally contain some tryptophan residues in their 
amino acid sequence vectors pMT-Ki-4(scFv) and pMT-M12(scFv) without W-tags were 
employed as expression controls (EC) to determine the background auto-fluorescence of 
the untagged single chains. The empty pET-27b+ vector was used as a true negative 
control (NC). 
5.2 Expression of W-tag fusion proteins 
5.2.1 Protein expression in bacterial pellet 
To illustrate protein expression, Wx-Ki-4(scFv) constructs with pelB leader are shown 
exemplary for all constructs with and without pelB leader as well as all corresponding 
Wx-M12(scFv) constructs. All five Wx-Ki-4(scFv) constructs including controls (EC and 
NC) were expressed under kanamycin selective pressure in BL21 Rosetta 2 (DE3) E.coli 
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(3.1.9.3) induced with IPTG via the lac operator. Samples were retrieved from bacterial 
pellet by heat lysis and successful target fusion protein expression was verified via 
SDS-PAGE and Western blot analysis against the His6-tag (Figure 5-3). Intense double 
bands ranging from 25 to 35 kDa were detected, confirming over-expression of the 
different W-tagged target proteins with and without the pelB leader peptide. NC did not 
show any protein expression on the Western blot. The double bands occurred due to 
incomplete cleavage of the pelB leader when the fusion protein was transported from the 
cytoplasm to the periplasmic space. The identity of each protein band was confirmed by 
mass spectrometry (3.3.8) (data not shown). The lower protein band (25 – 30 kDa) 
corresponded to the calculated weight of the protein, the higher band (30 – 35 kDa) 
included the uncleaved pelB leader peptide. Remaining visible protein bands on the 
SDS-PAGE were contaminating bacterial proteins. 
 
Figure 5-3 Wx-Ki-4(scFv) protein expression analysis on SDS-PAGE and Western blot.  
(A) SDS-PAGE: lane 1 – Prestained Broad Range Protein Marker, lane 2 – empty vector as negative control 
(NC), lane 3 – Ki-4(scFv) expression control (EC), lane 4 – W1-Ki-4(scFv), lane 5 – W2-Ki-4(scFv), lane 6 
– W3-Ki-4(scFv), lane 7 – W4-Ki-4(scFv), lane 8 – W5-Ki-4(scFv). (B) Western blot of proteins detected 
with a monoclonal anti-polyHis IgG antibody, a goat anti-mouse-peroxidase conjugated antibody and DAB. 
In figures (A) and (B) the proteins are detected as double bands. [246] 
The cytoplasmic constructs without pelB leader peptide and the Wx-M12(scFv) target 
fusion proteins were expressed in the pellet likewise (data not shown). [246] 
5.2.2 Protein secretion into cultivation medium 
Non-tagged Ki-4(scFv) antibody (EC) and the W1-Ki-4(scFv) protein were partially 
secreted and found in both the supernatant and the cell pellet (Figure 5-4A). Target fusion 
proteins containing between two and five tryptophan residues within the W-tag were 
almost exclusively detected in the cell pellet fraction and barely secreted into the medium,  
displayed by the very weak band visible in the Western blot (Figure 5-4B). Even though 
the bacterial pellet was thoroughly separated from the medium by centrifugation, these 
weak bands may be residual protein from cells damaged during centrifugation. 
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Wx-M12(scFv) constructs showed the same trend of protein secretion during expression as 
the W-tagged Ki-4(scFv) proteins. 
 
Figure 5-4 SDS-PAGE and Western blot analysis of Wx-Ki-4(scFv) proteins secreted into cultivation 
medium.  
(A) SDS-PAGE and (B) Western Blot of cultivation medium: Lanes 1 and 2 were loaded with the NC 
showing no protein, lanes 3 and 4 contain the Ki-4(scFv) expression control which was secreted into the 
cultivation medium (band at ~25kDa). In lane 5 and 6 the W1-Ki-4(scFv) protein secretion in to cultivation 
medium is shown. Lanes 7 to 15 display the Ki-4(scFv) protein tagged with W2 to W5 which were only 
detected as weak bands in the cultivation medium if at all. All lanes display various bands of bacterial 
protein. 
None of the cytoplasmatically expressed proteins without pelB leader were released into 
the medium since they were not transported to the periplasmic space after translation. 
5.2.3 Protein expression in different types of media 
Moreover, the proteins were expressed as 5 mL cultures using different media to test for 
differences in expression: (a) modified Wilm-Reuss synthetic minimal medium (2.3), 
(b) LBkan medium induced with 1 mM IPTG (2.3) and (c) LBkan auto-induction medium 
(2.3). Comparing the protein expression in these different types of media, all Wx-Ki-
4(scFv) target fusion proteins were over-expressed to a similar degree in all three types of 
media, although expression in LBkan auto-induction medium sometimes yielded slightly 
better results (data not shown). As a consequence, modified Wilms-Reuss synthetic 
medium was chosen for all subsequent fermentations and on-line fluorescence 
measurements. A huge advantage is that synthetic medium displays lower background 
fluorescence than complex medium, thus resulting in a clearer signal during measurements. 
It was confirmed that control cultures lacking induction with 1 mM IPTG or lactose, never 
featured any protein expression during any time of cultivation in any cultivation medium. 
5.2.4 Percentage of over-expressed Wx-Ki-4(scFv) 
To evaluate the time point of maximum target protein over-expression, samples of all 
induced Wx-Ki-4(scFv) target fusion proteins were taken from a fermentation at five 
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different time points (t0 = 4.44 h, t1 = 6.22 h, t2 = 9.11 h, t3 = 12.2 h, t4 = 26.7 h) as well as 
the NC and EC controls. All cultures were induced with 1 mM IPTG after 4.44 h of 
fermentation when the bacteria entered the exponential growth phase. The bacterial pellet 
of each sample was harvested and the protein concentration within each pellet was 
analyzed via SDS-PAGE (3.3.1) and AIDA analysis software (3.3.3.1). After determining 
the total bacterial protein concentration as well as the concentration of target protein from 
the respective protein band on the SDS-PAGE, the percentage of the target protein was 
calculated referring to the total bacterial protein amount. Target protein concentration 
peaked between 9 and 10 h of cultivation (Figure 5-5). Subsequently target proteins were 
harvested after 9.5 h of fermentation to obtain optimal yield for further investigations of 
the target proteins. The graph below clearly shows a lower protein yield for EC and 
W1-Ki-4(scFv) than for the target proteins. W3-Ki-4(scFv) was produced best. Target 
protein concentration decreased again between 10 and 12 h of fermentation due to protein 
degradation or accumulation of biomass without target protein.  
 
Figure 5-5 Calculated percentage of Wx-Ki-4(scFv) proteins referring to total bacterial protein after 
determination of protein concentration with AIDA.  
NC did not produce any protein. All target proteins reached a peak of over-expression between 9 and 10 h, 
except EC which kept growing and producing target protein until the fermentation ended. EC and W1-Ki-
4(scFv) display lower expression of the target protein than the other constructs. W3-Ki-4(scFv) has the best 
over-expression at the peak. Between 10 and 12 h of fermentation the target protein concentration decreased. 
5.3 On-line measurement data 
In the following, W-tagged Ki-4(scFv) and M12(scFv) fusion proteins were examined for 
bacterial cell growth and cytotoxic effects eventually influencing biomass production using 
a self-made Respiratory Activity Monitoring System (RAMOS) (data not shown). 
Additionally, target fusion protein production was monitored on-line with a non-invasive 
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BioLector-like device via the auto-fluorescence signal of the different W-tags which 
optically detected protein production in real-time (3.5.1). BioLector on-line measurement 
data was performed and analyzed by Esther Gartz at the Department of Biochemical 
Engineering at RWTH Aachen University. 
5.3.1 On-line fluorescence intensity measurements 
One aim of this thesis was to create a short and optically active protein tag exploiting the 
auto-fluorescence properties of accumulated tryptophan residues in an on-line 
measurement set-up with an adapted BioLector® device to simultaneously measure 
biomass and product formation via tryptophan fluorescence during fermentation of induced 
and non-induced cultures (Figure 5-6A-D). Fermentation in the BioLector-like apparatus 
was carried out in 96-well MTPs (3.1.9.3). During cultivation, bacterial growth was 
determined by measuring the scattered light signal at 620 nm [224]. Tryptophan was 
excited at 280 nm and its emission was measured at 350 nm in form of a tryptophan 
fluorescence signal. Mean measurement values of quadruplicate samples of parallel 
induced and non-induced cultures, representing each Wx-Ki-4(scFv) target fusion protein 
as well as the EC and NC constructs, are displayed in Figure 5-6A-E. The relative 
percentage deviation of these measurements was less than 6% (data not shown). [246] 
Scattered light signals of the non-induced cultures (Figure 5-6A) similarly increased for all 
constructs during the exponential growth phase up to 7.5 h of fermentation. At this stage, 
glucose was almost depleted and the signals then declined until 10 h. For all non-induced 
clones, the different W-tag clones had no influence on the growth behavior. From 10 h 
onwards, the scattered light signals increased for the EC and NC cultures and, after a short 
stationary period, in the other cultures as well (Figure 5-6A). Tryptophan fluorescence 
curves of the non-induced cultures were comparable to the corresponding scattered light 
curves (Figure 5-6C) and reached a plateau after 7.5 h, indicating no further growth when 
the bacteria switched from consuming glucose to the overflow metabolite acetate. The 
similar curves for scattered light and tryptophan fluorescence suggest that both signals 
provide data about biomass formation (discussed later in more detail). [246] 
A slight increase for scattered light and tryptophan fluorescence signals was also observed 
in the non-inoculated control wells with pure medium (Figure 5-6A-D). Still no cell growth 
was detected towards the end of the experiment (no pellet after centrifugation). [246] 
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Induction of protein expression with 1 mM IPTG in the early exponential phase (after 3.2 h 
of cultivation) profoundly impacted the resulting growth curves. Only a moderate increase 
in biomass formation was observed (Figure 5-6B) but tryptophan fluorescence signals of 
all cultures rapidly increased except the negative control (NC) (Figure 5-6D). It was 
observed that the W-tags with a higher number of tryptophan residues did not return a 
proportional increase in fluorescence intensity. Nevertheless, the fluorescence intensity 
increases even with a stagnating biomass formation apart from the EC which keeps 
growing until the end of the fermentation (Figure 5-6D). Glucose depletion was observed 
after 9 – 10 h and at the same time the tryptophan fluorescence intensity declined in all 
induced cultures. [246] 
In the non-induced bacteria (Figure 5-6A and C), the increasing biomass (scattered light 
signal intensity) and tryptophan fluorescence intensity correlate which each other, and thus 
with the presence of tryptophan in the biomass. The tryptophan fluorescence was plotted as 
a function of the scattered light where all data points were almost concurrent with one 
another (Figure 5-6E). This means that all five W-tag constructs performed in a similar 
manner with regard to tryptophan fluorescence vs. scattered light intensity in non-induced 
cultures. The connection between tryptophan fluorescence and scattered light intensity was 
described using the power function (fluorescence intensitycalc = 4780·[scattered light 
intensitymeas]
0.077
-7715). Consequently, tryptophan fluorescence in the non-induced cultures 
was independent of the W-tag variant and only mirrored the scattered light intensity 
depicting the amount of cells. This so called fit indicates the effect of the biomass 
fluorescence signal on the tryptophan fluorescence intensity. Using the biomass signal of 
the uninduced clones, this factor was subtracted from the tryptophan fluorescence signal 
(Figure 5-6E). [246] 
Thus, tryptophan fluorescence coming from the biomass could be calculated with the 
power function and was subtracted from the overall tryptophan fluorescence to retrieve the 
partial tryptophan fluorescence signal actually resulting from the W-tag. This implies no 
observations of correlation between the quantitative and exact concentration value of target 
protein and tryptophan fluorescence. Only an increased product formation was documented 
where the curves of the W-tagged proteins provided a differing signal from the untagged to 
the W-tagged target fusion proteins. [246] 
In the induced cultures, the overall tryptophan fluorescence signal is the sum of the 
fluorescence signal from the biomass and the fluorescence signal from the W-tagged fusion 
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proteins. When plotted against time (Figure 5-6F) it became apparent that the fusion 
protein begins to accumulate after induction only. Fluorescence intensity then increased 
until about 10 h of cultivation and declined after that, possibly reflecting protein 
degradation. Containing six tryptophan residues, the EC construct also generated 
tryptophan fluorescence but its tryptophan signal intensity was substantially lower than 
that of the W-tagged proteins. [246] 
 
Figure 5-6 On-line detection of biomass formation and production of Wx-Ki-4(scFv) target fusion 
proteins.  
The intensities of (A,B) represent the scattered light (620 nm) and (C,D) tryptophan fluorescence 
(280/350 nm excitation/emission) and were measured for the non-induced and induced cultures (induction 
with 1 mM IPTG is indicated by the vertical broken line after 3.2 h). For the non-induced cultures (no 
product), tryptophan fluorescence is plotted versus scattered light intensity (symbols). (E) The appropriate fit 
shown as a continuous line (power function: fluorescence intensitycalc = 4780·[scattered light 
intensitymeas]
0.077-7715). The plot of the residuals between the calculated and the measured fluorescence is 
displayed within the diagram as an inset box. (F) Product fluorescence intensity calculated by subtracting the 
biomass fluorescence of the non-induced cultures from the total fluorescence of the induced cultures. Data 
and figure were provided by Esther Gartz. [246] 
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To demonstrate the general applicability of the W-tagging concept the on-line 
measurement experiments were repeated using the second single chain M12(scFv) 
antibody [238] unrelated to the Ki-4(scFv) (Figure 5-7). This second antibody had been 
fused to the five different W-tags as well and was expressed in E.coli likewise (3.1.9.3). 
Fluorescence behavior of this antibody and the W-tags were similar to that of the original 
Ki-4(scFv) model antibody (Figure 5-6) confirming the Wx-Ki-4(scFv) data and thus 
provided a proof-of-concept of the W-tag as a reporter tag. 
 
Figure 5-7 On-line detection of biomass formation and production of Wx-M12(scFv) fusion target 
proteins.  
On-line fermentation signals measured with a modified BioLector® device during cultivation of E.coli BL21 
Rosetta 2 (DE3) expressing the M12 single chain variable fragment in modified Wilms-Reuss medium with 
20 g/L glucose using a 96-well microtiter plate. The intensities of (A,B) the scattered light (ex:620 nm/em) 
and (C,D) tryptophan fluorescence (ex:280 nm/em:350 nm) were measured for the non-induced and induced 
cultures (induction with 1 mM IPTG: vertical dash-dotted line after 3.2 h of cultivation). For the non-induced 
cultures (no product), tryptophan fluorescence is plotted versus scattered light intensity (symbols). The 
appropriate fit is given as the continuous line (power function: fluorescence intensitycalc = -
4190·108·[scattered light intensitymeas]
1,35+6415); the plot of the residues between the calculated and the 
measured fluorescence is displayed within the diagram as inserted. (F) Product fluorescence intensity 
resulting from the total fluorescence of the induced cultures derived from product and biomass minus the 
fluorescence originated from biomass calculated from the fit (E) for the uninduced cultures [246]. Data and 
figure were provided by Esther Gartz. 
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The W-tagged Ki-4(scFv) and M12(scFv) target proteins without pelB leader peptide 
featured similar curves as in Figure 5-6 and Figure 5-7, except that the overall measured 
values for the tryptophan fluorescence intensity were weaker than the signal for clones 
with pelB leader (data not shown). 
5.4 Protein purification of Wx-Ki-4(scFv) proteins 
Different detergents were tested for bacterial lysis and the non-denaturing recovery of 
over-expressed W-tag target fusion proteins: (a) TES buffer lysis (3.3.5.2), (b) lysozyme 
(3.3.5.1), (c) NP-40 (3.3.5.3) and (d) sonication (3.3.5.4). Lysis results and yield of protein 
recovery were examined via SDS-PAGE and Western blotting, and the best recovery 
method was chosen for down-stream processing and protein preparation for further 
characterization of W-tagged proteins. 
5.4.1 Protein recovery by TES buffer lysis 
Non-denatured periplasmic protein was recovered by TES buffer lysis as instructed in 
(3.3.5.2) and Wx-Ki-4(scFv) proteins were used representatively. Figure 5-8A displays 
multiple bands of all bacterial proteins as well as the target protein in the TES lysate as a 
result of a successfully lysed cell pellet. Western blotting (Figure 5-8B) shows protein 
bands ranging from 25 – 35 kDa specifically staining the Wx-Ki-4(scFv) proteins. EC 
showed some bands of lower molecular weight from degraded proteins and the band for 
W5-Ki-4(scFv) was very weak. Apparently the W5-Ki-4(scFv) protein was not released 
from the bacterial pellet as well as the other proteins.  
 
Figure 5-8 SDS-PAGE and Western blot of Wx-Ki-4(scFv) fusion proteins after bacterial lysis with 
TES buffer.  
(A) shows the bacterial total lysate indicating a successful cell lysis by osmotic shock. In (B) the 
Wx-Ki-4(scFv) target proteins were detected via the His6-tag using an anti-His mouse IgG and an anti-mouse 
GAM-PO antibody followed by detection with DAB substrate. Distinctive protein bands between 25 and 
35 kDa were visible for all proteins, although the W5-Ki-4(scFv) band was only faint. 
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A disadvantage of the TES buffer method is the EDTA content of the lysis buffer. EDTA 
complexes Ni
2+
 and Co
2+
 ions, elutes them from the purification columns and therefore, the 
His6-tag intended protein purification would not be able to bind to the purification matrix. 
To render subsequent protein purification via IMAC (3.3.4.1) with Ni-NTA/Talon columns 
or further experiments feasible, the EDTA was removed from the bacterial crude lysate.  
The EDTA-containing TES buffer was exchanged with PBS via PD10-desalting columns 
(3.3.6, Figure 5-9). During this process, the sample volume was increased so that the target 
protein concentration was diluted. Proteins W4-Ki-(scFv) and W5-Ki-4(scFv) were not 
detected during immunoblot analysis after dialysis and it was assumed that elution from 
the PD10-desalting columns had been unsuccessful. EC and W1-Ki-4(scFv) were 
recovered at a high protein concentration (lane 2 and 3) but W2-Ki-4(scFv) and 
W3-Ki-4(scFv) showed weak protein concentrations in the PBS eluate. 
 
Figure 5-9 Documentation of protein dialysis with SDS-PAGE and Western blot analysis of EC, 
W1-Ki-4(scFv), W2-Ki-4(scFv) and W3-Ki-4(scFv) after TES lysis and buffer exchange to PBS.  
(A) Crude lysate with all bacterial proteins stained via coomassie. (B) shows the Western Blot analysis of 
EC, W1-Ki-4(scFv), W2-Ki 4(scFv) and W3-Ki-4(scFv) detected via the His6-tag. EC and W1-Ki-4(scFv) 
show a high amount of protein in the sample whereas W2-Ki-4(scFv) and W3-Ki-4(scFv) reach only a weak 
protein concentration in the PBS eluate. The W4-Ki-4(scFv) and W5-Ki-4(scFv) proteins got lost on the 
PD10-desalting columns. 
For further protein analysis the sample concentration of EC, W1-Ki-4(scFv), 
W2-Ki-4(scFv) and W3-Ki-4(scFv) was increased with Vivaspin 6 or Vivaspin 20 columns 
depending on the sample volume. Protein recovery by other lysis methods was not 
successful. 
5.4.2 IMAC protein purification 
Subsequently, the IMAC purification potential of the recovered native proteins was 
examined using the standard IMAC purification protocol (3.3.4.1) via His6-tag and Talon 
or Ni-NTA columns. For binding analysis or other applications of the target protein, it 
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would be ideal to use purified Wx-Ki-4(scFv) or Wx-M12(scFv) proteins with few 
contaminating substances as possible. Non-tagged expression control proteins Ki-4(scFv) 
and M12(scFv) were successfully purified with the IMAC method via Ni-NTA and talon 
columns. For the purification, W1 and W3 tagged constructs of Ki-4(scFv) and M12(scFv) 
were applied to the IMAC columns. Both W1 constructs resulted in successful protein 
purification with a decent amount of protein in the sample (data not shown), W3-tagged 
constructs could not be purified by IMAC. No protein was eluted from the talon or 
Ni-NTA columns, neither during elution nor during washing steps. The procedure was 
repeated at pH 7 and pH 8, with different imidazole concentrations (10, 20, 50, 75, 100, 
150, 200, 250 and 500 mM for elution but with without positive result. 
5.5 Measurement of protein binding activity 
Due to unsuccessful IMAC purification, the bacterial crude lysate after TES buffer lysis 
and dialyzed into PBS was applied for analysis of target protein binding activity. 
Biological functionality as well as the binding specificity of the W-tagged target proteins 
were examined. As shown in 5.4.1, only EC, W1-Ki-4(scFv), W2-Ki-4(scFv) and 
W3-Ki-4(scFv) could be used for binding analysis. The concentration of the W-tagged 
target proteins in the dialyzed samples was calculated to be between 3 and 40 µg/mL 
which was enough for the subsequent analysis experiments.  
5.5.1 Wx-M12(scFv) binding analysis on MCF7 and MDA-MB-231 
Flow cytometric binding analysis with the Wx-M12(scFv) fusion proteins was not 
successful since the M12(scFv) fragment antibody, even without W-tag, did not display 
binding on the MCF7 or MDA-MB-231 cells, neither during flow cytometry nor in a 
protein binding ELISA on MCF-7 membranes. Consequently, both cell lines were tested 
for the presence of the MucI surface protein which was detected to be positive on both cell 
lines with a commercially available anti-(human)MucI mouse IgG antibody (Abcam, 
Cambridge, dilution 1 : 150 in PBS) and goat-anti-mouse-FITC conjugated IgG antibody. 
A flow cytometric experiment verified MucI expression on the cell lines by a clear shift of 
75% of the cells (data not shown). 
It was concluded that the M12(scFv) fragment antibody simply does not bind to the MucI 
antigen unlike described by Wong et al., 2001 [238]. Binding analysis of M12(scFv) was 
not investigated further. 
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5.5.2 Protein ELISA of Wx-Ki-4(scFv) fusion proteins 
Binding activity of Wx-Ki-4(scFv) target fusion proteins was tested in a protein ELISA 
(3.3.9.3) on L540cy membrane fractions via ABTS detection at 405 nm. PBMC membrane 
fractions were used as negative control antigen. Wx-Ki-4(scFv) proteins were applied as 
TES lysates without further processing at a concentration of 3 µg/mL protein per well 
(Figure 5-10). The untagged EC showed sufficient binding on the L540cy membrane 
fractions. Binding of W1-Ki-4(scFv) was present on L540cy membranes significantly 
reduced by 25% compared to EC. Binding activity further decreased for the W2-Ki-
4(scFv) (by 40%) and W3-Ki-4(scFv) (by 50%) constructs, although binding for the 
W3-tagged version was slightly stronger. ABTS absorption signals were even more 
diminished for W4 and W5 tagged proteins, displayed absorption values equal to the 
PBMC negative control measurements. As a general observation, binding activity 
decreases with increasing number of tryptophan residues in the W-tag. 
 
Figure 5-10 Protein ELISA binding analysis of dialyzed TES crude lysate containing all five 
Wx-Ki-4(scFv) fusion proteins.  
Protein binding was detected via His6-tag, anti-His mouse IgG and GAM-PO antibodies and ABTS substrate. 
EC displays strong binding of untagged Ki-4(scFv) protein on L540cy membrane fractions. But amount of 
binding continuously decreases from W1-Ki-4(scFv) to W5-Ki-4(scFv) almost reaching ABTS absorption 
level of the PBMC negative controls, indicating no binding activity. Overall absorption values were weak 
(<0.3). 
5.5.3 Flow cytometric analysis of Wx-Ki-4(scFv) on L540cy 
Binding activity of Wx-Ki-4(scFv) target fusion proteins was analyzed by flow cytometry 
using the untagged Ki-4(scFv) antibody (EC) and the W-tag constructs with one, two and 
three tryptophan residues as dialyzed TES lysis crude extracts. W1-Ki-4(scFv), 
W2-Ki-4(scFv) and the W3-Ki-4(scFv) as well as the untagged EC antibody bound to 
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CD30-positive L540cy cells (Figure 5-11). The W-tagged fusion protein variants showed a 
slightly lower binding activity than EC indicated by a slightly lower fluorescent signal of 
the anti-His-AF488 conjugated detection antibody. 
 
Figure 5-11 Flow cytometric binding analysis of Wx-Ki-4(scFv) fusion proteins on L540cy cells.  
(A) EC (Ki-4(scFv)), (B) W1-Ki-4(scFv), (C) W2-Ki-4(scFv) and (D) W3-Ki-4(scFv). The black curve 
represents L540cy cells incubated with only the secondary antibody (background). The grey curve represents 
the different versions of the Wx-Ki-4(scFv) proteins. The signal shift to the right means increased 
fluorescence intensity in relation to the black curve as the antibody binds to the CD30 receptor. 
Moreover, the mean fluorescence intensity (MFI) was slightly lower for W-tagged fusion 
proteins when EC was assumed to be 100% binding activity (Table 5-3). This reconfirmed 
that binding between the fusion proteins and CD30 is slightly weaker than the 
corresponding interaction involving untagged Ki-4(scFv).  
Table 5-3 Mean fluorescence intensity (MFI) values and geometrical mean of the fusion proteins. 
The MFI of the W-tagged fusion proteins is only marginally reduced compared to the MFI of the Ki-4(scFv), 
which is arbitrarily set at 100%. The same tendency is illustrated with the geometrical mean values. The 
similar mean fluorescence of the W-tagged fusion proteins compared to EC indicates that the binding of the 
Ki-4(scFv) is reduced when a W-tag is present. 
(scFv) protein Mean Fluorescence Intensity % G-mean 
Ki-4(scFv) (EC) 7.13 100 
W1-Ki-4(scFv) 6.67 93.6 
W2-Ki-4(scFv) 6.73 94.4 
W3-Ki-4(scFv) 6.69 93.8 
For this experiment, HEK293T cells were used as negative control cell line. As expected 
neither the Ki-4(scFv) without W-tag nor the W-tagged fusion proteins displayed any 
binding on HEK293T cells. 
5.5.4 Competitive FACS 
In addition, a competitive flow cytometric analysis was performed to prove that even 
though the binding activity was effected, specificity of Ki-4(scFv) binding was not 
impaired by the presence of the W-tags (Figure 5-12). Increasing concentrations of the 
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hybridoma-derived bivalent Ki-4 full length antibody were incubated on L540cy cells 
parallel to the Wx-Ki-4(scFv) proteins thus replacing the monovalent single chain 
fragment variable by the full length antibody. It was shown that the fluorescence intensity, 
indicating specific binding of the Wx-Ki-4(scFv) fusion proteins, decreased with an 
increasing concentration of Ki-4 full length antibody. As a result the binding curves of 
Ki-4(scFv) shifted to the left displaying lower fluorescence intensity. Binding of the 
Ki-4(scFv) and W1-Ki-4(scFv) was stronger so that higher concentrations of the Ki-4 full 
length antibody were necessary to suppress single chain binding than the binding of the 
W2-Ki-4(scFv) and W3-Ki-4(scFv). It was concluded that the Wx-Ki-4(scFv) fusion 
proteins still possessed active and specific binding ability. Although, the binding 
specificity of the fusion proteins was not impaired, a higher number of tryptophan residues 
results had a negative influence on the binding affinity. This was shown by deletion of the 
Ki-4(scFv) binding signal with a lower concentration of full length antibody for W2 and 
W3. [246] 
 
Figure 5-12 Competitive flow cytometry of Ki-4(scFv), W1-Ki-4(scFv), W2-Ki-4(scFv), W3-Ki-4(scFv) 
against a monoclonal Ki-4 full length antibody.  
(A) Ki-4(scFv), (B) W1-Ki-4(scFv), (C) W2-Ki-4(scFv) and (D) W3-Ki-4(scFv). The black curve displays 
the measurement of the L540cy cells incubated with the secondary antibody α-His AlexaFluor 488 (Qiagen, 
Germany), the red curve presents the binding measurement of the Wx-Ki-4(scFv) protein detected via the 
α-His AlexaFluor 488 antibody without competitive addition of the monoclonal Ki-4 full length antibody. 
The green curve displays the fluorescence intensity of the Wx-Ki-4(scFv) proteins after adding and co-
incubation with 0.5 µg Ki-4 full length antibody. The blue curve presents the fluorescence intensity of the 
Wx-Ki-4(scFv) proteins after adding and co-incubation with 2 µg Ki-4 full length antibody and the purple 
curve after the addition of 5 µg Ki-4 full length antibody. [246] 
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5.6 2D fluorescence measurement of Wx-Ki-4(scFv) 
To ensure that the W-tagged target fusion proteins maintained their ability to fluoresce 
after TES buffer extraction and buffer exchange to PBS, extracts containing the 
W1-Ki-4(scFv), W2-Ki-4(scFv), W3-Ki-4(scFv) and EC constructs were analyzed by two-
dimensional (2D) fluorescence intensity scanning in a suitable MTP using a protein 
concentration of 3 µg/mL in 200 µL volume. Only dialyzed fusion proteins, containing one 
to three tryptophan residues plus the lysate of the EC, were analyzed since the protein 
concentration for the W4 and W5 constructs was too low. Tryptophan fluorescence was 
excited between 250-300 nm and the resulting emission was detected in a range from 
300-400 nm, using 2 nm steps for multiple measurement points. It was observed that the 
fluorescence intensity correlated with the number of tryptophan residues in the tag. 
Whereas no fluorescence was detected in empty wells (Figure 5-13A) or wells containing 
pure PBS (Figure 5-13B), the fluorescence intensity increased visibly from the EC (Figure 
5-13C) over W1-Ki-4(scFv), W2-Ki-4(scFv) and W3-Ki-4(scFv) (Figure 5-13D-F).All 
crude extracts generated maximum fluorescence values at comparable excitation/emission 
wavelengths of 290/338 nm. [246] 
 
Figure 5-13 Two-dimensional fluorescence intensity scan of concentrated Ki-4(scFv) tagged with 
different Wx-tags.  
Depicted are fluorescence measurements of (A) an empty well, (B) 100% PBS buffer, (C) EC Ki-4(scFv), 
(D) W1-Ki-4(scFv), I W2-Ki-4(scFv) and (F) W3-Ki-4(scFv). For each well, the concentration of the 
Ki-4(scFv) and Wx-Ki-4(scFv) fusion proteins amounts to 3 µg/mL, harvested after 10 h cultivation. The 2D 
scan shows that the increased fluorescence depends on the number of tryptophan residues in the tag. The 
empty well and PBS buffer do not generate significant signals. The cross in the diagram denotes the 
wavelength combination (280/350 nm excitation/emission) applied for the measurements [246]. 
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6 Discussion 
6.1 Isolation and characterization of pancreas-specific scFv antibodies 
Identification of novel recombinant monoclonal antibodies specifically binding 
tumor-associated antigens on metastasizing pancreatic cancer cells was a major aim of this 
thesis. New cancer targets are desperately needed to advance potential immunotherapeutic 
for targeted tumor elimination and removal of residual malignant cells to improve 
prognosis of patients. Additionally, reliable tools for early diagnosis and follow-up 
examinations are essential for a solid prognosis. Using phage display technology [145] a 
combination of different panning strategies was applied, for the in vitro isolation of 
specific human scFv antibodies against the metastasizing pancreatic carcinoma cell line 
L3.6pl [155, 156]. In the process, subtractive and positive selection [138] of the human 
naïve Tomlinson libraries I and J [135, 136, 142] was performed under selective pressure 
for internalizing scFv-phage particles [138, 139, 248] or supporting surface-displayed 
cancer targets only [134]. The ability for internalization is favorable for a direct drug-
delivery of therapeutic agents to ensure their translocation to an intracellular specific target 
of action. Isolation was followed by monoclonal phage ELISA screening on L3.6pl 
antigen. In addition to the already existing 14.1(scFv) antibody fragment isolated from an 
immunized murine phage display library (1.3.7), the successively eliminating 
characterization process of this thesis identified:  
(1) Nine novel and sequence-unique L3.6pl-specific scFv antibody fragments featured 
surface binding and thus are promising for potential use as diagnostics and 
therapeutics.  
(2) Four of these scFv antibody fragments displayed internalizing properties which 
renders them excellent candidates for in-cell delivery of therapeutic cytolytic fusion 
proteins. 
In the following chapters, results will be discussed with respect to the state-of-the-art as 
well as to certain discrepancies and difficulties which occurred during experiments and 
data analysis. 
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6.1.1 Enrichment of L3.6pl-specific binders 
Successful enrichment of antigen-specific phage particles mostly depends on three basic 
parameters:  
(a) The antigen source (purified protein, membrane fractions, viable cells),  
(b) the selection method (internalizing conditions, washing stringency, antigen dilution, 
phage valency) and  
(c) the scFv-phage library (naïve/immunized, diversity, insert-carrying phage). 
Each selection round, independent of panning strategy, was started with a scFv-phage 
concentration between 1 x 10
11
 pfu/mL and 5 x 10
12
 pfu/mL, but selection results varied 
widely. 
6.1.1.1 Influence of antigen presentation on enrichment 
Solid-phase panning on adherent L3.6pl cells [138, 248, 249] was adopted to select 
pancreas-specific scFv-phage particles with explicitly internalizing potential. Whole 
adherent cells present their antigens in a native form and thus allow the identification of 
antibodies against proteins with complex conformations, such as multiple 
membrane-spanning regions or protein interaction domains as well as glycosylation or 
post-translational modifications and non-proteinogene targets [250] in their natural active 
form [138, 251, 252]. To eliminate irrelevant or non-specific scFv-phage particles binding 
to the many abundant immunogenic cell-surface epitopes regardless of tumor specificity, a 
competitive selection approach on non-metastasizing FG cells was applied to remove 
unspecific scFv antibodies from the phage pool [138, 253] before positive selection the 
L3.6pl target cell line (1.3.4). Competition cells (FG) and selection cells (L3.6pl) were 
adherently grown in tissue culture flasks to maintain cell surface appearance during 
panning as original as possible [248]. Intact outer-membrane protein structure and intra-
cellular metabolic functions were supposed to favor internalization of scFv-phage particles 
during incubation at 37 °C under internalization pressure (3.4.5.1). Conditions for 
internalizing selection protocol were chosen to favor metabolically active uptake of 
surface-bound scFv-phage molecules into viable cells through translocation mechanisms of 
surface receptors [254]. Yet, using FG cells as competitive cell line proved problematic 
since no positive scFv binders without non-sense mutation emerged from this panning 
strategy. FG and L3.6pl cells feature a great similarity since the metastasizing L3.6pl cell 
line was directly derived, from the progenitor cell line FG, after several passages of 
pancreas-liver transplantations in nude mice [155, 156]. Originally exactly this similarity 
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should be exploited to isolate unique and extremely specific scFv binders against 
metastasizing and advanced forms of pancreatic cancer by application of a very stringent 
selection protocol. But even though a rigorous depletion of non-homogeneously presented 
universal background antigens is obligatory, the expression pattern on both cell lines was 
apparently related too closely for distinguished isolation of specific scFv binders. 
Consequently, potential tumor-specific binders were removed from the panning system 
during subtractive selection and were hence lost for the positive selection process.  
During panning on L3.6pl cells in suspension, unspecific binders were excluded from the 
system by introducing peripheral blood mononuclear cells (PBMCs) for negative selection. 
Although PBMCs are of non-epithelial origin [138] and do not represent healthy pancreas 
tissue, they typify a highly essential cell type in the human body. Unspecific 
cross-reactivity of a monoclonal antibody of clinical relevance to PBMCs has to be 
avoided on any account. But owing to lower competitive pressure during subtraction on 
PBMCs, isolated clones may feature less affinity. Nevertheless, this selection method 
resulted in one L3.6pl-positive binder that exhibited strong binding and internalization 
potential. 
One possibly problematic aspect of suspension panning, using originally adherent L3.6pl 
cells is the treatment with the enzyme-containing solution Accutase
®
 for cell detachment 
and singularisation before panning [255]. Even though Accutase
®
 is gentler than 
trypsin-EDTA and enhances cell viability, it still digests the protein anchorage of adherent 
cells thus altering their surface structure. Destruction of complex surface conformations 
during the singularisation process may result in isolation of scFv antibody fragments that 
are unable to bind antigens with intact outer protein structure. To circumvent this 
problematic aspect of cell manipulation by Accutase
®
 treatment in the course of this thesis, 
cryo sections of primary pancreatic tumor tissue were introduced for phage display 
selection of antigens expressed in situ [256]. However, no enrichment of pancreas-specific 
scFv-phage particles was documented (data not shown) and the method was not 
investigated further. 
Alternatively, selection antigen can be presented in form of membrane fractions (3.4.5.3), 
which almost behave like isolated and purified protein [134]. Those membrane vesicles 
were immobilized on artificial surfaces, such as Maxisorb plastic tubes or MTPs by means 
of hydrophobic interactions. Even though this protein presentation is uncomplicated and 
reliable during panning, hydrophobic immobilization may lead to exposure of 
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non-physiological epitopes on those synthetic surfaces. Especially membrane proteins only 
exist in their optimal conformation within the lipid membrane. This may result in the 
isolation of scFv antibodies unable to recognize the native protein in its natural 
surrounding [257, 258]. Moreover, the imbalanced surface-to-length ratio of the membrane 
fractions holds another problem since it may favor the formation of inside-out particles to 
compensate surface tension. Literature states that vesicles exposing the apoplastic surface 
right-side-out are formed initially, but repeated thawing and freezing cycles promote 
formation of vesicles turning out their cytoplasmic side [134]. Selection of unspecific scFv 
fragments binding to cell-internal proteins may be the consequence. During monoclonal 
phage ELISA and protein ELISA analysis inverted membrane vesicles resulted in seven 
false-positive clones, whose target proteins only existed inside the cells but was presented 
on the surface of wrong-side out membrane particles. Consequently, there was no 
guarantee that living cells during flow cytometry analysis were recognized by those 
binders. A drawback of membrane-based panning is that the selection pressure is 
automatically on surface-binding scFvs antibodies. Nevertheless, three clones also 
displaying internalizing properties were isolated by that panning strategy.  
6.1.1.2 Influence of washing stringency and buffers on enrichment 
Moreover, variety and quantity of washing steps are important criteria for a successful 
selection process. Even though basic phage display principles are universal, it is difficult to 
transfer protocols to any selection antigen. Ideal panning conditions have to be determined 
empirically before starting a selection to ensure that cells are still intact after washing and 
elution [259]. Application of intensive washing steps with detergent-complemented buffers 
(e.g. 0.05% Tween20) might impair antigen immobilization during selection rounds. 
Adherently grown L3.6pl cells turned out to be very sensitive towards buffers, pH value 
(pH 2.2 of elution buffer) as well as shearing stress or the combination of all three 
parameters. Continuously changing incubation, washing and elution buffers during the 
panning, as well as constant motion of the liquid in the shaken vessels, had a negative 
effect on cell adhesiveness and membrane stability. By the second washing step, cell 
clusters detached from the plastic surface and burst cells were lost by partial lysis. As a 
result, proteases were set free from inside the cells which again had an adverse proteolytic 
effect on the structure of the cell surface proteins and the scFv-phage proteins itself. 
Hence, binding of scFv-phage particles to tumor-associated cell surface protein might have 
been impaired by damaged protein structures on both sides resulting in a negative panning 
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outcome and repetition of panning round to obtain a sufficient output titer. Tests with 
different buffers such as PBS, PBST, RPMI medium or NaCl (4.1.2) confirmed the 
sensitive nature of the L3.6pl selection cell line. Although the non-ionic detergent 
Tween20 destabilizes lipids and destroys membrane proteins at high concentrations [260], 
it resulted in the least sensitive reaction of L3.6pl cells. FG and PBMC subtraction cells 
were not affected since the depletion time was limited to one hour. Fixation of L3.6pl cells 
with 4% PFA resulted in PFA-binding scFv antibody fragments and did not solve the 
problem. Implementing acetone or 100% ice-cold ethanol for cell fixation was not 
sufficient to oppose shearing stress and cells still detached during washing steps. While 
permanent fixation of sensitive living cells on plastic was challenging, no antigen 
detachment was observed with membrane fractions due to the highly affine immobilization 
on the MTP plastic surface. However, varying fixation of membrane fractions was 
observed depending on pH of coating buffers and cell line. Experiments demonstrated that 
PBMC membranes reached better immobilization with PBS (pH 7.4) whereas L3.6pl and 
FG membranes displayed optimal adsorption to the MTP surface using standard ELISA 
coating buffer (pH 9.6). 
Nevertheless, the number of washing steps defines selective stringency. Isolation of clones 
with high specificity usually fails if washing steps are not stringent enough and results in 
enrichment of unspecific clones [261]. Respectively, washing intensity and related optimal 
enrichment strongly depends on the cell line and practical realization.  
Normally, ideal washing conditions are determined according to quantity of excess 
scFv-phage particles detectable in washing waste. But destruction of cells and release of 
internalized scFv-phage particles into the surrounding medium before panning was 
completed rendered this impossible. Consequently, selection stringency was adapted to cell 
sensitivity even though optimal selectivity was not achieved.  
6.1.1.3 Internalizing selection conditions 
Besides specific antigen recognition, development of therapeutic antibodies requires a 
direct or indirect effector function (1.2) [68-70]. Direct effects are induced only by 
antibody binding performance which can alter signal transduction pathways via cross-
linking or disruption of receptor-ligand interactions, thus suppressing or stimulating cell 
proliferation [262]. An effector molecule fusion to a proapoptotic protein can enhance the 
therapeutic effect of the indirect antibody binding function. Therefore, it is essential that 
the recombinant antibody is transported to the target-site of pharmaceutical action located 
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inside of a malignant cell [83, 263]. This increases effective therapeutic concentration at 
the target-site and reduces systemic side-effects. 
In this work, a direct method for selection of internalizing scFv antibodies was employed 
[138, 139] where intact L3.6pl cells were incubated at 37°C to induce internalization 
instead of a 4°C incubation step for surface-binding scFv antibodies. Originally, elution 
buffer (pH 2.2) was utilized to recover surface-bound scFv-phage before collecting 
internalized scFv-phage particles via cell lysis at pH 12. Even though the acidic pH was 
supposed to remove only surface-bound scFv-phage molecules, it also caused partial lysis 
of the sensitive L3.6pl cells. Hence, it was impossible to distinguish between eluted and 
internalized phage and difficulties occurred during output titer determination of lysis 
fractions after previous elution. To improve output titer results, the elution step was 
skipped during suspension panning to ensure that L3.6pl cells were not affected by the 
acidic milieu of the elution buffer and that the whole pool of binding and internalized 
scFv-phage particles was rescued after final cell lysis (pH 12) without loss.  
6.1.1.4 Enrichment analysis by titer determination 
A selection progress during panning rounds is commonly determined by analyzing the 
input and output titers before and after each selection round, as well as calculation of the 
resulting enrichment factor. However, this parameter is only suitable to a limited extent to 
inform about enrichment of specific scFv clones. Phage titer was determined using the 
plaque method which has some significant limitations, such as a limited dynamic range, 
dependence on environmental conditions on media resulting in decreased infectivity, 
viability of host cells, visual counting errors, and multiple pipetting and dilution steps as 
errors source [264]. Other methods for titer determination have been investigated in 
literature but even though it is quite time-consuming, the plaque assay is still most easily to 
realize without expensive equipment. Frequently, a considerable decrease of phage output 
titer is observed after the first panning round due to removal of unspecific scFv-phage 
particles. An increase in phage output titer is monitored after the second panning round 
caused by amplification of specific binders and continuing elimination of unspecific ones 
[265]. Results of this work could not confirm these findings for titer development during 
panning. No enrichment was observed by titer development for any of the selection 
strategies. By dividing input and output titer results of the same selection round, the 
enrichment factor was calculated (EF = output [pfu/mL] / input [pfu/mL]). Enrichment 
factors of two selection rounds were divided to obtain the actual enrichment of 
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L3.6pl-specific scFv-phage particles (AE =  EFx / EFx-1). These factors allowed a better 
interpretation of enrichment by means of titration. 
As expected, during panning on adherent L3.6pl cells, lysis and elution output titers after 
the first selection round were much less than the input titer, output titers after all selection 
rounds decreased further, documenting potential loss of binding phage (4.2.1). These 
calculations are consistent with the observations of cell sensitivity during panning and may 
explain the negative screening result. Aside from the plaque method as error source, these 
results suggest that due to their high sensitivity selection on adherent L3.6pl cells is not the 
most suitable method to isolate scFv fragments from the Tomlinson phage library. 
Panning on L3.6pl cells in suspension was performed without the elution step before lysis. 
The calculated output titer after the first selection round decreased according to literature. 
Output titers of selection rounds two and three increased slightly, indicating a gain of 
binding scFv-phage particles (4.2.2). Additional panning rounds did not improve the 
amount of rescued phage particles (data not shown). It was concluded that suspension 
panning followed by cell lysis without preceding elution step was the better choice for 
panning on whole L3.6pl cells with internalization pressure. 
Comparing input and output titers as well as enrichment after selection on membrane 
fractions displayed unexpected results. Both libraries exhibited only a slight increase of 
L3.6pl-binding scFv fragments throughout the three selection rounds (4.2.3). The attempt 
to increase stringency by applying a fourth selection round with even more stringent 
washing conditions resulted in “over-panning” without any determinable output titer. 
When merely considering the enrichment results, selection on membrane fractions seems 
to be a non-feasible panning strategy. Nevertheless, 16 L3.6pl-binding clones resulted from 
this selection strategy. 
6.1.1.5 Enrichment analysis by polyclonal phage ELISA 
Titer and enrichment calculations (4.2, 0) might not be necessarily significant. Even a 
small number of isolated binders could represent a set of scFv fragments with strong 
affinity and high specificity but still project a low output titer. To further evaluate 
successful and successive enrichment of specific scFv antibodies during selection rounds, a 
polyclonal phage ELISA (4.2) was performed, on L3.6pl selection membranes using 
PBMC or FG membranes as negative control. Thus, specifically L3.6pl-binding scFv-
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phage particles were quantitatively analyzed from precipitated phage pools after each 
panning round by measuring ABTS absorption signals at 405 nm.  
For the non-metastatic FG cell line generally less binding signal was observed than for 
L3.6pl during panning on adherent cells. Even though the cell lines are directly related this 
was expected since FG cells were used for negative selection. Binding signals of the 
unselected library J were quite strong pointing towards a large number of potential binders. 
Selection round one displayed a significant increase of binders of 150%. Compared to the 
first selection round, quantity of binding phage decreased by 25% after the second round 
and over 50% after the third round, which may be attributed to cell loss by lysis caused by 
buffers and shear stress. Nevertheless, the negative selection outcome might partially be 
due to morphological chances of the target cell line after too many passages. Moreover, it 
is problematic that ELISA experiments were always carried out on membrane fractions 
instead of whole cells as employed during panning. Presence of inside-out vesicles also 
might have tampered with the results when isolated scFv antibodies were unable to bind 
[134]. 
Regarding the observed enrichment of L3.6pl-binding scFv-phage units after suspension 
panning, the polyclonal phage ELISA displayed a contradicting result. Again absorption 
values of library I were very high and a 15% increase of binding scFv-phage particles was 
observed after the first selection round. In contrast to enrichment calculations, the amount 
of binders decreased by 10% during the second selection round and by another 10% during 
the third. One explanation for this contradiction may be the use of membrane fractions 
instead of whole cells [134]. In addition the Accutase
®
 treatment might have had an 
altering effect on the surface antigen conformation of suspended cells. PBMC absorption 
values did not change during selection rounds but were about 25% lower than L3.6pl 
absorption measurements. Consequently, either general overall absorption values obtained 
of library I were very low or may reflect a poor quality of the new batch of L3.6pl 
membrane fractions used during this experiment. 
During panning on membrane fractions, titer and enrichment calculations stated a slight 
increase of L3.6pl-binding scFv-phage units for both libraries. However, data analysis of 
binding documentation by polyclonal phage ELISA was able to display growing numbers 
of L3.6pl-binding scFv-phage particles with continuing selection. Repeatedly, absorption 
values of both unselected libraries were very high. After the first selection round, a 57% 
decrease of binders was reported for the library I and 90% decrease for the library J. After 
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panning round two, quantitative binding increased by 88% for library I and by 800% for 
library J. L3.6pl-positive binders increased another 20% for library I whereas the third 
selection round showed no significant increase of binders for the J library. For the library J 
no significant binding was observed on PBMC membranes. Very unexpected, binding 
value even slightly higher than the respective one for L3.6pl was measured on PBMC 
membranes after the first selection round. That implies that during this selection round 
scFv fragments binding against a universal epitope were selected. Still, the ELISA 
absorption values for PBMCs decreased after the second selection round indicating 
successful depletion of these ubiquitous surface proteins. 
Tendency of polyclonal absorption values after selections of both libraries on L3.6pl 
membranes (4.2.3) varied from values measured after selection on whole cells (4.2.2, 
4.2.3). Observed overall absorption values are much stronger than after selection on whole 
cells. This discrepancy may be caused by morphological alterations of cells processed for a 
different batch of membrane preparations of L3.6pl cells and coated for membrane panning 
as well as all subsequent polyclonal and monoclonal phage ELISA experiments. 
6.1.1.6 Influence of phage valency 
The semi-synthetic Tomlinson phage library was employed to generate recombinant scFv 
antibodies targeting pancreatic cancer cells. To avoid the presence of empty phage 
particles, which occur during production of monovalent phage [129], the polyvalent 
M13KO7ΔpIII hyperphage was utilized during the first panning round and only substituted 
by the monovalent M13KO7 helperphage during following selection rounds [266, 267]. 
The polyvalent phage particle presents scFv molecules on all five pIII coat proteins and is 
supposed to improve selection efficiency [130] due to its increased avidity as a result of the 
multiplied valence-related affinity of the five binding sites. To isolate high-affinity scFv 
binders, the monovalent M13KO7 helperphage was applied during the second and third 
panning round. This monovalent structure displays strong intrinsic affinity and accuracy of 
fit towards a single surface epitope, whereas the multivalent phage particles may still 
feature strong binding activity attributable to inaccurate fit at multiple sites. By comparing 
of the bacterial infection rate of multivalent and monovalent phage particles via input titer 
calculation, no negative influence was observed. By combining these two phage valences, 
the first selection was supposed to retain as many L3.6pl-specific binders as possible after 
cross-reactivity elimination on PBMC antigen. Selections with the monovalent phage on 
the other hand had the aim to hold only the highly affine binders. 
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ELISA experiments performed with polyvalent phage particles always displayed much 
higher absorption signal (up to twice as high) than when performed with monovalent ones, 
even though the trend of binding activity was identical. This effect is due to the higher 
avidity of the multivalent phage format [254].  
6.1.2 The Tomlinson Phage Library 
6.1.2.1 Single clone analysis via monoclonal phage ELISA 
After panning and enrichment analysis, single clones were picked and screened in a 
monoclonal phage ELISA for binding activity on L3.6pl membrane fractions. Clones with 
absorption signal at least 2.5-fold stronger than the background were defined positive. In 
summary, 1656 single clones were tested of which 12.6% were identified as 
L3.6pl-positive binders. Thus the overall percentage of positive scFv antibody fragments 
was much lower than the 50% documented in literature [267, 268]. 
Whole adherent cells: Of 288 picked single clones only 13 were identified as 
ELISA-positive binders after solid-phase panning on whole adherent cells. On the one 
hand, the low number of positive binders was attributed to the close relation the of FG as 
competition cell line to L3.6pl, and on the other hand, to the selection strategy itself being 
not compatible with the sensitive L3.6pl selection cell line regarding washing, blocking 
and elution steps as well as shear stress. 
Whole cells in suspension: Merely three positive binders evolved from 216 picked clones. 
Although subtractive FG cells had been replaced by PBMCs, cell damage during washing 
was still assumed to be too severe to create optimal selective conditions even though 
scFv-phage enrichment was documented. 
Membrane fractions: Starting with 576 clones from both libraries, best selection results 
were observed during panning on membrane fractions with an outcome of 193 
ELISA-positive clones. A variation of ABTS absorption intensities was measured resulting 
in seven weak binders (absorption twice the background), six medium binders (absorption 
2 – 5 x background) and seven strong binders (absorption 5 – 10 x background).  
The large number of 1447 L3.6pl-negative clones (87.4%) during screening is conspicuous 
and suggests an ineffective and insufficiently stringent selection. As discussed in 0, reasons 
therefore might be the L3.6pl cell line as antigen source or non-compatible selection 
strategies concerning this special antigen source. Laboratory intern observations indicate 
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that such a low selection rate is very untypical. When compared to other selection 
processes with the Tomlinson Library generally only 20% of the picked clones were 
identified as negative during screening by monoclonal phage ELISA after application of 
the same panning protocols. 
6.1.2.2 Sequence analysis of single clones 
After screening via monoclonal phage ELISA, the scFv insert was investigated by colony 
PCR (3.1.1.2) and DNA sequence analysis (3.1.4). Subsequent to PCR analysis, 137 clones 
were found without intact scFv insert but false-positive ELISA signals. DNA sequencing 
identified 72 clones carrying a scFv insert, but only 20 clones containing an insert without 
a frame shift. 
Table 4-10 shows, the localization of hypervariable CDRs in VH and VL numbered after 
Kabat [100]. For all clones, conserved framework regions (FWR) were identical [146] but 
alignment revealed varying amino acid sequences in CDRs. During artificial library 
synthesis diversification were limited to positions H50, H52, H52a, H53, H55, H56, H58, 
H95, H96, H97, H98 of the heavy chain, and to positions L50, L53, L91, L92, L93, L94, 
L96 of the light chain [146]. 
Moreover, the amount of 137 false-positive clones not carrying a scFv-insert (65% of 209 
positive clones) was high [133] considering that only 4% of library I and 12% of library J 
are initially insert-free [135]. Apparently, insert-free phagemid vectors have a selective 
advantage [133]. On reason may be the contamination of the Tomlinson library with 
scFv-free vectors [133] or incomplete restriction, as well as phagemid self-ligation during 
library cloning [133]. In addition, low efficiency of helperphage-dependent packing of 
phage particles during phage rescue may lead to generation of phage particles without 
incorporation of scFv-pIII fusion proteins. Since the majority of phage proteins just 
expresses native pIII protein phage enrichment by non-specific binding activity to any 
antigen is favored. Besides that, a reduced vector size diminishes enrichment of specific 
phage. All these reasons result in a growth advantage of insert-free phage that cannot 
always be compensated by choice of selection strategy [133]. Selection of clones without 
ORF could be avoided when exclusively using the hyperphage with pIII deletion for 
selection [269]. Limited library size caused by a growth advantage of insert-free or 
defective clones results in their enrichment and may lead to an unsuccessful selection and 
failed enrichment during panning for all selection strategies. 
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Summarized, only 20 of 1656 analyzed clones displayed an intact DNA sequence for the 
scFv insert. Sequence analysis revealed that 8 clones contained an amber stop codon 
(TAG) within CDR 2 of VH. TAG triplets were formed during synthetic triplet generation 
in CDRs of library J according to the NNK distribution (1.3.3) [147]. Library I has been 
produced using DVT triplet distribution (1.3.3), and thus random TAG triplet formation 
should not occur during library synthesis. Nevertheless, stop triplets were detected in 
isolated clones. This phenomenon has not been described in literature before but was 
observed during all selections performed with Tomlinson library I by the AG Barth. 
Literature states, that only 3% of the scFv antibody fragments in the original Tomlinson 
phage library carry an amber stop codon. But after screening, 90% of the isolated clones 
were found with TAG triplet. Still, high percentage of amber stop codon containing clones 
after selection from the Tomlinson libraries has been shown by several other groups before 
[153, 154, 270-272]. The amber-suppressor strain TG1F+ E.coli used for phage 
propagation was suspected to be the source of this phenomenon [154]. During panning this 
strain translates the amber stop codon as CAG, encoding for glutamine, instead of TAG. 
Clones that bind to a target antigen and contain amber stop codons have a considerable 
growth advantage in TG1F+ E.coli [153, 269]. Propagation for stock amplification and 
distribution before panning, results in evolutionary changed scFv-phage pools and 
subsequent selections were started with more clones carrying stop codons than the original 
library. Consequently, each growth cycle additionally created even more clones with stop 
codons. But this was not investigated further. 
Aside from that, six clones were detected with ochre stop codons (TGA) in the conserved 
framework region FWR2 of VH in isolated clones from both libraries. For their 
characterization, TGA triplets were therefore mutated back to TGG, encoding for 
tryptophan, according to the actual framework sequence documented for the Tomlinson 
library. It is proposed that these framework mutations could be caused by spontaneous 
mutation [273]. They occur always at the same position in the FWR2. Apart from 
spontaneous mutations, this also suggests a systemic problem which might have already 
existed in the initially purchased Tomlinson library.  
Another explanation for the presence of TAG, as well as TGA stop codons, is the 
occurrence of mutations during PCR amplification reactions. DNA of positive clones was 
not sequenced from the phagemid vector directly but amplified first by colony PCR whose 
product was sequenced. When using goTaq polymerase without a proof-reading function 
for PCR reactions, the enzyme creates an error about every 9000 bases. In 30 reaction 
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cycles this statistically adds up to an incorrect base every 300 bases. Thus, the application 
of a non-proof-reading polymerase enzyme during PCR amplifications may also account 
for integration of TAG and TGA stop codons. Besides, inaccurate PCR amplification 
products might be an explanation for the 52 ELISA-positive scFv binders found with frame 
shift in CDR2. Resulting characteristics of single clone analysis and DNA sequencing are 
summarized in Figure 6-1. 
 
Figure 6-1 Illustrated distribution of L3.6pl-positive clones with regard to panning strategy and 
characteristics of scFv insert.  
Colony PCR revealed 137 false-positive clones (65.6%) without scFv insert. Of the 72 clones carrying a scFv 
insert, 52 clones contained a frame shift in CDR2 whereas DNA sequencing verified 20 clones (marked in 
red) with an intact scFv sequence which could be applied for further analysis. 
Moreover, clone diversity of isolated L3.6pl-positive scFv antibodies was analyzed by 
DNA sequencing. A total number 16 unique L3.6pl-specific binders was identified from 20 
positive clones of all three selection strategies. The sequence of clone E3 was found four 
times and clone D12 twice. Normally, much stronger enrichment of sequence-identical 
clones is expected during selection on complex heterogeneous epitopes as literature states 
for other cell systems [274].  
1656 single clones
209 (100%) 
L3.6pl-positive
Positive clones vs. panning strategy Distribution of insert properties
137 (65.6%) 
no insert
72 (34.4%)
insert
13 (6.2%)
adherent
3 (1.4%)
suspension
193 (92.4%)
membrane fractions
20 (9.6%) 
intact
52 (24.9%)
frame shift
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6.1.3 Protein Expression 
After analyzing of binding activity on phage-level and DNA sequencing to identify unique 
binders, L3.6pl-positive scFv clones were expressed as soluble proteins in order to evaluate 
binding independent of phage proteins in further characterization experiments. According 
to the Tomlinson protocol [135], it is possible to express library-derived scFv antibodies 
after transformation of the pIT2 phagemid into the non-suppressor strain HB2151 E.coli 
after removal of CDR-internal stop codons. This HB2151 non-suppressor strain reads the 
TAG stop codon down-stream of the genetic information for the scFv antibody and 
terminates translation before pIII expression. Consequently, soluble scFv proteins are 
produced without the pIII fusion protein and are then transported into the periplasmic 
space via the pelB leader peptide and are ideally secreted into the surrounding medium. 
The oxidizing milieu of the periplasm favors correct protein folding (chaperones) and 
formation of disulfide bonds [172]. In contrast to the Tomlinson protocol, experiments, 
using the HB2151 for soluble protein expression and subsequent ELISA binding analysis, 
showed very inconsistent results. Clones tested positive during monoclonal phage ELISA 
analysis did not display reproducible binding as soluble protein.  
SDS-PAGE and Western blot analysis showed that soluble scFv proteins were secreted 
only partially. Osmotic lysis of bacteria (TES buffer) to free enriched scFv proteins present 
in the periplasmic space did not yield better results. Generally, protein production in 
HB2151 bacteria was observed to be very low and inconsistent. 
Expression of clones was strongly dependent on time point of IPTG-induction of the lacZ 
gene which controls the lac promoter. Moreover, shaking radius and velocity during 
cultivation were not ideal since the surface tension, as a result of a small culture volume, 
prevents sufficient oxygenation capacity [223]. This means that not all clones were 
induced properly and were therefore unable to express enough protein for repeatable and 
comparable binding results. 
To solve this problem, the scFv were subcloned into the pET-derived pMT vector for 
prokaryotic protein expression in the BL21 Rosetta 2 (DE3) E.coli strain [171]. This 
expression system is under the control of the IPTG-inducible T7 promoter. Additionally, 
these bacteria carry the pRARE plasmid which enables them to translate DNA triplets of 
human origin. Nevertheless, an improvement in terms of reproducibility of protein 
expression and subsequent binding data was not achieved. 
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Therefore, and because prokaryotes are generally not able to form glycosylation or other 
post-translational modifications, soluble scFv proteins were expressed in a mammalian 
expression system [172]. Eukaryotic glycosylation also improves correct folding and 
conformation essential for production of functional proteins and also leads to better 
solubility [172]. For eukaryotic expression, the scFv genes were subcloned into the 
bicistronic pMS-SNAPMut vector [183] which was transfected into HEK293T cells and 
cultivated under Zeocin selection pressure (3.2.3). Successful transfection was monitored 
directly under the fluorescence microscope through co-translated eGFP down-stream of the 
IRES sequence. Production of scFv-SNAP fusion protein and its secretion into the tissue 
culture supernatant (TCSN) was evaluated via SDS-PAGE, where the prominent FBS band 
did not allow protein detection, and Western blotting. Therefore, protein concentration in 
the unpurified TCSN could not be quantified via AIDA-analysis (3.3.3.1) before 
scFv-SNAP proteins had been purified by means of IMAC (3.3.4). Thus, binding activity 
in relation to protein concentration could only be determined with pure protein. 
Nevertheless, presence of FBS in the unpurified TCSN favored scFv-SNAP protein 
stability in the HEK293T supernatant during long-term storage. 
Moreover, flow cytometric binding analysis with unpurified TCSN containing scFv-SNAP 
displayed even better binding results than the purified scFv-SNAP proteins.  
6.1.4 Soluble protein ELISA analysis 
Clones identified as positive by means of monoclonal phage ELISA and sequencing, were 
produced as soluble proteins in HEK293T cells via the eukaryotic pMS expression system 
[183]. Specific binding was analyzed by indirect ELISA against functional membrane 
fractions of the target cell line [134]. 
Here, only eleven of the 16 clones, showing reproducible binding activity during 
monoclonal phage ELISA analysis, were identified as positive binders after soluble protein 
expression. Five clones did not display positive binding activity when tested in a soluble 
protein ELISA. This loss in functionality may be attributed to the separation of the scFv 
fragment from the pIII phage coat protein during subcloning into the pMS-SNAPMut 
vector [183]. It is possible that the phage protein had a stabilizing effect on the scFv which 
is now missing on the C-terminal end so that the VL chain, normally adjoining the constant 
region, is now exposed to non-physiological buffers. Another reason might be the 
expression in HEK293T cells which rendered post-translational modifications and 
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glycosylation possible which did not exist during phage display selection in TG1F+ 
bacteria before [172]. Such post-translational changes of surface patterns may result in 
different binding behavior. 
6.1.5 Flow cytometric binding and cross-reactivity observations 
It is crucial for therapeutic applications that isolated scFv antibodies recognize the target 
antigen in its natural conformation (1.3.2). Most scFv antibody fragments were isolated on 
membrane fractions which display still functional proteins in a slightly changed 
conformation [134]. Another disadvantage of selection on membrane fractions is the 
possibility that isolated scFv candidates may bind to cytolytic epitopes on inside-out 
vesicles [134]. To ensure epitope recognition of native protein conformations, flow 
cytometric binding analysis was performed on viable L3.6pl cells. Nine out of eleven 
clones were tested positive on intact L3.6pl cells, only clones E5(scFv)-SNAP and 
F11(scFv)-SNAP did not bind to living L3.6pl cells. Loss of binding was attributed to the 
artificial antigen presentation of membrane fractions lacking the original complex protein 
conformation of intact cells (glycosylation, post-translational modifications) [138]. 
Moreover, isolation of scFv-phage binders to inside-out membrane particles had resulted in 
false-positive binding activity during previous monoclonal phage ELISA and soluble 
protein ELISA analysis [134]. 
A normalized amount of 2 µg total protein per sample demonstrated various degrees of 
binding strength on viable L3.6pl cells (4.6.2), caused by recognition of different surface 
epitopes with varying expression density. A high percentage of right-shifted cells in the 
histogram implied a high receptor density. Pointed curves indicated homogenous antigen 
expression whereas abroad and flat curves implied highly variable antigen expression 
within the measured cell population [275]. Gating around living cells ensured evaluation of 
binding activity on viable cells only, apart from dead ones or cell debris. 
Even though binding reactions are highly specific, it is possible that recognized epitopes 
are also present on tumor cells of different origin. This cross-reactivity may lead to the 
identification of a ubiquitously expressed tumor-associated antigen (TAA) as potential new 
cancer target. Selected clones displayed cross-reactive binding on various cell lines to 
different degrees, since tumor-assiciated antigens vary in differentiation and activation in 
different organ-derived tissue. Very interesting was the binding activity on the pancreatic 
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carcinoma cell line PancTuI/PancTuI-luc [189] since clones featuring strong 
L3.6pl-binding were only weak binders on PancTuI/PancTuI-luc and vice versa (4.6.2.1). 
6.1.6 Hypothesis on clones D5(scFv) and D9(scFv) 
When comparing all DNA sequences of the unique scFv clones, a general sequence 
similarity of 93% was found. In the course of this, clones D5(scFv) and D9(scFv) attracted 
special attention since their sequence only differed by one amino acid in CDR2 of VH due 
to one changed base pair in the DNA sequence. D5(scFv) contains aspartic acid (D) at the 
same position where asparagine (N) is found in D9(scFv). These amino acids are similar in 
atomic structure and properties (Figure 6-1). 
Table 6-1  Comparing illustration of structure and characteristics of aspartic acid and asparagine. 
 D5(scFv) D9(scFv) 
Amino acid Aspartic acid (D) Asparagine (N) 
Molecular structure 
 
 
MW = 133.10 g/mol 
 
 
MW = 132.12 g/mol 
Molecular formula C4H7NO4 C4H8N2O3 
Properties 
Acidic Polar but uncharged side chains 
Negatively charged via proton dissociation Electronegative groups 
Hydrophilic Hydrophilic 
Aspartic acid is formed via hydrolysis of the highly polar side chains of asparagine 
exchanging the amide group at to a carboxyl group. Hydrolysis generally occurs when a 
weak acid, such as an amino acid, is dissolved in an aqueous milieu. H2O is constantly 
subjected to spontaneous ionization into hydroxyl and hydrogen ions thus promoting 
hydrolysis of polar substances. This fact does support the theory that D5(scFv) and 
D9(scFv) not only share high similarity but might even be transformed into identical 
molecules when exposed to an appropriate environment [276]. 
Highly similar or even equal amino acid sequences are likely to share the same protein 
fold. This can be analyzed by homology modeling based on the assumption that unknown 
proteins of similar molecular structure are also predicted with a similar protein fold, as it 
may be the case for the CDR2 regions of D5(scFv) and D9(scFv) [277]. Proteins featuring 
identical 3D structures are expected to recognize similar or even the same antigen target 
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structures. Binding behaviors of both clones during monoclonal phage ELISA as well as 
the protein ELISA and flow cytometric experiments were almost identical. 
As already described in 4.6.2, clones D5(scFv) and D9(scFv) feature a strong right-shifted 
cell group comprising only 2.5% and 2% of the cell population, respectively (Figure 4-15), 
which could indicate existence of a certain cell subpopulation within the highly 
metastasizing L3.6pl cell line . 
Very specific characteristics of pancreatic cancer are its high potential to metastasize and 
its resistance against standard chemotherapy and radiotherapy. Recent findings indicate 
cancer stem cells (CSC) may assume a function in the aggressive development and 
progression of tumors [278-282]. This stem cell hypothesis has been explored in pancreatic 
cancer [283] and literature describes the specific identification of CSC within digested 
human pancreatic tumor tissue decisively featuring the expression of CD133 [284]. 
Moreover, a reproducible number of CD133+ cells (1 – 2%) were identified within the 
human pancreatic cancer cell line L3.6pl which possesses highly metastatic properties and 
succeeds in inducing tumor formation after orthotopic implantation with only 10
3
 cells 
[284]. The in vitro resistance of the CD133+ cells is mediated by the Chk1/Chk2 pathway, 
and CD133+ cells were observed to preferentially activate the DNA damage apparatus. 
Through up-regulation of DNA damage checkpoint response activation, CD133+ cells 
were able to more efficiently repair radiation-induced DNA damage than CD133- cells 
[285]. It is also described in literature that treatment with the first-line agent gemcitabine 
leads to enrichment of the CD133+ subpopulation in the L3.6pl cells cell line [284].  
The hypothesis is proposed that clones D5(scFv) and D9(scFv) may recognize that 
CD133+ cancer stem cell subpopulation within L3.6pl (7.1). Both could be an excellent 
target for further investigations to remove residual and aggressively metastasizing cells 
following surgical tumor removal or to identify tumor antigens associated with tumor 
migration and proliferation. 
6.1.7 Internalization behavior 
Internalizing properties are a critical factor for the development of novel potentially 
therapeutic immunotoxins, as their effectiveness depends on the drugs’ delivery and uptake 
into the cell metabolism [83]. 
Internalization was clearly verified for the murine clone 14.1(scFv), originated from a 
self-made immunized phage library (1.3.7) and for clones A3(scFv)-SNAP, 
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D4(scFv)-SNAP and F1(scFv)-SNAP isolated from the Tomlinson phage library by means 
flow cytometry (4.6.3.1), immunofluorescence staining and confocal-based internalization 
assays (4.6.3.2). Those three internalization-positive clones, originating from the 
Tomlinson library, represent only 2.1% of the 193 ELISA-positive clones (4.3). Literature 
states that phage particles with multiple scFv copies undergo receptor-mediated 
endocytosis more efficiently than monovalent ones since they are able to cross-link 
receptors [254]. Nevertheless, this effect was not confirmed for panning processes under 
internalization pressure within this work since only clone D4(scFv)-SNAP is the result on 
internalizing selections. Clones 14.1(scFv)-SNAP, A3(scFv)-SNAP and F1(scFv)-SNAP 
on the other hand display internalization potential despite isolation on membrane fractions. 
Different patterns of surface binding and internalization were observed for the murine 
14.1(scFv)-SNAP and the human clones A3(scFv)-SNAP, D4(scFv)-SNAP and 
F1(scFv)-SNAP. All Tomlinson-derived clones featured a spotted binding pattern on 
L3.6pl cells whereas the 14.1(scFv)-SNAP protein bound to the cell surface continuously 
(4.6.3.2). These variations of binding pattern may be caused by varying expression 
regulation of surface antigens or unequal distribution of receptor density. Recognition of 
different surface epitopes may result in different internalization mechanisms and up-take 
rates during translocation into the cytosol. 
Observed intracellular internalization pattern was the same for all four clones. Small 
vesicles were transported from the cell membrane towards a location in the cell center 
(4.6.3.2). Internalization periods varied between 1 – 2 h for clone 14.1(scFv), ranging over 
clone A3(scFv) with 3 – 4 h, to clones D4(scFv) and F1(scFv) with an internalization time 
of 6 – 12 h. This suggests at least three different target proteins presenting different surface 
receptors, different internalization mechanisms or a combination of both. Generally, 
internalization of fusion proteins is mediated by endocytosis [286]. Receptor-mediated 
internalization occurs in most cases by clathrin-mediated endocytosis but many other 
proteins are internalized by clathrin-independent cholesterol-dependent endocytic 
pathways with involvement of caveolin (cholesterol, glycolipids) [83, 287]. Such lipid rafts 
may in consequence account for the vesicle-like spotted biding to the cell surface. The 
three main ways of endocytosis are: (a) Phagocytosis, (b) clathrin-dependent 
receptor/ligand-mediated endocytosis (also extracellular fluids), and (c) 
clathrin-independent endocytosis [286-288]. 
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During internalization, scFv antibodies undergo endocytosis by entering endosomal 
compartments which provide an environment for sorting entering molecules. Endosomes 
regulate targeting of different destinations before lysosomal degradation, avoid degradation 
through translocation to the Golgi apparatus via retrograde trafficking pathways or 
relocation to the plasma membrane [287-289]. Following endocytosis, endosomal 
compartments are created which often fuse with lysosomes where enzymes degrade the 
present proteins. Thus, phage particles are either already lost during phage display 
selection or potential therapeutic scFv antibodies becomes useless. Besides retrograde 
transport ways, clathrin-independent endocytosis is sometimes able to bypass  the 
endosome-to-lysosome pathway by offering pathogens an alternative route to avoid 
lysosomal enzymes [287]. 
Phage molecules eventually lost through lysosomal degradation during panning can be 
rescued by rolling circle amplification which recovers the phagemid DNA instead of the 
complete phage particles [290]. Thereby recovered scFv antibodies can still be used for 
diagnostic applications but not for clinical treatment since the lysosomal transport way 
might end in degradation of the therapeutic agent. Nevertheless, the conducted 
internalization experiments did not hint at lysosomal uptake since no diffuse fluorescent 
background signal was measured in L3.6pl cells during confocal microscopy. 
6.2 Design of optically active W-tags 
Screening of numerous large-scale cultures in parallel during production of recombinant 
proteins is a huge challenge when cell growth and target protein quantification have to be 
assessed simultaneously without disturbing the actual cultivation process. Micro-scale 
fermentation in MTPs [224, 228] is a very convenient technique to evaluate efficient 
production of enzymes or other pharmaceutically relevant target proteins. Product 
quantification is usually achieved by sampling and off-line analysis, e. g. by measuring 
enzymatic activity [231] or performing an enzyme-linked immunosorbent assay (ELISA). 
Still, non-invasive on-line detection systems are preferable over sampling with subsequent 
separate sample analysis. Using representative parameters such as optical density (OD600), 
oxygen transfer rate (OTR) or culture fluorescence [223, 245] for monitoring, clones with 
optimal performance can be identified. Here, product quantification can be achieved in 
real-time by measuring intrinsic protein fluorescence or by expressing the target protein 
tagged with a fluorescent marker [231], e. g. a conventional fluorescent protein such as 
GFP [191] or a FMN-based fluorescent proteins [196, 200]. The second aim of this thesis 
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has been the design, development and characterization of a novel short and optically active 
reporter tag for on-line measurement purposes. Results of tag design, expression, 
purification and its use for the on-line monitoring of product formation in micro-scale 
bacterial cultures, as an alternative to GFP or FMN-based fluorescent proteins, are 
discussed below. [246] 
6.2.1 W-tag design 
A major drawback of GFP and its derivatives is the molecular large size, which may 
increase metabolic stress, inhibit protein folding or interfere with protein secretion into the 
supernatant. Moreover its ability to fluoresce is fully dependent on an aerobic environment 
since an anaerobic surrounding leads to a delay between expression and fluorescence 
development and thus its detection [191, 194, 196, 291]. In contrast to GFP, FMN-binding 
proteins are approximately half the size of GFP and do not depend on oxygen, but they 
may still cause metabolic stress and interfere with the folding of small target proteins. On 
the other hand, the short-chained W-tags developed in this thesis, are very small with 
comparatively 5-11% of the molecular weight referring to GFP. Tryptophan is known for 
its ability to auto-fluoresce and it does not need oxygen to mature like GFP. Therefore, it 
was presumed that the W-tags have full functionality even under oxygen-limited 
conditions. This renders them suitable for the multiplex parallel on-line analysis of 
bacterial cultures producing fusion proteins without any of the disadvantages caused by 
larger tags. Unfortunately, tryptophan is also counted to the hydrophobic amino acids. First 
approaches to design a tryptophan tag as imitation of the His6-tag, with several tryptophan 
residues simply in series, were not pursued any further since the accumulation of highly 
hydrophobic properties was assumed to be problematic during expression and purification. 
Therefore, the tryptophan residues were embedded in the originally occurring natural 
structure of a protein loop derived from a cold shock protein (BcCsp) of Bacillus 
caldolyticus [236]. The natural structure was meant to compensate for the hydrophobic 
quality of tryptophan through neighboring residues (Figure 5-1). 
With the assistance of Dr. Heinrich Delbrück (Fraunhofer IME, Aachen), energetically 
ideal W-tags were developed in silico using modeling software tools (CHARMM 
(www.charmm.org) in Discovery Studio (www.accelrys.com)). Corresponding DNA 
sequences were optimized by triplet configuration for expression in E.coli and then fused 
genetically in-frame with the coding sequence for the Ki-4(scFv) [237] or M12(scFv) 
[238], respectively. The tightly regulated IPTG-inducible expression vector pMT [171], 
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based on the pET expression system [292], was used as plasmid backbone to be able to 
compare non-induced cultures lacking the recombinant protein production to cultures 
expressing different W-tagged forms of the same recombinant antibody (Figure 5-2). [246] 
6.2.2 W-tag protein expression and purification 
6.2.2.1 Over-expression of W-tagged fusion proteins 
SDS-PAGE and Western blot analysis of W-tagged scFv target fusion proteins after 
fermentation showed a generally strong over-expression of Wx-Ki-4(scFv) and 
Wx-M12(scFv) proteins in 96-well micro-scale cultures as well as in larger culturing 
volumes. Very peculiar are the protein bands in Figure 5-4 since their molecular weights 
do not correspond to the calculated values. The molecular mass of the W-tagged proteins 
containing two to five tryptophan residues, show a continuously decreasing trend in size on 
the immunoblot even though molecular weight should increase with higher residue number 
(Table 5-1). The migration of proteins during SDS-PAGE analysis strongly depends on the 
negative charge attached to the protein as well as its length. Electrophoresis running buffer 
is supplemented with the ionic detergent SDS which binds to the hydrophobic protein 
regions. SDS places a negative charge on proteins with a constant charge-to-mass ratio, 
and in addition disrupts secondary and tertiary structures. Since tryptophan contains the 
hydrophobic indole ring system as side chain, it was assumed that proteins with more 
tryptophan residues and consequently increased hydrophobicity are surrounded by a higher 
negative charge, and simply move faster despite their higher molecular mass. But this 
phenomenon could also be explained by incomplete denaturation of some W-tagged 
proteins resulting in limited mobility at this certain polyacrylamide content. Addition of 
more reducing agents, such as ȕ-mercaptoethanol or DTT, into the protein loading buffer 
could solve this problem [293]. 
Expression evaluation of the W-tags revealed that fusion proteins were not secreted into 
the medium which essentially complicated protein retrieval and quantification. Lacking 
secretion was probably caused by the hydrophobicity of the tryptophan residues and their 
placement on the outer shell of the protein loop. High amounts of protein were detected in 
the bacterial pellet for periplasmic as well as cytoplasmic expression of W-tagged proteins 
(5.2.1). The double bands during immunoblot analysis (Figure 5-3) occurred due to the 
incomplete cleavage of the pelB leader when the fusion protein was transported from the 
cytoplasm to the periplasmic space. The identity of each protein band has been confirmed 
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by mass spectrometry (data not shown). The oxidizing environment of the periplasmic 
space promotes the correct disulfide bond formation and folding [172] of recoverable 
proteins in a soluble state. 
Nevertheless, excessively produced proteins, especially when expressed in the cytoplasm, 
may be present as insoluble precipitate, called inclusion bodies (IBs). These protein 
aggregates, consisting mostly of incorrect or only partially folded proteins, can reach a 
diameter of 0.2 – 1.5 µm, so that a single IB may fill out a single cell. IBs feature a porous 
but defined conformation and can accumulate up to 50% of the total amount of cell protein 
[178, 294, 295]. The proportion of biologically active protein within a cell can vary widely 
depending on the production organism and the target protein. To rescue inactive protein 
from IBs, often requires labor-intensive and expensive protein back-folding during 
down-stream processing. Even though the formation of IBs is very likely to occur in the 
neutral and aqueous milieu of the cytoplasm during expression, this possibility was not 
investigated further [178, 294, 295]. 
Considering observations of protein formation over time (Figure 5-5), it was found that the 
target protein concentration in MTP cultures peaked between 9 and 10 h of fermentation 
but decreased afterwards. A possible explanation is that the W-tagged proteins are 
degraded by the temperature used for fermentation (37 °C), or that the bacteria simply kept 
growing and produced more biomass but no target protein. Since the target protein content 
was calculated referring to the total bacterial protein concentration, this would account for 
the diminished quantity. [246] 
6.2.2.2 W-tag fusion protein recovery and purification 
Extraction of soluble Wx-Ki-4(scFv) and Wx-M12(scFv) protein with EDTA-containing 
TES buffer resulted in the partial release of proteins, tagged with W1, W2 and W3, from 
the cell pellet. W-tagged fusion proteins with four and five tryptophan residues (W4, W5) 
could not be detached from the bacterial pellet and were consequently analyzed by neither 
flow cytometry nor 2D-fluorescence intensity scanning. It was assumed, that the protein 
recovery rate decreased with increasing number of tryptophan residues in the W-tags due 
to increased adherence to the cell membranes as a result of enhanced hydrophobicity. Since 
the negative hydrophobic effects of tryptophan become stronger with the accumulation of 
residues, it can be said that protein yield is strongly dependent on the number of tryptophan 
in the W-tag. Application of stronger lysis buffers with different detergents might improve 
the recovery of soluble target fusion protein in the future [221]. 
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Purification of the tagged recombinant proteins by immobilized metal ion chromatography 
(IMAC) was unsuccessful. This was attributed to the close proximity of the W-tag to the 
His6-tag under the assumption that the affinity tag was obscured by the larger 
tryptophan-rich tag. Another possibility is the incomplete removal of EDTA from the TES 
lysis buffer via dialysis. EDTA can form complexes with Co
2+
 ions and elute them from 
the IMAC resin, thus preventing the capture of His6-tagged proteins. Moreover, steric 
hindrance might prevent protein recovery by IMAC which leads to potential solutions that 
include switching the order of the His6-tag and W-tag, separating them with an intervening 
linker, or appending them to different termini. If the presence of EDTA is preventing 
sufficient recovery, then a potential solution would be to replace the His6-tag, for example 
with a FLAG epitope [186]. This would also prevent EDTA disrupting down-stream 
purification strategies involving the use of Ni-NTA or talon columns. 
Difficulties during IMAC purification could also be caused by the formation of dimeric 
complexes between the accumulated tryptophan residues and the positively-charged Co
2+
 
and Ni
2+
 metal ions [296]. Such interactions of the negative end of the indole ring system 
with double-charged metal cations play a role in some ion channels (e.g. gramicidin-A 
channel [297]). Both metal ions applied via IMAC columns form so-called open-shell 
monomeric or dimeric complexes with tryptophan, but Ni
2+
 complexes are by far more 
stable [296]. Even though the IMAC purification system exploits binding of 
histidine-based affinity tags to the Ni
2+
 or Co
2+
 purification matrix, the strong binding and 
very stable complexes might be a problem during elution. Since none of the target protein 
was detected in the flowthrough, it was assumed that the W-tagged target proteins 
containing two to five tryptophan residues potentially complexed with the metal ion matrix 
to such a degree that rendered a successful protein recovery impossible. 
This purification problem could eventually be solved by aqueous two-phase extraction as 
described by Nilson et al. [221, 298, 299], where the hydrophobicity of accumulated 
tryptophan residues is utilized to specifically concentrate those tryptophan-enriched target 
proteins within an organic solvent by extraction. [246] 
6.2.3 Online measurement of fluorescence intensity 
During non-invasive on-line measurements of micro-scale fermentations in 96-well MTPs 
(3.1.9.3, 5.3.1), the induced cultures showed a strong over-expression of the 
Wx-Ki-4(scFv) fusion proteins. Target fusion proteins equipped with the different tags 
could be distinguished according to the intensity of the fluorescence signal in comparison 
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to the untagged protein. Statistically, every cell contains proteins that include tryptophan 
residues, resulting in a mixed fluorescence signal which is produced by all induced cultures 
expressing W-tagged recombinant target proteins. This signal is composed of the 
fluorescence intensity of both, the product fusion protein and the biomass. Therefore, 
induced and non-induced cultures had to be cultivated in parallel to determine the biomass 
signal, which was then subtracted from the total fluorescence to calculate the signal for the 
W-tagged recombinant target protein alone (Figure 5-6E). Normally, this would double the 
number of assays required for one experiment as well as the number of wells occupied in 
MTPs. However, since the correlation between fluorescence intensity and scattered light 
intensity for the non-induced cultures was the same for all fusion protein variants, it should 
be sufficient to cultivate just one of the variants as a non-induced control to determine 
biomass fluorescence. Moreover, fluorescence intensity of each fusion protein was 
substantially greater than that of the corresponding untagged target protein (Figure 5-6F), 
even when that protein contained multiple tryptophan residues [300-302]. 
This calculated product fluorescence intensity increased with the number of tryptophan 
residues from EC over W1 to W3. Even though W4 and W5 comprise a higher number of 
tryptophan residues they featured slightly weaker fluorescence intensity than W3. 
Supposedly, the enhanced hydrophobicity of the accumulated tryptophan residues resulted 
in a preferential interaction of the fusion proteins with the cell membranes, which may 
have caused partial quenching of fluorescence intensity. However, instead of 
hydrophobicity, the formation of exciplexes presents another probable explanation for the 
quenched fluorescence signals. Exciplexes are photo-induced electron transfer reactions, 
which occur during bimolecular encounter of an excited molecule and a quencher [303, 
304]. The dense packing of tryptophan residues in W4 and W5, as well as the increasing 
target product concentration towards the end of the fermentation, may support exciplex 
formation. Quenching, and thus a decrease in fluorescence signal intensity may be a 
consequence of that effect. Nevertheless, when comparing protein expression by means of 
immunoblotting and fluorescence intensity development via on-line monitoring, it could be 
confirmed that an increase in fluorescence intensity was equivalent to protein product 
formation. 
Slightly increased scattered light and tryptophan fluorescence signals were monitored 
during MTP fermentation, but no bacterial growth was detected. Even though the MTPs 
were sealed with a gas permeable membrane, some small degree of evaporation was 
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present. Consequently, the medium components became more concentrated and the 
signals, especially the scattered light signal, increased.  
From 10 h onwards, the scattered light signals increased for the EC and NC cultures and, 
after a short stationary period, in the other cultures as well (Figure 5-6A). This occurrence 
may reflect morphological changes of the bacteria [305]. 
The W-tagged Ki-4(scFv) and M12(scFv) target proteins produced without pelB leader 
peptide, featured similar curves as cultures with pelB leader in Figure 5-6 and Figure 5-7, 
except that the overall measured values for the tryptophan fluorescence intensity were 
weaker than the signal for clones with pelB leader (data not shown). This is a logic result 
since, without pelB leader, the proteins are transported into the cytoplasm inside the 
bacterial cells and not to the periplasmic space which is located between the outer and 
inner cell membrane. 
Identical results for the on-line analysis in MTPs were obtained with a second but 
unrelated M12(scFv) antibody fragment [238], demonstrating that the W-tagging concept 
is generally applicable. But bearing in mind that the W-tags described in this thesis are 
prototypes only, it is also possible that their general performance could be improved by 
additional structural modifications. [246] 
6.2.4 2D-scans 
Dialyzed crude cell lysates of EC and Ki-4(scFv) tagged with W1 to W3 were analyzed by 
two-dimensional scanning (5.6) to prove whether W-tagged target proteins outside the cell 
display similar fluorescence behavior than within bacterial cultures. It is known, that 
excitation and emission properties of tryptophan are strongly influenced by other 
compounds in the solution [302]. During on-line monitoring, tryptophan fluorescence was 
excited at 280 nm and fluorescence emission was recorded at 350 nm. Unfortunately, these 
wavelengths could not be adopted for the tryptophan fluorescence 2D scans of dialyzed 
crude extracts (Figure 5-13). Instead, maxima were observed at 292 nm (excitation) and 
338 nm (emission). This discrepancy was attributed to the different ionic strength 
(polarity) and buffer composition, resulting from the surrounding solution during the 
cultivation (Wilms-Reuss medium, (2.3)) and the off-line measurement of the 2D-analysis 
(PBS, (2.7)). Nevertheless, these differences in the excitation and emission wavelengths do 
not principally affect the values of the data, but it is necessary to determine optimal 
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measurement wavelengths on a case-by-case basis for individual fusion proteins, media 
compositions, pH values and other parameters. 
6.2.5 Flow cytometric binding analysis 
Binding activity of the Ki-4(scFv) target fusion proteins was tested for the untagged EC as 
well as for the W-tagged versions comprising one, two and three tryptophan residues using 
dialyzed TES lysis extracts (5.5.3). The binding activity of Ki-4 (scFv) [237] was not 
affected by the presence of the W-tags. All different W-tagged versions of the Ki-4(scFv) 
antibody fragment were able to bind the L540cy cell line that over-expresses the 
corresponding CD30 receptor. The slight decrease of fluorescence signal (especially for 
W3-Ki-4(scFv)), illustrated by the MFI and geometrical mean (%G-mean), may result 
from the binding of the secondary antibody to the His6-tag of the fusion proteins (Figure 
5-11). It is possible that the His6-tag is partially obscured by the W-tag, or that the W-tag 
folding itself causes this change (Table 5-3). It may also be that the W-tag negatively 
influences binding activity with increasing number of tryptophan residues in the tag as 
already shown in Figure 5-11. 
Binding of the W-tagged M12(scFv) antibody fragment could not be tested due to 
non-existent binding activity on the mamma-derived carcinoma cell lines MCF-7 and 
MDA-MB-231, despite proven presence of the MucI receptor on the cell surface. 
Competitive flow cytometry revealed that, notwithstanding adverse effects binding 
activity, the binding specificity against CD30 was not influenced by the W-tags (5.5.4) but 
that the binding affinity of W2-Ki-4(scFv) and W3-Ki-4(scFv) was lower when incubated 
against a Ki-4 full length antibody. 
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7 Outlook 
7.1 Pancreas-specific scFv antibody fragments 
Evaluation of the generated L3.6pl-positive antibody fragments (4.6.2) for application in 
diagnostic pathology could provide data on early tumor diagnosis. The detailed functional 
binding activity of the scFv-SNAP antibodies could be tested on primary human tumor 
material, using cryo-preserved and paraffin-embedded tissue blocks alike. 
Immunohistochemistry staining on as many different patient tissues as possible would lead 
to valuable conclusions on their clinical relevance. Co-staining with known tumor markers, 
such as CA19-9 (gold standard), CA 124 or CEA [19, 50, 306] could verify or exclude 
binding to tumorous tissues and possibly classify new ubiquitous tumor antigens. 
Additional prospective experiments may focus on the antigen identification of the 
tumor-associated epitopes bound by the pancreas-specific scFv antibodies. Since the 
isolated ligands were selected on undefined antigen binding sources, this could pave the 
way for the categorization of novel diagnostic cancer targets and insights into the structure 
of cancerous surface proteins used as potential immunotherapeutic targets. Therefore, 
conventional cell lysis followed by immunoprecipitation and Western blot analysis [233] 
with subsequent mass spectrometry is exploited before analysis of the antigen molecules 
using the MASCOT protein data base (Matrix Science, London, UK). Another method is 
the generation of a cDNA library originated of the mRNA from L3.6pl cells [307]. 
Antigens expressed from cDNA-carrying vectors are screened for binding activity by 
means of ELISA and analyzed via comparison in protein data banks after PCR 
amplification. Mammalian-based libraries have the advantage of antigen presentation in a 
natural surrounding including post-translational modification whereas prokaryotic 
expression libraries are more diverse but do not always fold proteins to their native 
conformation. 
Ligands with the biological function for internalization are promising candidates for 
immunotoxin fusions, prospectively used during targeted therapeutic approaches. Their 
small size is ideal for delivery to a target location within the cytosol resulting in a high 
value for adjuvant therapy and the focused elimination of residual cancerous cells. In vitro 
examinations of immunotoxin fusions of the scFv antibodies to the truncated version of 
Pseudomonas aeruginosa Exotoxin A‘ (ETA‘) [157, 159, 171, 175] for binding activity 
and cytotoxicity on L3.6pl and PancTuI-luc cell lines (XTT assay) will indicate whether or 
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not one of the ligands at hand are therapeutically relevant. Compared to other toxins, ETA’ 
is very efficient so that the internalization of one to ten molecules into the cytosol is 
theoretically enough to destroy the cell [85, 87]. As a drawback, ETA’ is not a human 
toxin and will provoke an immune response during repeated application. Systemic 
application of ETA’ fusion proteins may lead to several dosage-dependent side effects [88, 
308], caused by the high immunogenicity. Human enzymes with cytotoxic effector 
domains, such as the human RNaseA (angiogenine) [89], the serine protease GranzymeB 
[91, 92] or DAPKinase [90] can be used instead. 
Succeeding in vitro analysis, recombinant immunotoxins will be characterized in vivo. This 
includes an analysis of the in vivo toxicity by establishing the maximum tolerable dosis 
[309, 310] as well as investigations of the effect of the novel recombinant immunotoxins 
on subcutaneous tumor growth during treatment in comparison to Gemcitabine. A pre-
clinical orthotopic mouse model (SCID or NOD-SCID strains) based on the PancTuI cell 
line marked with click-beetle red luciferase (PancTuI-luc) [189] can be used for 
investigations on targeted tumor imaging.  
Therapeutic recombinant antibody-SNAP fusions not only hold the potential for in vivo 
optical imaging techniques after fluorescence-labeling [158, 211] but can also be applied 
as theranostics when for example coupled to Fe-particles. Here, the SNAP-tag technology 
could be applied to generate scFv fusion antibodies, labeled with supermagnetic iron oxide 
nanoparticles. This would create a non-invasive in vivo detection system, combining tumor 
localization as well as treatment and post-operative monitoring. For diagnosis, the 
molecules can be detected by MRI [311] without radiolabeling [312], and then an 
alternating magnetic field (AMF) can be used to induce mild heating [313], raising the 
temperature of the targeted cancer cells above 42.5°C and thus destroying the cells through 
a combination of protein denaturation and aggregation, cytoskeletal disruption, inhibition 
of DNA, RNA and protein synthesis, lipid peroxidation and inhibition of repair. 
7.2 Characterization of optically active W-tag 
Optically active reporter tags are essential tools for the on-line monitoring of product 
formation during fermentation of recombinant target proteins. The W-tags, newly 
developed during this work, show great promise. Due to their high fluorescence intensity 
compared to untagged recombinant proteins, future research may focus on optimizing the 
presented W-tags to improve secretion or ways to release the W-tagged proteins from the 
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bacterial pellet. Empirical switching of number and order of the tryptophan residues might 
result in optimized fluorescence intensity during on-line measurement and increase protein 
recovery yield. Apart from free energy calculations (CHARMM (www.charmm.org) in 
Discovery Studio (www.accelrys.com)), it is very difficult to predict fluorescence and 
expression behavior of newly designed W-tags and their protein fusions by means of 
software analysis and additional empirical data collection is unavoidable. 
Protein extraction via aqueous two-phase extraction techniques [221, 298] could solve the 
problematic of low to non-existent protein yield during purification via the IMAC method. 
The highly hydrophobic character of the W-tags posed a huge disadvantage throughout the 
experiments of this thesis. Here, the capability of the aromatic ring system to interact with 
a long-chained organic solvent might actually be advantageous to the extraction process 
which could result in highly concentrated W-tagged recombinant proteins in the 
hydrophobic phase. Afterwards, enterokinase digest could cleave the tag-region from the 
recombinant protein and finally functionalize the target protein for potential therapeutic 
approaches, such as immunotoxin treatment during targeted cancer therapy. 
Adaptation of the W-tags to a eukaryotic expression system offers the benefit of 
incorporated glycosylation and other posttranslational modifications within proteins of 
mammalian origin. Appropriate enzyme restriction sites (XbaI) to insert the W-tag into the 
pMS-SNAPMut expression vector [183] have already been included into the cloning 
constructs ordered from GENEART. Subsequent transfection and expression in HEK293T 
cells would reveal information about the applicability of the novel W-tags in eukaryotes. 
Small size and repeated insertion of tryptophan residues within short distance, makes the 
W-tags potentially suitable for the application as affinity tag. Phage display selection 
against the purified W-tag protein [314, 315] could generate a highly specific antibody for 
use during immunodetection. 
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8 Summary 
Pancreatic cancer is a most aggressive type of neoplasia characterized by its high potential 
for metastasis with a most devastating prognosis. Initial stages are almost asymptomatic, 
thus preventing early detection before local tissue invasion due to the lack of reliable 
diagnostics. Surgical removal in combination with standard first-line chemotherapeutic 
Gemcitabine treatment and radiation-based therapy are merely life-prolonging options. 
High resistance towards conventional therapeutics and the huge metastasizing potential 
leaves minimal residual micrometastasis accountable for an enormously high relapse rate. 
Despite its low incidence (3%), pancreatic cancer is the 4
th
 leading cause of death caused 
by malignant diseases. Therefore, the first aim of this thesis was to develop novel 
tumor-specific human single chain antibody fragments (scFv) for possible future 
application as cytolytic therapeutics for adjuvant treatment of metastasizing pancreatic 
cancer, as well as more efficient molecular tools for early diagnosis. Antibody-based 
approaches using highly specific scFv fragments present a promising alternative to 
conventionally applied therapies. Phage display technology was employed to generate 
pancreas-specific scFv-phage antibodies from the naïve human Tomlinson phage libraries I 
and J binding against unknown tumor-associated antigen. Highly specific scFv-phage 
ligands were isolated in a two-step panning strategy via depletion on human peripheral 
blood mononuclear cells (PBMC), followed by a positive selection on the metastatic 
pancreatic cancer cell line L3.6pl. Monoclonal phage ELISA identified 16 unique 
L3.6pl-positive scFv binders, subsequently expressed in eukaryotic HEK293T cells as 
soluble scFv proteins fused to the SNAP-tag (scFv-SNAP). Additionally, clone 
14.1(scFv)-SNAP, originally isolated from a laboratory-own murine immunized phage 
display library, was included into the expression and characterization process. Analysis of 
binding specificity of IMAC-purified scFv-SNAP proteins by soluble protein ELISA and 
flow cytometry identified nine clones recognizing L3.6pl cells with differing 
cross-reactivity to various pancreas-derived cell lines. Of these, four clones displayed 
internalizing properties during flow cytometric and OPERA-based internalization tests. All 
positive candidates are clinically relevant pancreatic carcinoma specific scFvs and may 
provide the prospect of a tumor-targeted cancer therapy to eliminate residual cancer cells. 
Moreover, they are highly promising candidates for diagnostic in vivo imaging tools 
besides an additional application as theranostics. 
To produce recombinant pharmaceutically relevant proteins on large scale, highly efficient 
screening technologies have been developed to characterize optimum cultivation 
Summary 
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conditions for bacterial growth and production formation. Microtiter plates (MTPs), in 
combination with measurement systems such as the BioLector
®
, are a practical tool for 
non-invasive on-line monitoring of product formation of continuously shaken microbial 
cultures on lab-scale. Conventional reporter proteins for on-line monitoring, such as GFP 
and its derivatives or flavin mononucleotide (FMN)-based fluorescent proteins, are very 
large (26.9 kDa and 15.7 kDa, respectively) which possibly imposes stress on the host 
organism. Additionally, GFP strongly depends on an oxygen-saturated environment for 
fluorophore formation. To circumvent mentioned drawbacks of conventional reporter tags, 
short but still optically active reporter tag for on-line detection were designed in this thesis. 
These novel reporter tags (W-tags) are based on the auto-fluorescence of the aromatic 
amino acid tryptophan (W). Using in silico techniques, between one and five tryptophan 
residues (W1 - W5) were accumulated in the naturally occuring protein loop of the cold 
shock protein (Bc Csp), originated from Bacillus caldolyticus, to have equilibrated charges 
with the tryptophan residues presented on the outer side of the loop. Genetic fusions of 
these five different W-tags (MW = 3.4 to 5.6 kDa) to the anti-CD30 Ki-4(scFv) as well as 
the anti-MucI M12(scFv) antibody fragment were produced in the pET-derived prokaryotic 
pMT expression system. Analysis of on-line product fluorescence intensity during 
fermentation in MTPs followed by molecular biological flow cytometric binding analysis 
showed that more tryptophan residues within a W-tag generated a stronger tryptophan 
fluorescence signal gaining intensity corresponding to product formation. Nevertheless, an 
increase in tryptophan residues also complicated concentration of W-tagged proteins in the 
cell lysate. Protein recovery was only possible for W-tagged constructs containing one to 
three tryptophan residues. W4 and W5 remained in the cell pellet due to highly 
hydrophobic properties of the accumulated tryptophan molecules. Normal and comparative 
flow cytometry of W-tagged Ki-4(scFv) proteins on L540cy cells, in combination with a 
Ki-4 full length antibody, confirmed that binding specificity was not influenced whereas 
W-tags with more than one tryptophan residue seemed to have a negative effect on binding 
activity and affinity. Lacking the main drawbacks of conventional reporter proteins, the 
novel W-tags are a generally applicable alternative during non-invasive monitoring of 
recombinant product formation. They present the possibility for rapid and qualitative 
on-line measurement during large-scale production of pharmaceutically relevant target 
proteins. 
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10 Appendix 
10.1 QuikChange Mutagenesis primers 
Table 10-1 Individual primer sequences for site-directed QuikChange Mutagenesis 
Clone Forward primer  5'--> 3' Reverse primer  5'-->3' 
A3 
GGGTCTCACAGATTAATCCTAATG 
GTCAGCCGACAAAGTACGC 
GCGTACTTTGTCGGCTGACCATTAGG 
ATTAATCTGTGAGACCC 
C5 
GGTTCTAGTACATCTCAGGCAG 
ACTCCGTGAAGGGCCGG 
CCGGCCCTTCACGGAGTCTGCCTG 
AGATGTACTAGAACC 
D1 
GGGAAGGGGCTGGAGTGGGTC 
TCAAGTATTTCTAATTATGG 
CCATAATTAGAAATACTTGAGAC 
CCACTCCAGCCCCTTCCC 
D4 No stop codon! 
D5 
CGGGAGGGTCAGAGGACAAGTTAC 
GCAGACTCCG 
CGGAGTCTGCGTAACTTGTCCTCTGA 
CCCTCCCG 
D6 
GGGAAAGGGCTGGAGTGGGTCTC 
AACGATTGAGTATCGG 
CCGATACTCAATCGTTGAGACCCACT 
CCAGCCCTTTCCC 
D9 
GGGTCTCAAATATTTATCGGGAGG 
GTCAGAGGACAAGTTACGCAAACTCC 
GGAGTTTGCGTAACTTGTCCTCTGAC 
CCTCCCGATAAATATTTGAGACCC 
D12 
GGGTCTCAGGTATTTGGCAGCG 
GGGTTCTACTACAGC 
GCTGTAGTAGAACCCCGCTGCCA 
AATACCTGAGACCC 
E3 No stop codon! 
E5 
GGGAAGGGGCTGGAGTGGGTCT 
CAGATATTTCTACTGCTGG 
CCAGCAGTAGAAATATCTGAGACC 
CACTCCAGCCCCTTCCC 
E7 
GGGTCCCTGAGACTCTCCTGCG 
CAGCCTCTGGATTCACC 
GGTGAATCCAGAGGCTGCGCAGG 
AGAGTCTCAGGGACCC 
E8 
CCAGGGAAGGGGCTGGAGTGGG 
TCTCAGTTATTGGG 
CCCAATAACTGAGACCCACTCCAG 
CCCCTTCCCTGG 
F1 
GGGCTGGAGTGGGTCTCAAGTAT 
TTATTCGCAGGGTAATCTTACAATTTACGC 
GCGTAAATTGTAAGATTACCCTGCG 
AATAAATACTTGAGACCCACTCCAGCCC 
F3 
GCGAAAAGTGCTACTCAGTTTG 
ACTACTGGGGCCAGGG 
CCCTGGCCCCAGTAGTCAAACTG 
AGTAGCACTTTTCGC 
F11 
GGGAAGGGGCTGGAGTGGGTCT 
CAGCTATTAGTACTTCTGG 
CCAGAAGTACTAATAGCTGAGACC 
CACTCCAGCCCCTTCCC 
 
Table 10-2 Overview of amber and ochre stop codons found in isolated scFv antibody fragments. 
Clone Length Stop codon Location of stop GC content Tm temperature 
A3 43 bp TAG-->CAG CDR2 46,50% 82,6 °C 
C5 39 bp TAA-->CAG CDR2 59,00% 85,8 °C 
D1 41 bp TGA-->TGG FWR2 48,78% 82,6 °C 
D4 No stop codon! 
D5 34 bp TAG-->CAG CDR2 58,80% 82,8 °C 
D6 39 bp TGA-->TGG FWR2 53,80% 83,7 °C 
D9 50 bp TAG-->CAG CDR2 46,00% 84,7 °C 
D12 37 bp TAG-->CAG CDR2 54,05% 82,7 °C 
E3 No stop codon! 
E5 41 bp TGA-->TGG FWR2 53,60% 84,6 °C 
E7 39 bp TGA-->TGC FWR1 64,10% 87,9 °C 
E8 36 bp TGA-->TGG FWR2 58,30% 83,9 °C 
F1 53 bp TAG-->CAG CDR2 43,40% 84,7 °C 
F3 38 bp TAG-->CAG CDR3 52,63% 82,6 °C 
F11 41 bp TGA-->TGG FWR2 53,60% 84,6 °C 
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10.2 Amino acids (IUPC letter codes) 
Table 10-3 Overview of codes for amino acids 
Amino acid 3-letter code 1-letter code Triplets coding for amino acid 
Alanine Ala A GCT, GCC, GCA, GCG 
Arginine Arg R CGT, CGC, CGA, CGG, AGA, AGG 
Asparagine Asn N AAT, AAC, 
Aspartic acid Asp D GAT, GAC 
Cysteine Cys C TGT, TGC, 
Glutamine Gln Q CAG, CAA, 
Glutamic acid Glu E GAA, GAG 
Glycine Gly G GGT, GGC, GGA, GGG 
Histidine His H CAT, CAC, 
Isoleucine Ile I ATT, ATC, ATA 
Leucine Leu L CTT, CTC, CTA, CTG 
Lysine Lys K AAA, AAG 
Methionine Met M ATG 
Phenylalanine Phe F TTT, TTC, 
Proline Pro P CCT, CCC, CCA, CCG 
Serine Ser S TCT, TCC, AGT, AGC 
Threonine Thr T ACT, ACC, ACA, ACG 
Tryptophan Trp W TGG 
Tyrosine Tyr Y TAT, TAC, 
Valine Val V GTT, GTC, GTA, GTG 
10.3 List of approved therapeutic mABs in Germany 
Table 10-4 List of recombinant antibodies approved for treatment in Europe. [77] 
Name of mAB Type Target of Action Condition Approved 
Arzerra 
(Ofatumumab) 
Human Anti-CD20 Chronic lymphatic leukemia 2010 
Avastin 
(Bevacizumab) 
Humanized Anti-VEGF 
Advanced colorectal, lung, breast, 
kidney and cervix carcinoma 
2005 
Benlysta 
(Belimumab) 
Human 
Inhibits B-cell 
activating factor 
(BAFF) 
Systemic lupus erythematous 2011 
Cimzia 
(Certolizumab) 
Humanized Fab Anti-TNFα 
Inflammatory gastro-intestinal 
disease, Crohn’s disease, 
rheumatoid arthritis 
2009 
Erbitux 
(Cetuximab) 
Chimeric Anti-EGFR 
Metastatic colorectal cancer, and 
head and neck cancer 
2004 
Herceptin 
(Trastuzumab) 
Humanized Anti-HER2 Breast cancer and stomach cancer 2000 
Humira 
(Adalimumab) 
Human Anti-TNFα 
Rheumatoid arthritis, psoriasis-
arthritis, spondylitis aknylosans, 
Crohn’s disease, colitis ulcerosa 
2003 
ILARIS 
(Canakinumab) 
Human Anti-IL-1ȕ 
autoinflammatory syndromes 
including familial cold 
autoinflammatory syndrome, 
Muckle–Wells syndrome, and 
neonatal-onset multisystem 
inflammatory disease 
2009 
Lucentis 
(Ranibizumab) 
Mouse Fab Anti-VEGF 
"wet" type of age-related macular 
degeneration (AMD, also ARMD), 
a common form of age-related 
2007 
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vision loss 
MabCampath 
(Alemtuzumab) 
Humanized Anti-CD52 
chronic lymphocytic leukemia, 
cutaneous T-cell lymphoma and T-
cell lymphoma, conditioning 
regimens for bone marrow 
transplantation, kidney 
transplantation and Islet cell 
transplantation 
2001 
Mabthera 
(Rituximab) 
chimeric Anti-CD20 
Attacks B-cells, lymphomas, 
leukemias, transplant rejection, and 
some autoimmune disorders 
1998 
Prolia 
(Denosumab) 
Human Anti-RANKL 
osteoporosis, treatment-induced 
bone loss, bone metastases, 
rheumatoid arthritis, multiple 
myeloma, and giant cell tumor of 
bone 
2010 
Remicade 
(Infliximab) 
Chimeric Anti-TNFα Autoimmune diseases 1999 
Removab 
(Catumaxomab) 
Hybrid 
Bispecific anti-CD3, 
anti-EpCAM 
malignant ascites, a condition 
occurring in patients with 
metastasizing cancer 
2009 
Reopro 
(Abciximab) 
Chimeric Anti-GPIIb/IIIa 
platelet aggregation inhibitor 
during and after coronary artery 
procedures like angioplasty to 
prevent blood clots formation 
within the coronary artery 
1995/2005 
Rilonacept 
Regeneron 
Dimer 
IL-1  
receptor inhibitor 
cryopyrin-associated periodic 
syndromes, including familial cold 
autoinflammatory syndrome, 
Muckle-Wells syndrome and 
neonatal onset multisystem 
inflammatory disease 
2009 
RoActemra 
(Tocilizumab) 
Humanized Anti-IL-6 
rheumatoid arthritis and systemic 
juvenile idiopathic arthritis 
2009 
Simponi 
(Golimumab) 
Human Anti-TNFα 
severely active rheumatoid 
arthritis, psoriatic arthritis, and 
ankylosing spondylitis 
2009 
Simulect 
(Basiliximab) 
Chimeric Anti-CD25 
prevent rejection in organ 
transplantation (kidney transplants) 
1998 
Soliris 
(Eculizumab) 
Humanized Anti-complement C5 
paroxysmal nocturnal 
hemoglobinuria (PNH), atypical 
hemolytic-uremic syndrome 
2007 
Stelara 
(Ustekinumab) 
Human Anti-IL-12/23 moderate to severe plaque psoriasis 2009 
Synagis 
(Palivizumab) 
Humanized Anti-RS-virus 
prevention of respiratory syncytial 
virus infections 
1999 
Tysabri 
(Natalizumab) 
Humanized Anti-α4-integrin multiple sclerosis and Crohn's 
disease 
2006 
Vectibix 
(Panitumumab) 
Human Anti-EGFR 
EGFR-expressing metastatic 
colorectal cancer 
2007 
Xgeva 
(Denosumab) 
Human Anti-RANKL 
osteoporosis, treatment-induced 
bone loss, bone metastases, 
rheumatoid arthritis, multiple 
myeloma, and giant cell tumor of 
bone 
2011 
Xolair 
(Omalizumab) 
Humanized Anti-IgE severe, persistent allergic asthma 2005 
Yervoy 
(Ipilimumab) 
Human Anti-CTLA-4 
turns off this inhibitory mechanism 
in cells and allows cytotoxic T-
lymphocytes to continue to destroy 
cancer cells 
2011 
Zevalin 
(Ibritumomab) 
Mouse Anti-CD20 
radioimmunotherapy treatment for 
relapsed or refractory, low grade or 
transformed B cell non-Hodgkin's 
lymphoma 
2004 
(12 approved recombinant antibodies against carcinoma are marked in grey) 
Appendix 
 
 
181 
10.4 Abbreviations 
Abbreviation Explanation 
♀ Female 
♂ Male 
 percent 
x g times gravity 
< smaller 
> larger 
°C degree Celsius 
∞ infinite 
2D two-dimensional 
2 squared 
3D three-dimensional 
α alpha 
ȕ beta 
Δ delta 
Ȝ lamda 
µ micro 
Ω ohm 
A adenine 
ABTS 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
ad fill volume up to 
ADC antibody-drug-conjugate 
AE actual enrichment 
AF Alexa Fluor 
AG antigen 
AIDA Advanced Image Data Analyzer 
AJCC American Joint Committee on Cancer 
AME Institute for Applied Biomedical Engineering 
amp Ampicillin 
AmpR Ampicillin resistance 
APS ammonium persulfate 
ATP adenosine triphosphate 
AUG RNA triplet coding for methionine 
BC bicinchoninic acid (also: BCA) 
BG benzylguanine 
bp base pairs 
BSA bovine serum albumine 
C cytosine 
CA carbohydrate antigen 
CAG DNA tripet coding for glutamine 
CD cluster of differentiation 
cDNA copy DNA 
CDR complementarity determining region 
CEA carcinoembryonic antigen 
CFP cyan fluorescent protein 
cm centi meter 
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CMV cytomegalovirus 
ColE1 origin of replication for E.coli 
CSC cancer stem cells 
CT computed tomography scan 
CTR carbon dioxide transfer rate 
Da Dalton 
DAB 3,3’,4,4’-Tetraaminobiphenyltetrahydrochlorid 
DAPI 4’,6-diamidino-2-phenylindole 
DAPK death-associated protein kinase 
ddH2O bi-destilled/double destilled water 
DF dilution factor 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsuloxide 
DNA desoxyribonucleic acid 
dNTP desoxyribonucleoside triphosphate 
DOT dissolved oxygen tension 
DPBS Dulbecco’s Phosphate Buffered Saline 
dsDNA double-stranded DNA 
DTT dithiothreitol 
DVT D = adenine, guanine or thymine, V = adenine, guanine or cytosine, T = thymine 
E405 extinction measured at 405 nm 
EC expression control 
E.coli Escherichia coli bacterial strain 
EDTA ethylenediaminetetraacetic acid 
EF enrichment factor 
e.g. “exempli gratia” (for example) 
eGFP enhanced green fluorescenct protein 
EGFR epidermal growth factor receptor 
EK enterokinase 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmic reticulum 
ESI/MS electrospray ionization mass spectroscopy 
ETA’ trunated version of Pseudomonas Exotoxin A 
EtOH ethanol 
EU/mL endotoxin units per mL 
F fertility factor 
f1 ori origin of replication for f1 phage 
Fab fragment antigen binding 
FACS Fluorescence activated cell sorting 
FbFP FMN-based fluorescent protein 
FBS fetal bovine serum 
Fc fragment crystallizable 
FDA Food and Drug Association 
FhG Fraunhofer Gesellschaft 
FITC fluorescein isothiocyanate 
FMN flavin mononucleotide-binding protein 
FP fluorescent protein 
FU fluorouracil 
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FWR framework region 
g gram 
G guanine 
GAM goat-anti-mouse 
GFP green fluorescent protein 
gluc glucose 
G-mean geometrical mean 
GS-linker glycine-serine linker 
h hour 
HACA human anti-chimeric antibody 
hAGT human O6-alkylguanine DNA alkyltransferase repair enzyme 
HAHA human anti-human antibody 
HAMA human anti-mouse antibody 
HEK human embryo kidney 
His histidine 
His6-tag protein affinity tag consisting of six histidine residues 
HPLC high pressure liquid chromatography 
HRP horseradish peroxidase 
I intensity 
IDA iminodiacetic acid 
i.e. “id est” (that is) 
IgG immunoglobulin G 
IF immunofluorescence 
IHC immunohistochemistry 
IMAC Immobilized metal-ion affinity chromatography 
IME Institute for Molecular Biology and Ecology 
IMRT intensity-modulated radiation therapy 
IPTG isopropyl ȕ-D-1-thiogalactopyranoside 
IRES internal ribosomal entry sequence 
IT immunotoxin 
IVS intervening sequence 
kan Kanamycin 
KanR Kanamycin resistance 
kb kilo bases 
KBE/mL “koloniebildende Einheiten“ per mL 
L liter 
LB medium Lysogeny Broth  medium 
LOV light-oxygen-voltage 
Luc cell line transfected with click-beetle red luciferase 
m milli 
M mega 
M molar 
mAB monoclonal antibody 
MFI mean fluorescence intensity 
min minute 
MOI multiplicity of infection 
mol moles 
MOPS 3-(N-morpholino)propanesulfonic acid 
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MRC Medical Research Council 
MRD minimal residual disease 
MRI magnetic resonance imaging 
MTP microtiter plate 
MW molecular weight 
myc myelocytomatosis oncogen 
n nano 
NC negative control 
NNK N = refers to any base, K = cytosine or guanine 
NOD non-obese diabetic 
NTA Nitrilotriacetic acid 
OD600 optical density measured at 600 nm 
O/N over night 
OPERA Oscillation Project with Emulsion-tRacking Apparatus 
ORF open reading frame 
OTR oxygen transfer rate 
p pico 
p p-value, probability, statistical significance 
pI – pXI M13 phage coat proteins 
PAA polyacrylamide 
PCR polymerase chain reaction 
pelB pectate lyase B 
PET positron emission tomography 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PBST Phosphate buffered saline supplemented with 0.05% Tween20 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PFA paraformaldehyde 
pfu plaque forming unit 
pfuTurbo DNA polymerase from Pyrococcus furiosus 
PO peroxidase 
pSV40 origin of replication for SV40 
Q-TOF quadrupole time-of-flight mass analyzer 
RAMOS Respiration Activity Monitoring System 
RB retinoblastoma-associated 
RBS ribosomal binding site 
RNA ribonucleic acid 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute 
RQ respiratory quotient 
RT room temperature 
s second 
SBP streptavidin binding peptide 
scFv Single chain fragment variable 
SCID Severe Combined Immunodeficiency 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
SOC SOB (Super Optimal Broth) containing 20 mM glucose 
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SOE Splicing by overlap extension 
SR selection round 
ssDNA single-stranded DNA 
SV40 Simian vacuolating virus 40 
SV40 pA SV40 polyadenylation signal 
t time 
T temperature 
T thymine 
TAA tumor-associated antigen 
TAE Tris-Acetate-EDTA buffer 
TAG amber stop codon 
TCSN tissue culture supernatant 
TEA triethylamide 
TEMED tetramethylethylenediamine 
TES Tris-EDTA-sucrose buffer 
TGA ochre stop codon 
TGG DNA triplet coding for tryptophan 
Tm melting temperature 
TSP-1 thromospondin-1 
TY medium tryptone-yeast medium 
UKA University Hospital Aachen 
UKGM University Hospital Giessen and Marburg 
UV ultraviolet 
V volt 
VEGF-A vascular endothelial growth factor A 
VG Vista Green 
VH heavy chain variable region 
VL light chain variable region 
vs. versus 
v/v volume per volume 
v/w volume per weight 
W tryptophan 
W1 – W5 one to five tryptophan 
Wx-tag short reporter tag containing accumulated tryptophan 
WB Western blot 
w/v weight per volume 
XTT 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt 
YFP yellow fluorescent protein 
Zeo Zeocin 
ZeoR Zeocin resistance 
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